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ABSTRACT 
Jennifer Bolin Dennison 
 
VINCRISTINE METABOLISM AND THE ROLE OF CYP3A5 
 
 
 Vincristine is metabolized by the cytochrome P450 3A subfamily of enzymes possibly 
including CYP3A5, a genetically polymorphic enzyme.  The contribution of CYP3A5 to 
the metabolism of vincristine was quantified by various in vitro models: cDNA-
expressed enzymes, human liver microsomes, and human hepatocytes.  With these 
models, the major CYP metabolite of vincristine, M1, was identified and extensively 
characterized.  The rates of M1 formation in the cDNA-expressed enzyme models were 
at least 7-fold higher with CYP3A5 than CYP3A4; approximately 90% of the hepatic 
metabolism was predicted to be CYP3A5-mediated.  For human liver microsomes with 
high CYP3A5 expression, the CYP3A5 contribution was substantial, approximately 
80%.  Human hepatocytes with at least one CYP3A5*1 allele also metabolized 
vincristine, albeit at a slower rate (10-fold) than human liver microsomes.  The CYP3A5 
low-expressing hepatocytes did not metabolize vincristine. We conclude that for high 
CYP3A5 expressers, the majority of the CYP metabolism is mediated by CYP3A5.  By 
in vitro/in vivo scaling with microsomes, the hepatic clearances of high CYP3A5 
expressers are predicted to have a 5-fold higher hepatic clearance than low expressers.  
However, the role of metabolism in the systemic clearance of vincristine is unknown.  
To study the disposition of vincristine in vivo, a sensitive and selective LC/MS/MS 
assay was validated for the quantification of vincristine and M1 quantification in human 
 v
plasma.  Vincristine and M1 were identified and quantified in select pediatric plasma 
and urine samples.  For future large-scale clinical studies, the vincristine and M1 
concentrations in plasma will be quantified to understand the role of CYP3A5 genotype 
in vincristine pharmacokinetics.  For patients that are CYP3A5 high expressers, the 
systemic clearance of vincristine may be higher than that of low CYP3A5 expressers.  
Thus, CYP3A5 genotype may be an important determinant of inter-individual variability 
in clinical outcomes.   
 
Stephen D. Hall, Ph.D., Chair 
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I. Introduction 
A. Vincristine 
1. Chemistry 
Vincristine, a monoterpenoide indole alkaloid, was originally discovered as a natural 
product produced by the Madagascar periwinkle plant, Catharanthus roseus, but only in 
trace quantities.1,2  For the commercial manufacture of vincristine today, vinblastine and 
N-desformylvinblastine are extracted from Catharanthus roseus leaves and chemically 
modified.3  Vincristine has been synthesized using biomolecular engineering strategies 
from less complex intermediates, such as vindoline and catharanthine.4  However, total 
biosynthesis from smaller molecules is not yet possible; to synthesize vinblastine in the 
periwinkle, at least 30 different enzymes and 35 chemical intermediates are required.4  
In fact, a chemical procedure for the de novo synthesis of vincristine was only recently 
discovered because the molecular structure of vincristine is unusually complex, even for 
a natural product.5 
Vincristine is a highly functionalized alkaloid with a molecular weight of 825 
and nine chiral centers (Fig. 1).  All Vinca alkaloids, including vinblastine and 
vinorelbine, are comprised of two distinct parts—the catharanthine and vindoline 
moieties.6  While the catharanthine moieties are the same as vincristine, vinblastine has 
a methyl substitution on the vindoline nitrogen in place of a formyl group (C-22’).  
Vinorelbine has the same structure as vinblastine without a hydroxyl group (C-14) on 
the catharanthine moiety but with a C14-C15 double bond on the piperidine ring.   
Vinblastine and vinorelbine, commonly used as internal standards for vincristine 
assays, are structurally similar to vincristine with desirable chromatography properties.  
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For all three Vinca alkaloids, the molecular conjugation characteristics are identical—
the catharanthine indole and the vindoline phenyl ring.  As a result, as compared to 
vincristine, vinblastine and vinorelbine have similar ultraviolet absorption properties.  In 
addition, the alkaloids have two nitrogens that are easily protonated: the allylic nitrogen 
on the vindoline side and the tertiary nitrogen on the catharanthine side.  The 
corresponding pKa values are approximately 5.4 and 7.4 for all the Vincas.6  Thus, by 
HPLC, the relative retention times of the compounds are similar regardless of eluent pH.  
Finally, the compounds separate by HPLC without difficulty because vinblastine and 
vinorelbine are more lipophilic than vincristine (12-fold higher partition coefficient for 
vinblastine).7   
Vincristine, as it is found in the vacuoles of plants, is present in multiple 
chemical forms including the free base, N-oxide, and salt.3  Only a few degradation and 
metabolism products of vincristine have been described by in vitro studies.  Vincristine 
was degraded after 72 h in glycine buffer to desacetylvincristine and N-formylleurosine 
(M4/M5 epoxide diastereomers in our studies).8  Vincristine was oxidized by peroxidase 
and ceruloplasmin, a human serum enzyme, to yield a N-formylcatharanthine product 
(M2 in our studies).9  Finally, in one hepatic metabolism study, vincristine was 
extensively metabolized by human liver hepatocytes to multiple compounds.10  
However, the chemical identities of these compounds were not determined.   
As described for human hepatocytes, vincristine sulfate is rapidly metabolized 
and/or degraded to multiple compounds when administered intravenously to humans.  
For radiolabeled vincristine studies, the recovery of the parent drug by HPLC was 50 to 
60%.11,12  However, the actual vincristine recovery was possibly lower because the 
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vincristine and the metabolite/degradation products may have co-eluted under the HPLC 
conditions employed.  Surprisingly, no compounds have been identified in vivo to 
account for the 40 to 50% loss of vincristine.  The only reported Vinca-related 
compounds isolated from urine or bile were small amounts of degradation products 
(desacetylated, epoxide, and N-oxide derivatives).13-15  These compounds are unlikely to 
have clinical significance because they accounted for less than 1% of the administered 
dose.13,14    
2. Mechanisms of Action 
Vincristine and other Vinca alkaloids bind to tubulin and as a result inhibit microtubule 
assembly.16  The Vinca binding site on tubulin is distinct from the taxane or colchicine 
binding site.17  X-ray structures of vinblastine and tubulin heterodimers revealed that 
vinblastine was equally bound to α and β-tubulin from adjacent heterodimers close to 
the GDP/GTP binding site on β-tubulin.17  Vinblastine (VLB) at the inter-dimer 
interface (i.e. α1β1-VLB-α2β2) caused curvature in the protofilaments leading to spiral 
formation.  As a result, vinblastine interfered with the dynamic instability at the (+) end 
of protofilaments and ultimately inhibited microtubule assembly.17   
Although all Vinca alkaloids bind to the same site on tubulin, the individual 
compounds have different potencies.  The overall binding affinity of vincristine to 
tubulin was 5-fold and 10-fold higher than the binding affinities of vinblastine and 
vinorelbine, respectively.18  The in vitro potencies of the Vinca alkaloids with tubulin 
are the same rank order as the clinical doses from lowest to highest dose (vincristine > 
vinblastine > vinorelbine).  This correlation may be expected if the dose-limiting 
toxicities of the drugs are caused by tubulin binding at the same site.  However, in 
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addition to tubulin affinity, the maximum dose administered in vivo is a function of 
distribution to the site of toxicity (neurons for vincristine, bone marrow for vinblastine 
and vinorelbine) and the systemic clearance of the drug.     
Therapeutic concentrations of Vinca alkaloids (less than 0.1 µM for vincristine) 
cause changes in microtubule dynamics and can block mitosis leading to cell-cycle 
arrest and apoptosis.18  Recent evidence suggests that the actin cytoskeleton and 
microtubule function are intimately connected; disruption of the actin cytoskeleton 
caused by antimicrotubule drugs may be part of a critical pathway leading to apoptosis 
in cancer cells.  For example, in multiple cell lines with resistance to antimicrotubule 
drugs, the actin cytoskeletal proteins such as γ-actin were mutated or had altered 
expression.19,20  In response to antimicrotubule drugs addition, cancer cells also 
underwent anoikis, apoptosis caused by detachment to the extracellular matrix.21   
The tubulin-binding characteristics of vincristine that destroy cancer cells are 
also likely responsible for the dose-limiting peripheral neuropathy in vincristine therapy.  
The binding of drug to microtubules in axons causes disarray characterized by a 
decrease in density and tangential orientation of the microtubules.22  Of the Vinca 
alkaloids, neurotoxicity is unique to vincristine; the dose-limiting toxicity of all other 
approved Vinca alkaloids is myelosuppresion.  Some investigators have hypothesized 
that compared to the other Vinca alkaloids, vincristine causes neurotoxicity because it 
has a higher affinity to tubulin isoforms primarily expressed in neurons (βII and βIII).  
However, with purified βII and βIII isoforms of tubulin, the in vitro data with 
vincristine showed only minor differences in affinity.23  At this time, it is unclear 
whether these small differences are responsible for the neurotoxicity observed in vivo 
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during vincristine therapy but not observed with the other Vinca alkaloids.  Other drug-
specific factors to consider include the penetration of the drug to the site of toxicity and 
the ability of the cells to transport the drug.   
3. Clinical Applications 
Vincristine is currently used to treat a variety of malignancies in both pediatric and adult 
patients.  In the United States every year, approximately 12,400 children less than 20 
years old are diagnosed with cancer (0.3% rate of incidence), and 2500 children die 
from their disease.24  The most common cancer in children is acute lymphoblastic 
leukemia (ALL, 19%) followed by lymphomas and reticuloendothelial neoplasms 
(16%).24  Vincristine is used as part of standard therapy for these cancers and a variety 
of other cancers including neuroblastoma, non-Hodgkins’ Lymphoma, Hodgkins’ 
disease, Wilms’ tumor, hepatic tumors, retinoblastoma, and rhabdomyosarcoma.25  In 
adults, vincristine is commonly used in combination chemotherapy in the United States 
to treat ALL (1420 deaths/year), non-Hodgkins’ Lymphoma (18,700 deaths/year), 
Hodgkins’ disease (1070 deaths/year), and multiple myeloma (10,800 deaths/year).25 
4. Dose-limiting Toxicity   
For vincristine, the dose-limiting toxicity is a distinctive type of peripheral neuropathy 
with the following symptoms: limb weakness, abdominal pain, numbness in extremities, 
and constipation.26  Severe toxic effects associated with vincristine treatment and 
overdose include seizures, paralytic ileus, bowel obstruction, urinary retention, 
hypertension, and severe musculoskeletal pain.27  However, once therapy is 
discontinued, even for patients with severe neurotoxicity, the neuropathy for almost all 
patients is fully reversible.27  No additional treatment during vincristine therapy is 
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known to alleviate neurotoxic symptoms.  The Pediatric Oncology Group in a phase III 
clinical trial is currently investigating glutamic acid as a neuroprotective agent.25  
Vincristine neurotoxicity can be a severe clinical problem with coadministration of 
certain antifungal and immunosuppressant drugs.  The most commonly reported drugs 
that interact with vincristine are itraconazole and cyclosporin A.28-31  Although the exact 
mechanism is unknown, these drug/drug interactions are most likely caused by 
inhibition of CYP3A enzymes and/or P-gp.32-34  According to a few clinical case studies, 
other drugs may also potentiate vincristine neurotoxocity including verapamil, 
nifedipine, and isoniazid.35  These drugs also inhibit CYP3A4 and, at least for 
verapamil, P-gp.36,37 
The maximum dose recommendation for vincristine is 1.5 mg/m2 per week with 
a maximum single dose of 2 mg and cumulative dose of 20 mg.  The dosing of 
vincristine was decided more than 30 years ago based on clinical observations of more 
frequent and a faster onset of neurotoxic events at higher doses (3 mg/m2).38  However, 
in this study, the recommended dose of vincristine may not be appropriate for pediatric 
patients because only 5 of the 78 patients were children.  The dosing recommendations 
for pediatric and adult patients were recently challenged by scientists and physicians 
because the maximum tolerated dose is not used for the majority of patients, especially 
for patients with a capped dose of 2 mg.27  An increase in the maximum recommended 
dose for vincristine may be possible as shown by a pediatric Dutch ALL study; the 
maximum dose was increased to 2.5 mg without causing severe neurotoxic events.39  At 
this time, it is unknown whether dose escalation of vincristine will result in clinically 
significant efficacy improvements.  Phase III clinical trials are currently underway to 
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evaluate the clinical outcome differences between high and low dose vincristine in 
relapsed pediatric ALL patients.25   
5. Effect of Ethnicity on Clinical Outcomes 
Unlike for other types of pediatric cancers such as AML, the prevalence and the rates of 
survival for pediatric ALL differ by race.24  Caucasian children have a 2-fold higher 
prevalence of ALL compared to African-American children (31 per million versus 15 
per million).24  On the other hand, African-American children have a lower survival rate 
relative to Caucasian children.  According to the NCI, the 5-year survival rate of 
African-American children was 64% versus 78% for Caucasian children (treatment 
period 1985–1994).24  The authors hypothesized that the lower survival rate of African-
American children possibly reflected differences in the pharmacokinetics and/or the 
pharmacokinetics of the chemotherapeutic agents; differences in access to health care; 
or a lower incidence of readily curable ALL subtypes.24  However, in an ALL study 
conducted by the Pediatric Oncology Group (treatment period 1981–1994), the survival 
rates were calculated after correcting for known prognostic factors such as compliance, 
clinical presentation, and tumor characteristics; African-American and Spanish surname 
children with vincristine combination chemotherapy had a 42% greater mortality rate 
when compared to Caucasian children.40  The Children’s Cancer Group also reported 
interracial differences in outcome for intermediate-risk ALL (treatment period 1990–
1993); event-free-survival (EFS) was only 54% for African-American children 
compared to a Caucasian EFS of 82%.41  In a larger retrospective study, the Children’s 
Cancer Group evaluated the outcomes of Asian, Caucasian, Hispanic, and African-
American children with standard and high-risk ALL (treatment period 1983–1995).42  
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After adjusting for risk factors, the 5-year survival rates of Hispanic and African-
American children were significantly lower than those of Asian and Caucasian children 
(p < 0.001): Asian, 75%; Caucasian, 73%; Hispanic, 66%; and African-American, 
62%.42   
As suggested by many investigators, the interracial differences in clinical 
outcomes for ALL may be caused by pharmacokinetic and/or pharmacodynamic 
differences.  However, to test such a hypothesis can be challenging because the 
individual effects of each drug given in combination often cannot be differentiated from 
each other.  In this context, vincristine is an exceptional drug because its dose-limiting 
neurotoxic effects are unique and thus attributed to vincristine therapy alone.  
Interestingly, in a retrospective study at Riley Hospital (Indianapolis, IN), vincristine-
related neurotoxicity was more commonly observed in Caucasian children compared to 
African-American children (35% versus 4.5%, p = 0.004).43  As a logical extension of 
this observation, African-American children may be more likely to have a reduced 
exposure to vincristine resulting in less neurotoxicity but reduced overall survival rates.  
This hypothesis is the basis for our study of vincristine disposition and the role of the 
genetically polymorphic enzyme CYP3A5, an enzyme more commonly expressed in 
African-Americans. 
6. Pharmacokinetics 
a) Distribution 
Vincristine diffuses into cells, binds to tubulin, and as a result, has a large steady-state 
volume of distribution (approximately 168 L/m2).44  Although many compounds with 
large volumes of distribution are highly lipophilic and concentrate in fat stores and cell 
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membranes, vincristine targets tubulin-rich tissues including muscle, intestines, 
platelets, and blood cells.45  Vincristine also accumulates in red blood cells, white blood 
cells, and platelets resulting in an overall blood-to-plasma ratio of 1.2.11  Interestingly, 
for specific cancer applications, vincristine-loaded platelets (incubated in vincristine and 
rinsed to remove excess drug) have been used for targeted drug delivery.46  Vincristine 
does bind to plasma proteins, specifically α-glycoproteins, albeit with low affinity.47  
Thus, the fraction of drug unbound in human plasma is approximately 0.5 and not 
dependent on vincristine concentration (40 to 256,000 ng/mL).48   
Tissue distribution of vincristine is also influenced by expression of multi-drug 
resistance proteins: P-gp, MRP1, and MRP2.  These transporters can actively efflux 
vincristine from the cytoplasm of many cell types.  Vincristine and/or its metabolic 
products are actively transported by hepatocytes into the bile most likely by P-gp and 
MRP2 in the cannalicular membrane.12,49  For one patient treated with radiolabeled 
vincristine, at any time point up to 72 h, the concentration of vincristine-related 
compounds was 40-fold higher in the bile than the plasma.12  As demonstrated in a 
mouse knockout model, expression of MRP1 reduced the accumulation of vincristine in 
several organs (kidney, lungs, and heart).50  In addition, the expression of both P-gp and 
MRP1 protected the bone marrow from myelosuppression.50  Vincristine penetration to 
the central nervous system is likely reduced by expression of P-gp and MRP1 at the 
blood-brain barrier.  In one pediatric study, no vincristine was detected in the cerebral 
spinal fluid.51  However, the peripheral nerve cells are apparently not as well protected; 
distribution and accumulation of vincristine are likely responsible for the cumulative 
peripheral neurotoxicity of vincristine.38 
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b) Clearance 
Vincristine pharmacokinetics are typically characterized by one or two distribution 
phases followed by a log-linear decline in plasma concentrations with a terminal half 
life in adults of 23 to 84 h.44,52  Some pharmacokinetic studies reported shorter terminal 
half lives (3 to 8 h) because the terminal elimination phase of vincristine was not 
adequately characterized by late time point samples.11,53  To accurately fit the 
distribution phases, two or three-compartment pharmacokinetic models are typically 
used with elimination occurring from the central compartment. 
The clearance of vincristine is primarily hepatobiliary with only 8 to 15% of the 
dose excreted in the urine.11  These radiolabel studies estimated the percentage excreted 
unchanged in the feces and urine to be 50 to 60%.11,12  However, the 
radiochromatograms from these studies are difficult to interpret for two reasons.  First, 
the degradation products and/or metabolites of vincristine may have been artifacts of the 
in vitro assay because the vincristine degraded in the control samples.  Also, as 
discussed earlier, the parent drug may have co-eluted by HPLC with other vincristine-
related compounds.    
Vincristine pharmacokinetic parameters, in particular clearance values, are 
highly variable between individuals and between studies.  Early vincristine clinical 
studies estimate an 11-fold variability in drug exposure (dose-corrected area-under-the-
curve, AUC) between adult patients.53  More recent pediatric clinical pharmacokinetic 
studies report an 19-fold variability in the dose-corrected AUC.54  Although the data are 
scattered, vincristine is generally reported to be a low to medium hepatic extraction ratio 
drug.  Thus, hepatic metabolic clearance should be a primarily a function of intrinsic 
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clearance, the maximum metabolic clearance independent of binding and hepatic blood 
flow.    
When evaluating vincristine pharmacokinetics in published studies, several 
issues need to be considered.  First, for early pharmacokinetic studies, only adult 
patients were recruited; later in 1994, the studies shifted almost exclusively to pediatric 
patients.11,12,44,52-61  This population change prohibits the direct comparison of 
pharmacokinetic data between the two eras.  Another major concern with all studies is 
the uncertainty of the fit with the selected model (two or three compartment).  Using a 
standard guideline for pharmacokinetic studies, the plasma should be sampled for at 
least three terminal half lives to account for the vast majority (~90%) of the drug 
exposure as determined by AUC, area under the curve.  However, few studies have 
reported vincristine concentrations past one half life (24 h).12,44,52,55  In fact, the pediatric 
studies routinely used limited sampling strategies and Bayesian approaches to estimate 
clearance.54,56-61  As a result, the variability in clearance reported between patients may 
in part be attributed to high uncertainty in the model estimated parameters.  Finally, over 
the last three decades, the analytical methods changed for vincristine quantification in 
plasma.  For studies prior to 1994, the vincristine concentration was quantified by 
several different radioimmunoassay assays.44,52,53,55  The specificities of these assays for 
vincristine are unknown.  Early radiolabel studies quantified the vincristine-related 
compounds by direct liquid scintillation counting.11,12  This method of detection was 
also non-specific for vincristine; by HPLC, only 40 to 50% of the parent drug was 
recovered.11,12  In the 1990’s, an HPLC assay was developed to quantify vincristine in 
plasma by electrochemical detection.62  This particular method was utilized in all 
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pediatric pharmacokinetic studies of vincristine 1994–2005.54,56-61  However, in 
common with the early radioimmunoassays, the specificity of this electrochemical 
detection method was unknown because vincristine-related compounds by HPLC could 
co-elute with the parent drug.  In addition, the method could not be used to assay plasma 
samples collected more than 24 h after treatment because the assay limit of 
quantification for vincristine was 0.5 ng/mL.62  For plasma samples collected more than 
24 h post treatment, all the assays utilized in previous pharmacokinetic studies lacked 
the selectivity and/or the sensitivity to quantify vincristine.  More sensitive and 
discriminating methods of detection, such as MS/MS, are required to effectively 
measure vincristine exposure over more than one terminal half life.  
B. Cytochrome P450 3A Subfamily 
1. Protein Function and Structure 
The cytochrome P450s (CYPs) are heme-thiolate enzymes expressed by almost all types 
of organisms including bacteria, plants, and mammals.63  For humans, at the time of this 
publication in GenBank®, the sequences of 54 functional CYPs are documented.  The 
CYP enzymes within cells are localized to the mitochondria or the smooth endoplasmic 
reticulum (microsomal CYPs).  Microsomal human CYP enzymes are expressed in the 
cells of multiple organs including the small intestines, lungs, kidney, and liver.63  
Hepatic CYPs and some intestinal CYPs are of particular importance because their 
activities are responsible for the systemic clearance of many drugs.  As a result, CYP 
expression can be a major source of variability in drug exposure.  Although at least 10 
hepatic CYPs are clinically important in drug disposition, for drugs metabolized by 
CYPs, the CYP3A enzymes (CYP3A4 and CYP3A5) metabolize more than 50% of 
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marketed drugs including macrolide antibiotics, immunosuppresants, and 
anticonvulsants.63  CYP3A substrates vary in chemical structure but compared to 
substrates of other CYPs, are typically high in molecular weight, approximately 200 to 
800.  CYP3A enzymes can metabolize even higher molecular weight substrates such as 
cyclosporin A with a molecular weight of 1203.63   
Microsomal CYP enzymes as holoenzymes (heme-bound) catalyze the 
oxidization of substrates and the reduction of molecular oxygen.63,64  Two molecules of 
NADPH provide the 2 e- and 2 H+ in the reaction; the redox partners are NADPH-
cytochrome P450 reductase and cytochrome b5.  First, the substrate binds to the enzyme 
at the substrate recognition sequences (SRS) and displaces water from the heme.  Upon 
substrate binding, the Fe3+ spin state changes from low to high spin.  The substrate 
binding facilitates the reduction of the heme Fe3+ to the ferrous state (Fe2+) by an 
electron transfer from NADPH-cytochrome P450 reductase.  The Fe2+ enzyme complex 
binds molecular oxygen to form an oxy-P450 complex.  Subsequently, the complex is 
reduced by a second electron transfer from NADPH-cytochrome P450 reductase or 
cytochrome b5.  After two protons are transferred, the O-O bond is cleaved to release 
water.  The oxyferryl intermediate (FeIV=O) then oxides the substrate prior to its release.  
For the CYP cycle, the change from the oxy-P450 complex to the oxyferryl 
intermediate is the rate-limiting step.65  The electron transfer of this step is mediated by 
NADPH-cytochrome P450 reductase and/or cytochrome b5.  However, the exact role of 
cytochrome b5 in this process is unknown.  As described in several reviews, cytochrome 
b5 in CYP reactions may transfer the second electron faster than with the reductase  
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alone, reduce P450 cycle uncoupling (increase the efficiency), or modulate activity of 
the complex as an allosteric effector.65,66 
In a reconstituted system, the in vitro reaction kinetics can change profoundly 
with the addition of cytochrome b5.  For example, in the presence of cytochrome b5, the 
6β-hydroxylation of testosterone by CYP3A4 was stimulated 10-fold.67  In a study with 
laurate and CYP4A7, not only was the activity 5-fold higher with cytochrome b5, the Km 
value increased 7-fold.68  In this case, the change in Km may have caused a conformation 
change in the enzyme complex.  Cytochrome b5 effects with the same substrate are also 
enzyme dependent.  In a study with ifosfamide at concentrations at least 5-fold less than 
the Km, the addition or co-expression of cytochrome b5 differentially stimulated the rates 
of N-dechloroethylation with CYP3A4 and CYP3A5.69  Using Supersomes with and 
without co-expressed cytochrome b5, the N-dechloroethylation activity increased 3-fold 
for CYP3A5 with cytochrome b5 but increased 16-fold for CYP3A4 with cytochrome 
b5.69  Finally, with the addition of cytochrome b5, the metabolic profile of a substrate 
can be altered.  For example, cytochrome b5 was required for CYP3A5 to metabolize 
17α-ethynlestradiol to 17α-oxirene metabolites; these metabolites were responsible for 
CYP3A5 mechanism-based inactivation.70 
The in vitro enzyme preparations commonly used to evaluate the drug 
metabolism of substrates contain different amounts of NADPH-cytochrome P450 
reductase and cytochrome b5.  cDNA-expressed enzymes, for example CYP3A4 and 
CYP3A5, can be commercially purchased with co-expressed NADPH-cytochrome P450 
reductase (1 pmol/pmol CYP) and/or co-expressed cytochrome b5 (7 pmol/pmol 
CYP3A4 or 18 pmol/pmol CYP3A5).  These concentrations of redox proteins are much 
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higher than those in human liver microsomes: NADPH-cytochrome P450 reductase 
(~0.1 pmol/pmol CYP) and cytochrome b5 (~1 pmol/pmol CYP).71,72  Even though the 
kinetic effects of various concentrations of redox factors have been studied using 
reconstituted enzyme preparations, the full implications are unknown for individual 
substrates.73  Also, given that the effects of cytochrome b5 are concentration and enzyme 
dependent,73 it seems unlikely that the cDNA-expressed enzymes (with or without 
cytochrome b5 expression) will accurately predict drug metabolism in vivo for every 
substrate.  Thus, models with physiological concentrations of proteins (human liver 
microsomes, hepatocytes) are necessary to validate the results of the reconstituted 
systems.    
2. Pharmacogenetics  
Only low frequency genetic mutations of the CYP3A4 gene are known to affect 
CYP3A4 activity.74  In contrast, CYP3A5 genetic variants (CYP3A5*3, *6, and *7 
versus the wild type CYP3A5*1) are common.  For individuals with at least one active 
CYP3A5*1 allele, significant quantities of CYP3A5 are expressed (CYP3A5 high 
expressers); approximately 75% of African-Americans, 47% of East Asians, and 19% of 
Caucasians express high levels of CYP3A5.75  For the CYP3A5*3 genotype, a single 
nucleotide polymorphism (SNP, 6986A>G) in intron 3 creates a consensus splice site.  
If the mRNA is incorrectly spliced, the mature mRNA contains a premature termination 
codon.  The resulting mRNA produces a truncated, non-functional protein of 101 amino 
acids; the full-length CYP3A5 protein contains 502 amino acids.  Although the vast 
majority of the mRNA is spliced incorrectly, a small fraction of the mRNA is properly 
spliced.  Consequently, functional CYP3A5 is produced by individuals with the 
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CYP3A5*3/*3 genotype, albeit in much lower quantities than that produced by 
CYP3A5*1 individuals.76  The less common CYP3A5*6 and CYP3A5*7 coding region 
variants also produce reduced amounts (CYP3A5*6) or no CYP3A5 (CYP3A5*7).76,77  
These allelic variants are primarily found in African-American (CYP3A5*6 and 
CYP3A5*7) and Hispanic (CYP3A5*6) populations.75  Because such a small amount of 
active CYP3A5 is produced in individuals without the CYP3A5*1 allele, the other 
genotypes described are effectively devoid of active CYP3A5 (CYP3A5 low 
expressers).   
3. Expression   
In the majority of Caucasian livers, CYP3A enzymes are the most abundantly expressed 
CYP enzymes in the liver, representing approximately 30% of the total microsomal 
CYP content.78  The expression of hepatic CYP3A4 is variable between individuals (i.e. 
1.1 to 40.8 pmol 3A4/mg for a liver biopsy study).79  However, the high inter-individual 
CYP3A4 variability as reported for human liver microsomal banks (up to 75-fold 
variation) may be a reflection of variation in the sample preparation methods and/or the 
diseased and medicated donor population.80,81  For healthy, unmedicated populations, 
the in vivo CYP3A activities between individuals are less variable; for example, the 
reported inter-individual variability was approximately 8-fold for midazolam 
intravenous clearance.82   
To understand the variability in CYP3A4 expression and the potential for drug-
drug interactions, the transcriptional regulation of CYP3A4 has been studied extensively 
using cultured human hepatocytes and cell-based reporter assays.83  Specifically, the 
following nuclear hormone receptors are known to modulate the transcription of 
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CYP3A4: the pregnane X receptor (PXR), the constitutive andostane receptor (CAR), 
the vitamin D receptor (VDR), and the glucocorticoid receptor (GR).84  GR activation 
by endogenous concentrations of glucocorticoids (up to modest therapeutic 
concentrations) most likely indirectly induces CYP3A4 by increasing the transcription 
rates of PXR and CAR while PXR, CAR, and VDR activation directly induce CYP3A4 
expression by increasing the transcription rates of CYP3A4 mRNA.  The induction of 
CYP3A4 by PXR, CAR, and VDR occurs at two binding sites on the CYP3A4 promoter: 
the ER6 motif (position -160) and the DR3 site (position -7700).83  Commonly studied 
ligands that directly induce CYP3A4 expression in vivo include phenobarbitol, 
phenytoin, and rifampin.   
In addition to CYP3A4, PXR ligands induce transporters (P-gp, MRP2, and 
BSEP) and other CYP proteins (CYP2C8, CYP2C9, and CYP3A5).83  The fold 
induction of CYP3A5 is generally reported to be less than that of CYP3A4 in vitro.  For 
example, in human hepatocytes cultures, 1 mM phenobarbital induced CYP3A4 mRNA 
200-fold but CYP3A5 mRNA only 10-fold.84  Although the CYP3A5 promoter contains 
an identical ER6 motif to the CYP3A4 promoter, the DR3 site is not present.84  As a 
result, even though CYP3A5 can be induced by PXR ligands, in a population potentially 
exposed to PXR ligands, the CYP3A5 protein content may vary less between 
individuals than that of CYP3A4 because CYP3A5 is less inducible.  In support of this 
hypothesis, the CYP3A5 protein content in human liver microsome banks is typically 
less variable than the CYP3A4 protein content (22 to 164 pmol 3A5/mg vs. 5 to 187 
pmol 3A4/mg).81 
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In some instances, the induction of CYP3A5 by nuclear receptor ligands may be 
equivalent or higher than the induction of CYP3A4.  For example, CYP3A5 
transcriptional regulation by PXR in hepatocytes may be different from the regulation of 
CYP3A5 in the intestines.  In vivo studies before and after rifampin treatment quantified 
the fold changes in intestinal CYP3A4 and CYP3A5 mRNA; for each subject, the fold 
increase in CYP3A5 mRNA was equivalent or higher than that of CYP3A4 mRNA.84  
Also, unlike the CYP3A4 promoter, the CYP3A5 promoter contains two glucocorticoid 
response elements and directly responds to GR activation.84  Therefore, as compared to 
an indirect induction of CYP3A4 by glucocorticoids, the expression of CYP3A5 may be 
more responsive.  Finally, the regulation of CYP3A4 is not significant for many extra-
hepatic tissues, such as the prostate and kidneys, because CYP3A5 is the primary 
CYP3A enzyme expressed.85   
For individuals with the CYP3A5*1 allele, CYP3A5 can represent more than 
50% of the total CYP3A content in human liver microsomes.71  The CYP3A5 protein 
contents for individuals with at least one CYP3A5*1 allele are not consistent between 
microsomal liver banks; Westlind-Johnsson, et al. (2003)80 estimated that CYP3A5 was 
13 to 27% of the total CYP3A, whereas Lin, et al. (2002)81 estimated a 40 to 80% 
contribution.  A meta-analysis was recently published of all reported CYP3A4 and 
CYP3A5 contents for human liver microsomal banks (n = 45 for CYP3A5 high 
expressers, Caucasian livers).86  In this report, regardless of the type of CYP3A standard 
used for immunoquantification, the mean contribution of CYP3A5 was approximately 
40% of the total CYP3A protein.  Thus, for CYP3A5 high expressers, the CYP3A5 
protein is a substantial fraction of the total CYP3A protein.  
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4. Inhibition         
CYP3A4 and CYP3A5 enzyme activities can be inhibited by a variety of clinically 
important drugs including macrolide antibiotics, HIV protease inhibitors, and 
antifungals.  Many clinically relevant drug-drug interactions occur by mechanism-based 
inactivation of the CYP3A protein; this inhibition is persistent because the protein is 
irreversibly modified.87  Alternatively, competitive inhibitors such as itraconazole 
continue to inhibit CYP3A enzymes for many days after the parent drug is eliminated 
from the plasma; the inhibition is likely caused by metabolites with long terminal half-
lives.  Interestingly, for most CYP3A inhibitors, regardless of the type of inhibition, 
CYP3A4 is more susceptible to inhibition than CYP3A5.88-91  As a consequence, for 
individuals with high CYP3A5 expression, drug/drug interactions with CYP3A 
substrates can be less pronounced.  For one clinical study with coadministration of 
itraconazole and clopidogrel, a protective effect on platelet aggregation was described 
for individuals with high CYP3A5 expression.92  Likewise, after itraconazole 
administration, the midazolam clearance was less inhibited for individuals with high 
CYP3A5 expression (60 vs. 70% reduction in clearance with low CYP3A5 
expression).93  Similar clinical results were reported for verapamil, a calcium channel 
blocker that inhibits its own metabolism by CYP3A4 mechanism-based inactivation.89  
In this case, the verapamil oral clearances of patients with high CYP3A5 expression 
were on average 2-fold higher than the clearances of patients with low CYP3A5 
expression.94   
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5. Roles of CYP3A4 and CYP3A5 in Drug Disposition 
cDNA-expressed enzymes are routinely utilized to evaluate the selectivity of a substrate 
for CYP3A4 and CYP3A5.  Because CYP3A4 and CYP3A5 have overlapping but not 
identical specificities for CYP3A substrates, the CYP3A5 contribution to metabolism is 
highly substrate dependent.  For most tested substrates, the CYP3A5 intrinsic clearances 
are similar to or less than those of CYP3A4.71,88,95,96  For example, the intrinsic 
clearances of tacrolimus with recombinant CYP3A4 and CYP3A5 were similar with less 
than a 2-fold selectivity for CYP3A5.97  Some studies with midazolam showed a modest 
selectivity (3-fold) for CYP3A5;71 in other studies with midazolam, the CYP3A5 
activity was equivalent or less than that of CYP3A4.95,96,98   
Because most CYP3A substrates are metabolized by both CYP3A4 and 
CYP3A5, the exact contribution of CYP3A5 to the metabolism of a CYP3A substrate is 
difficult to determine when both enzymes are present, as with HLMs.  The role of 
CYP3A5 in the metabolism of CYP3A substrates can be evaluated using pairs of HLMs 
with similar CYP3A4 protein content but different CYP3A5 expression.71  The pairing 
of liver samples by CYP3A4 content assumes that the CYP3A4 protein measured by 
Western blot is enzymatically equal for all HLMs.  A highly selective CYP3A4 activity 
probe, such as itraconazole, can also be used to normalize the activities of CYP3A test 
substrates.71  For this type of analysis, statistical differences of the normalized activities 
between high and low CYP3A5-expressing groups can be calculated.  However, this 
technique cannot quantify the contribution of CYP3A5 of individual livers at different 
expression levels of CYP3A4.  Nevertheless, for studies that utilized these approaches 
with various CYP3A substrates, up to 30 to 40% of the CYP3A metabolism was 
 21
attributed to CYP3A5 activity in high expressers.71,99  If most substrates are equally 
selective for CYP3A4 and CYP3A5, this percent contribution is consistent with the 
CYP3A5 protein expression in the liver (~40% of the CYP3A).86   
Because CYP3A5 intrinsic clearances are typically lower than or equal to those 
of CYP3A4, some investigators have proposed that CYP3A5 is not clinically significant 
in drug disposition.80  The clinical studies that evaluate the impact of CYP3A5 genotype 
on drug disposition are confounded by the variability in CYP3A4 expression and often 
show substrate dependence.  The best studied CYP3A substrates in vivo are midazolam 
and tacrolimus.  For clinical studies with midazolam, a common CYP3A in vivo probe, 
the clearance was increased for CYP3A5*1 carriers93,100 while other studies did not find 
a statistical difference between the CYP3A5 genotypes.82,101  In contrast, as reported by 
more than 20 clinical studies, the oral clearances (a function of systemic clearance and 
bioavailability) of the immunosuppressant tacrolimus were consistently a function of 
CYP3A5 genotype.102  To maintain therapeutic concentrations, the dosage requirements 
of CYP3A5 high expressers were approximately 25 to 45% higher than those of low 
expressers.102  Because tacrolimus is an orally administered drug, CYP3A5 expression 
in the gut wall may have reduced the bioavailability and thus contributed to the 
increased dose requirements for CYP3A5 high expressers.  However, as shown by two 
clinical studies of liver transplant patients, hepatic CYP3A5 at least in part contributes 
to the tacrolimus systemic clearance.  For these studies, the majority of the variability in 
tacrolimus dosing one month post-transplantation was accounted for by the CYP3A5 
genotype of the donor liver, not the recipient CYP3A5 genotype; the tacrolimus blood 
concentration/dose ratios were 30 to 60% higher for recipients of CYP3A5*3/*3 donor 
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livers.103,104  Thus, the reduced bioavailability caused by CYP3A5 expression in the gut 
wall may be less important to tacrolimus disposition than the effect of CYP3A5 
expression in the liver.     
6. CYP3A-mediated Metabolism of Vincristine 
The CYP-mediated metabolism of vincristine has not been evaluated thoroughly using 
in vitro models.16  Based on data from clinical and in vitro studies, CYP3A enzymes are 
hypothesized to metabolize vincristine.  Consistent with CYP3A metabolism, numerous 
clinical drug-drug interactions were reported between vincristine and CYP3A inhibitors 
or inducers including itraconazole, nifedipine, and carbamazepine.28,29,55,105  In addition, 
the role of CYP3A in the metabolism of vincristine is consistent with other Vinca 
alkaloids: vindesine and vinblastine.  In studies with these Vinca alkaloids and human 
liver microsomes, CYP3A was the major CYP enzyme responsible for the formation of 
one major metabolite.106,107  The rates of metabolite formation from vindesine and 
vinblastine were selectively inhibited by CYP3A chemical inhibitors: ketoconazole, 
troeandomycin, and erythromycin.106,107  Vincristine was also a chemical inhibitor of 
metabolite formation; thus vincristine, like vinblastine and vindesine, may be a substrate 
of CYP3A enzymes.106,107  Using fresh human hepatocytes, vincristine, vindesine, and 
vinblastine were transformed to four unknown compounds, presumably metabolites.10  
Unfortunately, experiments were not performed to conclusively determine the 
mechanisms of formation; for example, incubations without cells or with a chemical 
CYP inhibitor were not presented.  In a different in vitro study, using Chinese hamster 
ovary cell lines, vincristine and vinblastine were less toxic for cells with CYP3A4 
overexpression.108  These results support the hypothesis that vincristine is a substrate of 
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CYP3A4.  However, the complete biotransformation pathways and enzyme kinetics of 
vincristine are not reported in the literature.109  The relative roles of CYP3A4, CYP3A5, 
or any other currently unidentified enzyme in the metabolism of vincristine are 
unknown.   
Based on evidence of interracial differences in clinical outcomes with vincristine 
therapy, we hypothesized that expression of the genetically polymorphic enzyme 
CYP3A5 increases the rate of metabolism and ultimately systemic clearance.  Thus, for 
individuals with high CYP3A5 expression, CYP3A5 is a major drug metabolizing 
enzyme.  To understand the roles of CYP3A4 and CYP3A5 in the metabolism of 
vincristine, we studied the biotransformation of vincristine using various in vitro 
metabolism models: cDNA-expressed CYPs, human liver microsomes, and human 
cryopreserved hepatocytes.  In addition, to understand the role of CYP3A5 genotype in 
clearance, we developed a sensitive assay to quantify therapeutic concentrations of 
vincristine and the major CYP3A metabolite of vincristine in human plasma.   
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II. Materials 
Amersham Biosciences [G-3H] vincristine sulfate (3.30 Ci/mmol) 
(Buckinghamshire, UK) 
 
Baxter (Deerfield, IL) cyclophosphamide  
 
Bedford Labs (Bedford, OH) methotrexate  
 
Bio-Rad Laboratories acrylamide 
(Hercules, CA) ammonium persulfate (APS) 
 bisacrylamide 
 2-mercaptoethanol 
 nitrocellulose (0.5 µm) 
 SDS 
 TEMED 
 
BioWhittaker hepatocyte maintenance media, cat CC3197 
(Walkersville, MD) 
 
BD Gentest Corporation “Supersomes” cDNA-expressed CYPs co- 
(Woburn, MA) expressed with or without CYP-reductase and 
cytochrome b5 
 (CYPs 1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 
2D6, 
 2E1, 2J2, 3A1, 3A2, 3A4, 3A5, 3A7, and 4A11) 
 insect cell control microsomes 
 WB-3A4  
 WB-3A5 
 WB-MAB-3A 
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CellzDirect cryopreserved hepatocytes  
(Pittsboro, NC) (Lot numbers: SD012, SD017, Hu418, Hu4008) 
Celsis In Vitro Technologies cryopreserved hepatocytes  
(Baltimore, MD) (Lot numbers: AIT, CHD, EHI, FKM, MRS, REL, 
RML, SCA, ZIJ, ZYZ) 
 hepatocyte thawing media, cat Z990006 
 
Eli Lilly and Co. LSN335984 
(Indianapolis, IN) 
 
Enzon Pharmaceuticals PEG-L-asparaginase  
(Bridgewater, NJ) 
 
Janssen Pharmaceuticals  hydroxyitraconazole (OH-ITZ) 
(Beerse, Belgium) methoxyitraconazole (MeO-ITZ) 
 
MetaChem Technologies Inc. C18 column Inertsil ODS3, 3.0 x 150 mm, 5-µm 
(Torrance, CA) particle size 
 
Millipore Centrifree YM-30 
(Bedford, MA) 
 
Ovation Pharmaceuticals dactinomycin 
(Deerfield, IL) 
 
PanVera Corporation cytochrome b5  
(Madison, WI)  
 
Phenomenex  C18 column, Luna, 4.6 x 150 mm, 5-µm  
(Torrance, CA) particle size 
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Sigma Chemical Co. 5-bromo-4-chloro-3-indoylphosphate 
(St. Louis, MO) coumarin  
 diethyldithiocarbamic acid (DDC)  
 DMSO 
 furafylline 
 glycine 
 6β-hydroxytestosterone 
 itraconazole (ITZ) 
 ketoconazole (KCZ)  
 N-desmethyl diazepam (DMDZ)  
 NADPH  
 nitrotetrazolium blue chloride 
 omeprazole 
 orphenadrine citrate 
 peroxidase, type VI 
 pyronin Y 
 quinidine 
 ScintiVerse 
 sulfaphenazole 
 testosterone (TST) 
 tris base 
 tween-20 
 vinblastine sulfate (VLB) 
 vincristine sulfate (VCR) 
 vinorelbine ditartrate (VRL) 
 
XenoTech cryopreserved hepatocytes 
(Lenexa, KS) (Lot number 652) 
 
All other reagents were of HPLC grade and were purchased from Fisher Scientific 
(Pittsburgh, PA). 
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III. Methods 
A. Vincristine Incubations with cDNA-expressed CYP Enzymes  
1. Human Enzyme Panel 
VCR (5 µM) was pre-incubated with CYPs 1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 
2E1, 2J2, 3A4, 3A5, 3A7, and 4A11 (50 pmol of CYP for CYPs 2A6, 2C8, and 2E1; 25 
pmol for remaining CYPs) and insect cell microsomes (control; matched protein content 
to highest CYP) in a suitable buffer (final volume 250 µL) at 37°C.  The insect cell 
microsomes were utilized to account for any endogenous CYP activity.  P450 reductase 
was co-expressed with all CYPs, and cytochrome b5 was co-expressed with CYPs 2J2, 
2E1, and 3A7.  Although CYPs 3A4 and 3A5 were also available with co-expressed 
cytochrome b5, the enzymes without cytochrome b5 were utilized to determine the 
relative CYP activity as a worst case.  In accord with the recommendation of the 
manufacturer, CYPs 2A6, 2C9, and 4A11 incubations were performed in 100 mM Tris 
buffer with 5 mM MgCl2, pH 7.4 at 37°C and the remaining incubations in buffer (100 
mM Na2HPO4 with 5 mM MgCl2, pH 7.4).  The reactions were initiated with the 
addition of NADPH (0.5 mM).  After 1 h, the incubations were quenched with an equal 
volume of acetonitrile, chilled, and centrifuged.  All incubations with the CYP enzymes 
were performed in duplicate with the duplicates split by at least three other incubations.  
The first and last incubations were controls, and the remaining two controls were 
inserted evenly between CYP incubations.  The supernatants were directly assayed by 
HPLC with UV detection.  Statistical significance (p < 0.05) was determined using one-
way ANOVA for multiple comparisons. 
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2. Rat CYP3A1 and CYP3A2 
cDNA-expressed rat CYP3A1 or CYP3A2 with co-expressed P450 reductase and 
cytochrome b5 (100 pmol/mL) was pre-incubated with VCR (40 µM) and buffer (100 
mM Na2HPO4 with 5 mM MgCl2, pH 7.4).  NADPH (0.5 mM) was added to start the 
reaction.  After 30 min, the incubation was quenched with an equal volume of 
acetonitrile and frozen at -80°C until analysis by HPLC.  
3. Inhibition of CYP3A4 Activity with Vincristine and Vinblastine 
VCR (0, 10, 20, or 40 µM) and VLB (0, 2.5, 5, or 10 µM) were coincubated in buffer 
(100 mM Na2HPO4 with 5 mM MgCl2, pH 7.4) with cDNA-expressed CYP3A4 with 
co-expressed cytochrome b5 (50 pmol/mL).  NADPH (0.5 mM) was added to start the 
reaction.  The incubations were quenched after 15 min with an equal volume of 
acetonitrile and frozen at -80°C until analysis by HPLC.  All possible combinations of 
VCR and VLB concentrations were used, except the zero/zero, for a total of 15 
incubations.  For each drug combination, the rates of formation were quantified for M1 
from VCR and for the equivalent M1 compound from VLB.  The identical experiments 
were also performed using cDNA-expressed CYP3A5 with co-expressed cytochrome b5 
(50 pmol/mL) and an incubation time of 3 min.   
4. Inhibition of CYP3A4 and CYP3A5 Activity with Cyclosporin A 
VCR (10 µM) in buffer (100 mM Na2HPO4 with 5 mM MgCl2, pH 7.4) was co-
incubated at 37°C with cyclosporin A (CsA, 10 µM) and enzyme (CYP3A4 or CYP3A5 
with co-expressed cytochrome b5, 48 pmol/mL).  The final concentration of methanol 
was approximately 2.4% (v/v).  This concentration was initially chosen because organic 
concentrations up to 4% (v/v) with cyclosporin A were previously reported.110  The 
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vehicle controls without CsA contained an equivalent amount of methanol.  The 
incubations were quenched with an equal volume of acetonitrile after 15 min for 
CYP3A4 reactions and 3 min for CYP3A5 reactions.  The rates of M1 formation were 
quantified by HPLC.   
For other incubations, VCR was co-incubated with multiple concentrations of 
CsA (0.4 to 25 µM) at a reduced methanol concentration (0% or 0.3%, v/v).  For 
incubations without methanol, the CsA in methanol was evaporated to dryness.  The 
residue was dissolved in buffer (100 mM Na2HPO4 with 5 mM MgCl2, pH 7.4) with 
VCR (20 µM) prior to addition of the enzyme (CYP3A4 or CYP3A5 without 
cytochrome b5, 50 pmol/mL).  The quench times were 15 min for CYP3A4 reactions 
and 3 min for CYP3A5 reactions.  For incubations at 0.3% methanol, CsA in methanol 
was added directly to the buffer (100 mM Na2HPO4 with 5 mM MgCl2, pH 7.4) and 
VCR at 37°C.  The enzyme (30 pmol/mL) and finally NADPH (0.5 mM) were added for 
a total volume of 667 µL, and the incubations were quenched with an equal volume of 
acetonitrile after 15 min.  VRL was used as an internal standard.  The vehicle controls 
contained 0.3% methanol but no CsA, and the negative controls lacked NADPH.  The 
fraction of activity not inhibited by CsA (f) and the inhibition dissociation constant (Ki) 
were estimated using a modified competitive inhibition Michaelis-Menten equation: 
Eqn. 1 
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The maximum rates of M1 formation (Vmax) were determined from the positive control, 
and the Km values were determined from incubations without inhibitors.  The substrate  
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concentration (S) was a constant, 20 µM, and the inhibitor concentration (I) was the 
concentration of CsA.   
5. Radiolabeled Vincristine 
3H-vincristine sulfate combined with unlabeled vincristine sulfate was purified by 
HPLC.  The fractions containing purified VCR as determined by retention time were 
evaporated to dryness at room temperature.  VCR at approximately 10 µM (2 x 106 dpm 
per incubation) was incubated with CYP3A4 with co-expressed cytochrome b5 (12.5 
pmol), CYP3A5 with co-expressed cytochrome b5 (25 pmol), and control insect 
microsomes (matched by CYP3A5 protein content) at a final volume of 250 µL for 15 
min.  The incubations were quenched with an equal volume of acetonitrile and frozen at 
-80°C until analysis by HPLC and scintillation counting. 
6. Kinetics of M1 Formation using CYP3A4 and CYP3A5 
To reduce the VCR-related impurities in the commercially available drug, vincristine 
sulfate was purified prior to use by HPLC.  For the HPLC fractions, a standard curve 
was used with VRL as an internal standard to quantify the concentration of VCR.  Just 
prior to use, the fractions containing purified VCR were evaporated to dryness at room 
temperature.   
To determine the Michaelis-Menten parameters for CYP3A4 and CYP3A5, 
VCR (1 to 45 µM) in buffer (100 mM Na2HPO4 with 5 mM MgCl2, pH 7.4) was pre-
incubated for 3 min with the appropriate CYP enzyme.  The reaction was initiated with 
the addition of NADPH (0.5 mM).  After a set incubation time, the incubation was 
quenched with an equal volume of acetonitrile, chilled, and centrifuged.  (For 
preliminary experiments, the quench and HPLC conditions are described in Methods, 
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pg. 31).  The supernatant (25 or 50 µL) diluted with an equal volume of 0.2% formic 
acid was directly assayed by HPLC.  The Michaelis-Menten parameters of CYP3A4 and 
CYP3A5 were estimated with enzyme preparations containing cDNA-expressed enzyme 
alone, with co-expressed cytochrome b5, and with supplemented cytochrome b5 
(PanVera Corp., Madison, WI) at a molar ratio of 3:1 immediately preceding the 
incubations.  For CYP3A4 and CYP3A5, the enzyme alone and the enzyme 
supplemented with cytochrome b5 were tested during the same experiment.  This design 
minimized the variability potentially caused by enzyme lot number or thaw cycle.  The 
incubation conditions for CYP3A4 (25 or 50 pmol, 15 min, 500 µL incubation) and 
CYP3A5 (25 pmol, 3 min, 500 µL incubation) reactions were optimized based on the 
HPLC assay limits of quantification and linear conditions.  To determine linearity, CYP 
concentrations and incubation times were varied, and the conditions were selected in 
which less than 15% of the parent drug was metabolized.  Microsomes without cDNA-
expressed CYPs (insect cell control Supersomes) were utilized as negative controls.   
The Michaelis-Menten constants (Km) and maximal rates of metabolism (Vmax) 
were estimated by fitting the data to a one-enzyme model using non-linear least square 
regression analysis (WinNonlin 4.0, Pharsight, Mountain View, CA).   
B. Quantification of Metabolite Formation and Vincristine Depletion by HPLC 
1. Base Extraction and Neutral pH Eluent 
The VCR incubation was quenched with ethyl acetate (3 volumes) and 5 N sodium 
hydroxide (10% by volume).  The organic layer was removed and evaporated at room 
temperature using a rotary evaporator, and the residue was dissolved in mobile phase A 
(defined below).  Separation of VCR and other compounds including M3 was achieved 
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using a Waters 600E HPLC system (Milford, MA) and a C18 column (Luna, 4.6 x 150 
mm, 5-µm particle size; Phenomenex, Torrance, CA) at a flow rate of 1 mL/min with 
UV detection at 254 nm.  The mobile phase consisted of 11 mM sodium phosphate, pH 
7.4: methanol (80:20, v/v, mobile phase A) and 11 mM sodium phosphate, pH 7.4: 
methanol (20:80, v/v, mobile phase B).  Starting at 0% B, the gradient conditions were 
as follows: 0–1 min 0% B, 1–5 min linear increase to 70% B, 5–30 min linear increase 
to 100% B, 30–35 min 100% B, 35–36 min linear decrease to 0% B, and 36–40 min 0% 
B.  For experiments designed to identify unknown peaks that were collected using the 
formic acid chromatography (below), the gradient conditions were optimized for 
separation of M3 from VCR: 0–3 min 66% B, 3–23 min linear increase to 80% B, 23–
28 min linear increase to 100% B, 28–42 min 100% B, and 42–50 min 66% B.    
2. Acidic pH Eluent 
Unless otherwise stated, the following procedure was routinely used to quantify and 
purify VCR and M1 by HPLC.  The VCR incubations with cDNA-expressed enzymes 
or human liver microsomes were quenched with an equal volume of acetonitrile and 
stored at -80°C.  The thawed samples were vortexed and centrifuged at 1800 g to 
remove any precipitate.  A 60 µL aliquot of the supernatant was diluted with an equal 
volume of 0.2% formic acid, and 100 µL of the solution was injected on the column.  
Chromatographic separation of M1, M2, VCR, and VRL (internal standard) was 
achieved with a C18 column (Inertsil ODS3, 3.0 x 150 mm, 5-µm particle size; 
MetaChem Technologies Inc., Torrance, CA) at a flow rate of 0.4 mL/min.  The HPLC 
system was an Agilent 1100 Series (Wilmington, DE) with a Hewlett Packard 1050 
Series UV detector (Wilmington, DE).  The mobile phase consisted of 0.2% formic acid 
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(mobile phase A) and methanol (mobile phase B).  The analytes were eluted using the 
following gradient conditions: 0–7 min 20% B, 7–42 min linear increase to 56% B, and 
42–52 min 80% B.  The parent drug and metabolites were detected by ultraviolet 
absorbance at a wavelength of 254 nm.   
For quantification of the radiolabeled compounds, fractions of the eluent were 
collected in 20-second aliquots.  The radioactivity of each fraction was determined by 
liquid scintillation counting (LS3801 scintillation counter; Beckman, Fullerton, CA) 
with 5 mL of scintillation cocktail (ScintiVerse; Fisher Scientific Co., Fair Lawn, NJ).  
Prior to counting, the counting efficiency of scintillation counter was calibrated to the 
quench level using eight tritiated solutions with various degrees of quench.  For product 
samples, the counting efficiencies were interpolated from the quench curve with typical 
values between 40 and 60%.  The target total radioactivity of triated compounds 
separated by HPLC was typically 500,000 dpm.  The unknown eluent aliquots were 
counted for 30 min or less to achieve final counts with 0.5 to 20% coefficients of 
variation.     
To allow quantification of M1 by UV detection using a VCR standard curve, the 
extinction coefficients of M1 and VCR were determined by synthesizing M1 from 
radiolabeled VCR.  The radiolabeled M1 and VCR were injected simultaneously on the 
HPLC column.  The eluent fractions for both compounds were collected for scintillation 
counting.  The ratios of the UV area and the radioactive counts (converted to dpm) of 
each peak were used to calculate the relative extinction coefficients of the compounds.  
Injections were performed in triplicate.  The relative extinction coefficients of M1 and 
VCR were not significantly different (p = 0.78).       
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C. Preparation of Metabolites and Derivatives for Structural Identification 
1. M1 and M1-acetate   
VCR (30 µM) was pre-incubated with cDNA-expressed CYP3A5 (100 pmol) and buffer 
(100 mM Na2HPO4 with 5 mM MgCl2, pH 7.4, total volume 1 mL).  The reaction was 
started with the addition of NADPH (0.5 mM).  After 40 min, the incubation was 
extracted with methylene chloride (1 mL).  The organic extract was evaporated at room 
temperature, and M1 was isolated by HPLC.  The M1 eluent fractions were extracted 
with methylene chloride (6 mL), and the solvent was evaporated at room temperature to 
yield M1.  M1-acetate was prepared by mixing M1 and 100 µL of acetic anhydride at 
room temperature.  After 30 min, the reaction was quenched with 200 µL of water and 
extracted with methylene chloride (3 x 1 mL).  The organic extract was dried and 
reconstituted in the HPLC mobile phase prior to LC/MS/MS analysis. 
2. M2 with Peroxidase 
Large quantities of M2 were prepared by the oxidation of VCR by horseradish 
peroxidase (HRP) and hydrogen peroxide, a procedure previously described9 with slight 
modifications.  Briefly, vincristine sulfate (1.5 mg) was dissolved in 7 mL of buffer (100 
mM Na2HPO4, pH 7.4) at 37°C.  A solution of HRP (1.2 mg), 100 mM Na2HPO4 buffer 
at pH 7.4 (350 µL), and hydrogen peroxide (125 µL, final reaction concentration 0.4 
mM) was added to the VCR solution and incubated at 37°C in a shaking water bath for 
2 h.  The final mixture was extracted with methylene chloride (6 mL), and the organic 
extract was dried at room temperature.  The residue was purified by HPLC, and the 
eluent fractions were dried to yield M2 (0.5 mg). 
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3. M3 
VCR (30 µM) was pre-incubated with cDNA-expressed CYP3A5 (100 pmol) and buffer 
(100 mM Na2HPO4 with 5 mM MgCl2, pH 7.4, total volume 1 mL).  The reaction was 
initiated with the addition of NADPH (0.5 mM).  After 40 min, the incubation was 
quenched with ethyl acetate (0.5 mL) and 5 N NaOH (100 µL) to promote the base 
rearrangement of M1.  Additional ethyl acetate (3 mL) was added, and the organic layer 
was evaporated.  The resulting residue was purified by HPLC to yield M3.   
The product M3 was also prepared directly from HPLC eluent fractions 
containing purified M1.  The fractions (50% of the available volume) were evaporated 
at room temperature, and the residue was dissolved in water (1 mL) and 5 N NaOH (20 
µL).  The solution was extracted with ethyl acetate (1 mL), and the organic layer was 
evaporated at room temperature to yield M3.  The residue was dissolved in mobile phase 
for direct HPLC injection.  For the control experiment, the purified HPLC fractions with 
M1 (the remaining 50%) were evaporated, and the residue was dissolved in mobile 
phase for HPLC analysis.  
D. Structural Determination of Vincristine Metabolites 
1. LC/MS Analysis 
LC/MS analysis for all non-radiolabeled compounds was performed on a Shimadzu VP 
Series HPLC (Shimadzu Scientific Instruments Inc., Columbia, MD) interfaced with 
either a triple quadrupole or ion trap mass spectrometer (TSQ Quantum or LTQ mass 
spectrometer, Thermo Electron Corporation, Waltham, MA).  The analytes were 
separated on a C18 column (Inertsil ODS-3, 2.1 x 150 mm, 5-µm particle size; 
MetaChem Technologies, Inc.) at a flow rate of 0.2 mL/min.  The mobile phase 
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consisted of 0.2% formic acid (mobile phase A) and methanol (mobile phase B).  The 
analytes were eluted using the following gradient conditions: 0–3 min 20% B, 3–28 min 
linear increase to 50% B, 28–45 min linear increase to 80% B, and 45–50 min 80% B.  
Full scan mass spectra were obtained between 150 to 1050 Da.  Positive ion MS/MS 
was conducted for the ions of interest using argon as the collision gas at 1.5 mTorr and 
the collision energy of -40 volts.  Accurate mass measurements were performed using a 
Waters Micromass Q-TOF II quadrupole/orthogonal time-of-flight mass spectrometer 
(Waters Corporation, Milford, MA).  The protonated ion (m/z 311.0814) of 
sulfadimethoxine (Sigma-Aldrich, St. Louis, MO) was used as the lock mass in all 
accurate mass determinations.  
2. NMR Analysis 
NMR spectra were acquired on an Inova 500 MHz NMR system equipped with either a 
5 mm cold triple-resonance probe or a 3 mm IFC indirect detection probe (Varian Inc., 
Palo Alto, CA).  Compounds were dissolved in either CD3OD or DMSO-d6, transferred 
to a 3 mm NMR tube, and sealed prior to NMR analysis.  Proton and carbon chemical 
shifts were referenced to the residual solvent signals at 3.3 and 49 ppm, respectively, in 
CD3OD and at 2.49 and 39.5 ppm, respectively, in DMSO-d6.  Two-dimensional NMR 
experiments were performed using Varian standard pulse sequences.111  
E. Preparation of Human Liver Microsomes 
Human liver microsomes (HLMs, n = 56) were prepared from human liver tissues from 
the Clinical Pharmacology Liver Bank at Indiana University as described previously.112  
Protein concentrations of the HLMs were determined using the Lowry method.113   
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F. CYP3A4 and CYP3A5 Characterization for Human Liver Microsomes 
1. Testosterone 6β-Hydroxylation 
Testosterone in methanol was added to incubation buffer (100 mM Na2HPO4 with 5 
mM MgCl2, pH 7.4) for a final concentration of 200 µM (0.3% methanol, v/v).  
Microsomal enzyme (0.1 mg/mL) was pre-incubated at 37°C for 3 min, and the reaction 
was initiated with NADPH (1 mM) for a total volume of 1 mL.  Incubations without 
NADPH were utilized as negative controls.  After 10 minutes, the reactions were 
quenched with an equal volume of chilled ethyl acetate and extracted with an additional 
4 mL of ethyl acetate.  DMDZ was used as an internal standard.  The solvent was 
evaporated at room temperature, and the residue was reconstituted in the HPLC mobile 
phase, 20 mM ammonium acetate (pH 6.4)/methanol (40:60, v/v).  Chromatographic 
separation of 6β-hydroxytestosterone from testosterone and other related metabolites 
was performed on a C18 column (Luna, 4.6 x 150 mm, 5-µm particle size; Phenomenex, 
Torrance, CA) at a flow rate of 1 mL/min with UV detection at 254 nm.  The limit of 
quantification for 6β-hydroxytestosterone was 330 pmol/mL.  Each HLM from the liver 
bank (n = 56) was incubated with testosterone in triplicate; the coefficients of variation 
for the replicates were on average <5 % with a maximum of 14%. 
2. Itraconazole Hydroxylation  
Itraconazole (ITZ) is hydroxylated by CYP3A4 on the methylene carbon of the 
secondary butyl side chain to form hydroxyitraconazole (OH-ITZ).34  ITZ was chosen as 
a substrate because its hydroxylation was reported to be CYP3A4 specific.34  To 
confirm these results, the hydroxylase activity at 200 nM ITZ was quantified for cDNA-
expressed CYP3A4 (10 pmol/mL, 2 min incubation) and CYP3A5 (100 pmol/mL, 15 
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min incubation) with co-expressed cytochrome b5; the results were compared to 
NADPH negative controls.  A higher protein concentration and longer incubation time 
were required for CYP3A5 because of its lower catalytic activity compared to CYP3A4.   
For HLM incubations, an ITZ stock solution was formulated; ITZ in methanol 
was added to incubation buffer (100 mM Na2HPO4 with 5 mM MgCl2, pH 7.4) for a 
final concentration of 1 µM (0.2% methanol, v/v).  The entire ITZ stock solution was 
aliquoted to 9 tubes, the number of tubes required for one set of incubations.  The 
experiments were also performed at 500 nM ITZ using one ITZ stock solution for 
multiple sets of incubations (more than 30 tubes).  The microsomal enzymes (0.04 to 
0.10 mg/mL) were pre-incubated at 37°C with the ITZ stock solution for 3 min, and the 
reactions were initiated with NADPH (1 mM) for a total volume of 1 mL.  After 3 min, 
the reactions were quenched with an equal volume of ethyl acetate:hexane (50:50, v/v) 
and 5 N NaOH (40 µL).   A time of 3 min was chosen to ensure linear conditions 
because extended incubations cause the formation of secondary metabolites from ITZ as 
described previously.34  To estimate the Vmax, the ITZ concentrations were chosen higher 
than the reported apparent Km, 44 nM.34  The apparent Km for one representative HLM 
with CYP3A5 expression (IUL-49) was estimated in a separate experiment; IUL-49 
(0.074 mg/mL) was incubated with a range of ITZ concentrations (1000, 500, 250, 125, 
63, 31, and 16 nM) and NADPH (1 mM) in buffer (100 mM Na2HPO4 with 5 mM 
MgCl2, pH 7.4) at 37°C for 3 min.  For all experiments, incubations without NADPH 
were utilized as negative controls.  MeO-ITZ was added as an internal standard, and 
each incubation was extracted with an additional 3 mL of ethyl acetate:hexane (50:50, 
v/v).  After the organic layer was evaporated at room temperature, the residue was 
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reconstituted in the HPLC mobile phase, 5 mM ammonium acetate/acetonitrile (20:80, 
v/v).  Chromatographic separations of OH-ITZ were performed on a C18 column (Luna, 
4.6 x 150 mm, 5-µm particle size; Phenomenex, Torrance, CA) at a flow rate of 1 
mL/min.  Atmospheric pressure chemical ionization mass spectrometry (LC/APCI-MS, 
Finnigan Navigator; Thermo Electron Corporation, Waltham, MA) was used to monitor 
the following ions: m/z 721 (OH-ITZ), 705 (ITZ), and 733 (MeO-ITZ).  The limit of 
quantification for hydroxyitraconazole was 1.6 pmol/mL.  Select HLMs (n = 22) were 
incubated with ITZ in triplicate, and the coefficients of variation were on average <10% 
with a maximum of 18%.    
3. Quantification of CYP3A4 and CYP3A5 by Western Blot 
Immunodetectable CYP3A4 was quantified in select HLMs (n = 22) from the Clinical 
Pharmacology Liver Bank.  Purified CYP3A4 (14 nmol/mg protein; Invitrogen 
Corporation, Carlsbad, CA) was used as a standard.  CYP3A4 standards at 3 
concentrations (0.3 to 1.2 pmol or 0.75 to 3.0 pmol) and protein from typically 4 
unknown HLMs were loaded on the same 15-lane gel (Trans-Blot cell, 16 x 20 cm, Bio-
Rad Laboratories, Hercules, CA).   All duplicate samples were separated by at least 3 
lanes, and lanes 1 and 15 were used for two of the six standards.  To account for matrix 
effects, IUL-39, a HLM preparation in which CYP3A4 could not be detected, was added 
to the standards to give approximately the same total protein content as the unknown 
samples.  Microsomal protein (20 to 50 µg) and the reference standards were diluted 
with an SDS and β-mercaptoethanol denaturing solution containing a dye (pyronin Y) to 
a final volume of 20 µl.  The diluted samples were heated for 5 min at 95 to 100°C and 
then loaded on a 0.1% SDS–9.6% polyacrylamide gel.  The proteins were separated by 
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electrophoresis at 44 mV for approximately 3 h until the dye migrated to the bottom of 
the gel.  The proteins were transferred to nitrocellulose over 5 h at 4°C using a constant 
current of 40 mA.  The membrane was soaked in blocking buffer (5% nonfat dry milk in 
phosphate buffered saline) for 1 h at room temperature and then incubated with a rabbit 
anti-CYP3A4 primary antibody (1:500, WB-3A4, Gentest, Woburn, MA) for 2 h.  After 
rinsing with phosphate buffered saline with 0.1% tween, the blot was incubated with a 
goat anti-rabbit secondary antibody (1:500, Gentest, Woburn, MA) for 1 h.  The 
membrane was rinsed with phosphate buffered saline with 0.1% tween and then 
developed using a 2% solution (m/v) of 5-bromo-4-chloro-3-indolyl phosphate in 
DMSO (125 µl) and a 0.002% solution (m/v) of nitro blue tetrazolium in 10 mM 
Tris/HCl, pH 9.5 (13 mL).  For all standard curves, the nitrocellulose was developed 
long enough to quantify the lowest standard concentrations but not too long to prevent 
saturation at the highest standard concentrations (typically 5 to 15 min).  For each gel, 
standards and unknown samples were assayed at least in duplicate and quantified by 
densitometry (Kodak 1D, Eastman Kodak, Rochester, NY).  The standard curve for each 
blot was fit by linear regression using the band intensities of the 6 standards; the 
linearity was maintained at the highest CYP3A4 concentrations.  The band intensities of 
the unknown HLMs were within the values of the high and low standards on the blot.  
The percent differences between unknown duplicates were less than or equal to 15%; for 
more than two values, the coefficient of variation was no more than 15%.  Similarly, the 
CYP3A5 content was determined for all high expressers of CYP3A5 (n = 10) in 
duplicate using a rabbit anti-CYP3A5 primary antibody (WB-3A5, Gentest, Woburn, 
MA) with 20 µg of loaded protein.  In an initial screening experiment, the CYP3A5 
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reference standard was chosen from three lots of CYP3A5 Supersomes without 
cytochrome b5 co-expression.  For each lot, equal amounts of CYP3A5 holoprotein per 
the manufacturer certificate of analysis were loaded on a gel, and the Supersomes lot 
with the weakest signal or the lowest concentration of apoprotein was chosen.  cDNA-
expressed CYP3A5 (lot 22), loaded with protein from IUL-52 (a HLM with no 
detectable CYP3A5), was used for the standard curves (0.23 to 1.2 pmol; 0.5 to 2.0 
pmol; or 1.0 to 3.0 pmol).  In addition, the CYP3A5 content at 150 µg of loaded protein 
was estimated for each of the CYP3A5*3/*3 HLMs.  For HLMs that did not express 
CYP3A5 contrary to their genotype, the HLMs (150 µg loaded protein) were assayed on 
at least two Western blots with other CYP3A5*3/*3 HLMs and at least one HLM with 
high CYP3A5 expression.  The purity of CYP3A5, lot 22, was directly compared to 
purified CYP3A4 utilizing a non-specific, monoclonal CYP3A antibody (WB-MAB-
3A, Gentest, Woburn, MA).  To generate a standard curve, multiple concentrations of 
CYP3A4 and CYP3A5 were loaded on the same gel (0.48 to 3.8 pmol CYP3A4 and 0.5 
to 8 pmol CYP3A5).  The slopes of the signal intensities for each CYP, excluding any 
signals that were saturated, were utilized to estimate the purity of CYP3A5.      
G. Vincristine Incubations with Human Liver Microsomes 
1. Kinetics of M1 Formation 
All HLMs with at least one CYP3A5*1 allele (n = 12) and select HLMs with 
CYP3A5*3/*3 genotype (n = 10) were used to determine the Michaelis-Menten 
parameters associated with M1 formation from VCR.  The HLMs with CYP3A5*3/*3 
genotype were chosen to include a range of CYP3A activities as determined by 
testosterone 6β-hydroxylation (700 to 11900 pmol/mg/min).  VCR (5, 10, 15, 25, 50, 
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and 100 µM) was dissolved in buffer (100 mM Na2HPO4 with 5 mM MgCl2, pH 7.4) 
and pre-incubated with select HLMs (0.7 to 3.0 mg/mL) at 37°C.  The reaction was 
initiated with the addition of NADPH (0.5 mM) for a final incubation volume of 250 
µL.  Incubations without NADPH were utilized as negative controls.  The incubations 
were quenched with an equal volume of acetonitrile, chilled, and centrifuged.  The 
supernatant (50 µL) diluted with an equal volume of 0.2% formic acid was directly 
assayed by HPLC.  For the chosen incubation times (4 to 20 min), the initial substrate 
concentrations were not reduced by more than 20%.  In addition, the incubation 
conditions for the HLMs were within the linear range for protein concentration and 
incubation time.  Prior to use, the vincristine sulfate starting material was not purified to 
remove an epoxide impurity (M5) that co-elutes with M1.  Even though M5 was 
included in the M1 integrated area, this impurity did not increase during incubations 
with or without NADPH (LC/MS/MS data not shown).  Thus, the epoxide content in the 
starting material was subtracted from the M1 area to calculate the final 
M1concentration.  The Michaelis-Menten constants, Km and Vmax, were determined by 
fitting the data to a one-enzyme model (WinNonlin 4.0, Pharsight, Mountain View, 
CA).  The 95% prediction intervals for CYP3A5 low expressers were calculated using 
SigmaPlot 8.0 (Systat Software, San Jose, CA).  The Vmax and Km values were estimated 
for each HLM with average coefficients of variation of 4.2% and 11.1%, respectively.   
2. Selective CYP Chemical Inhibition of M1 Formation 
Selective chemical inhibitors were used to quantify the contribution of human drug 
metabolizing CYPs to the formation of M1 from VCR using HLMs.114  Vinca alkaloids 
that are known CYP3A substrates, VLB and VRL, were used as additional positive 
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controls at concentrations demonstrated to inhibit VCR metabolism with cDNA-
expressed enzymes.16   HLMs (n = 3, low CYP3A5 expressers; n = 2, high CYP3A5 
expressers) were pooled by combining equal amounts of protein.  VCR, 15 µM, was 
incubated with furafylline (CYP1A2, 20 µM), coumarin (CYP2A6, 20 µM), 
orphenadrine (CYP2B6, 100 µM), sulfaphenazole (CYP2C9, 10 µM), omeprazole 
(CYP2C19, 10 µM), quinidine (CYP2D6, 5 µM), DDC (CYP2E1, 50 µM), 
ketoconazole (CYP3A, 1 µM), VLB (10 µM), and VRL (10 µM).  All chemical 
inhibitors were dissolved in methanol and evaporated to dryness.  For incubations with 
competitive inhibitors, pooled HLMs (2 mg/mL), VCR dissolved in buffer (100 mM 
Na2HPO4 with 5 mM MgCl2, pH 7.4), and NADPH (0.5 mM) were added at 37°C for a 
final volume of 250 µL.  The incubations were quenched with acetonitrile after 15 
minutes, and VRL (or VLB if an inhibitor co-eluted with VRL) was used as an internal 
standard.  VCR without inhibitor was used to determine the non-inhibited rate of M1 
formation.  For mechanism-based inhibitors (DDC, furafylline, and orphenadrine), the 
inhibitors were pre-incubated with the HLM pool (2 mg/mL) and NADPH (0.5 mM) for 
15 minutes prior to adding VCR (9.2 µL) in water for a total volume of 250 µL.  The 
reactions were then quenched after 15 min.  The HLM pool incubated without inhibitor 
was used as the control.  Sample preparation and HPLC/UV analysis of M1 were the 
same as described above for VCR metabolism.  No interfering peaks from the inhibitors 
were detected for M1. 
3. Cyclosporin A Inhibition of M1 Formation   
The rates of M1 formation were quantified for select HLMs (n = 12, CYP3A5 low 
expressers; n = 10, CYP3A5 high expressers) at one concentration of CsA.  VCR (10 
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µM) was incubated in buffer (100 mM Na2HPO4 with 5 mM MgCl2, pH 7.4) at 37°C 
with CsA (25 µM; 4.8% methanol, v/v).  Vehicle controls with 4.8% methanol were 
used without CsA.  The incubation time (4 to 20 min) and protein concentration (1.0 or 
2.0 mg/mL) were selected for each HLM; for these conditions, the initial VCR 
concentration was not reduced by more than 15%.  The incubations (250 µL) were 
initiated with NADPH (0.5 mM) and quenched with acetonitrile.  VRL was added as the 
internal standard.  The samples were frozen at -80°C until analysis by HPLC.           
Using two HLMs (IUL-59 and IUL-86), the rates of M1 formation were 
quantified with CsA at various concentrations (0, 0.5, 1, 2, 5, 10, 20, and 40 µM).  Prior 
to the incubations, the methanol from the CsA stock solution was evaporated in the 
incubations tubes.  To facilitate CsA dissolution, the microsomal protein (1.0 mg/mL) 
was added to the incubation tubes first.  All incubations were quenched with acetonitrile 
after 10 min.  The other incubation and quench conditions were identical to the 
screening experiments at 4.8% methanol (above).   
The rates of M1 formation were quantified at 20 µM VCR with HLMs (n = 3, 
CYP3A5 low expressers; n = 3, CYP3A5 high expressers) at different concentrations of 
CsA (0.4 to 25 µM, 0.3% methanol).  VCR in buffer (100 mM Na2HPO4 with 5 mM 
MgCl2, pH 7.4) was co-incubated at 37°C with CsA and microsomal enzyme (1.0 or 2.0 
mg/mL).  The incubations were initiated with NADPH (0.5 mM) in a total volume of 
667 µL and quenched with an equal volume of acetonitrile after 20 min.  The vehicle 
controls contained 0.3% methanol but no CsA; the negative controls lacked NADPH.  
The fraction of activity not inhibited by CsA (f) and the inhibition dissociation constant 
(Ki) was estimated using Eqn. 1.  The maximum rates of M1 formation (Vmax) were 
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determined from the positive control, and the Km values were determined from 
incubations without inhibitors.  The substrate concentration (S) was a constant, 20 µM, 
and the inhibitor concentration (I) was the concentration of CsA.  For IUL-79, because 
the model did not fit the data, the highest concentration of CsA was used to estimate the 
uninhibited fraction.  
4. Inhibition of M1 Formation by Methanol and Acetonitrile 
VCR (20 µM) and IUL-42 (1.2 mg/mL) were co-incubated in buffer (100 mM Na2HPO4 
with 5 mM MgCl2, pH 7.4 at 37°C) in the presence of methanol or acetonitrile (0, 0.25, 
0.5, 1, and 2%).  The incubations were initiated with NADPH (0.5 mM) in a total 
volume of 200 µL and quenched after 4 min.  VRL was added as an internal standard.  
The rates of M1 formation were quantified by HPLC.   
H. Binding of Vincristine 
1. Microsomal 
The fraction unbound of VCR with HLMs was quantified using ultrafiltration 
(Centrifree YM-30, Millipore, Bedford, MA).  Pooled HLMs (described by Methods, 
pg. 42) were assayed at 5 µM VCR in buffer (100 mM Na2HPO4 with 5 mM MgCl2, pH 
7.4) at 0.7, 1.2, 2.0, and 3.0 mg/mL of protein.  After the VCR solution was incubated at 
37°C for 30 minutes, 800 µL aliquots were added in triplicate to the filtration devices 
and the control tubes to determine initial concentrations.  For the chosen centrifugation 
conditions (37°C, 4 minutes, 1400 g), less than 15% of the total volume was filtered.  
VRL was the internal standard, and an equal volume of acetonitrile was used to 
precipitate protein.  VCR concentrations were quantified by HPLC.  The apparent 
fraction unbound (fu,app) was defined as the ratio of the unbound concentration in the 
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filtrate to the total concentration.  A partition approach assuming non-saturable binding 
of VCR to protein and the ultrafiltration apparatus115 was used to calculate the fraction 
unbound caused by non-specific binding to the ultrafiltration device (fu,nsb) and the 
fraction unbound (fu) at any protein concentration (Cp) using fu,app.  The binding 
parameter (K) and fu,nsb were estimated by non-linear regression (WinNonlin 4.0, 
Pharsight, Mountain View, CA) for the pooled HLMs using the following relationship:  
Eqn. 2 
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2. Plasma 
The fraction unbound of VCR was quantified using human plasma from three donors.  
The plasma samples with VCR (1 µM) were incubated at 37°C for 30 minutes.  For one 
donor, the plasma was diluted (1:1, 1:4, and 1:9) with phosphate buffered saline (0.14 M 
NaCl, 0.01 M Na2HPO4, pH 7.4).  As described previously with microsomes, the 
apparent fractions unbound (fu,app) were used to estimate the binding parameter (K) and 
the fraction unbound caused by the non-specific binding to the ultrafiltration apparatus 
(fu,nsb) by Eqn. 2.  For the plasma dilutions, the protein concentration (Cp) was expressed 
as a percentage of the plasma.  For all samples, VRL was used as an internal standard, 
and an equal volume of acetonitrile was used to precipitate protein.      
3. Whole Blood 
Freshly collected, heparinized whole blood (250 µL) was incubated at 37°C for 15 
minutes with HPLC purified 3H-VCR (100 nM final concentration, 1.0 x 104 dpm).  
After the samples were centrifuged for 5 min at 1800 g, aliquots of the supernatant (2 x 
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50 µL) were collected for scintillation counting (LS3801 scintillation counter; Beckman, 
Fullerton, CA).  For the control experiments, human plasma was used in place of whole 
blood.  The blood-to-plasma ratio (BPR) was calculated by dividing the dpm values 
from the controls by the dpm values from the whole blood.  All incubations were 
performed in duplicate.        
The partitioning of VCR and M1 in whole blood and plasma was also 
determined at high and low concentrations of drug at room temperature.  Freshly 
collected, heparinized blood (1.3 mL) was spiked with different volumes of VCR/M1 
stock solution (4.6/2.3 and 0.2/0.1 ng/mL final concentrations).  The samples were 
rocked at room temperature for 15 min and then held stationary for 15 min.  The whole 
blood samples were centrifuged for 10 min at 1800 g, and the plasma (0.5 mL) was 
aliquoted into polypropylene extraction tubes.  The plasma was stored at -80°C until 
extraction and quantification of VCR and M1 by LC/MS/MS.       
I. Incubations with Cryopreserved Human Hepatocytes 
1. Cell Preparation 
Cryopreserved human hepatocytes (Celcius In Vitro Techonologies, CellzDirect, or 
Xenotech) were rapidly thawed in a water bath at 37°C for 75 to 90 s.  The vials were 
emptied into pre-warmed hepatocyte thawing media and suspended by gentle inversion.  
To isolate the cells, the suspension was centrifuged at 50 g for 5 min at room 
temperature.  After the supernatant was removed, 2 mL of hepatocyte maintenance 
media (37°C, perfused with oxygen:CO2, 95:5) was added.  The cells were suspended 
by gently inverting the tube.  The viability of the cells was quantified using an 
automated viability analyzer (Vi-Cell, Beckman-Coulter, Fullerton, CA); the post-thaw  
 48
viability was more than 50%.  The cell suspension was diluted with hepatocyte 
maintenance media to target a concentration of 3.0 x 106 cells/mL.   
2. Vincristine and Testosterone Incubations   
For intact cell incubations with VCR, 50 µL of the cell suspension (150,000 cells/well) 
was added to an individual well of a 96-well flat bottom plate with 50 µL of VCR (4 
µM final concentration) in hepatocyte maintenance media.  In some wells, chemical 
inhibitors (ketoconazole, 10 µM; CsA, 20 µM; and LSN335984, 5 or 50 µM) were 
coincubated with VCR.  The plates were incubated in a humidified CO2 incubator with 
shaking for up to 4 h at 37°C.  Each well was quenched with 100 µL of 20 µM VRL 
(internal standard) in acetonitrile.  For certain wells, the cells were separated from the 
media by centrifugation at 50 g for 5 min prior to the quench.  In this case, an aliquot of 
the media after centrifugation was added to an equal volume of quench solution.  After 
the excess media was removed, the cell pellet was dissolved in 100 µL of quench 
solution.  Two additional negative control experiments were performed at each time 
point using the same 96-well flat bottom plates; VCR was incubated in media without 
cells, and the cell suspension was sonicated prior to mixing with VCR.  All solutions 
were stored at -80°C until analysis by LC/MS (Methods, pg. 51).  
Additional experiments were performed with sonicated cryopreserved 
hepatocytes supplemented with NADPH.  After the hepatocytes were counted and 
diluted to the target concentration as described in the previous section, the cells were 
centrifuged at 50 g for 5 min.  The media was removed and replaced with incubation 
buffer (100 mM Na2HPO4 with 5 mM MgCl2, pH 7.4).  The hepatocyte suspension was 
sonicated to create the “cell lysate.”   This cell preparation (50 µL) was added to 50 µL 
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of a VCR (4 µM final concentration) and NADPH (0.5 mM final concentration) solution 
in incubation buffer.  The solution was incubated for up to 2 h at 37°C in a shaking 
water bath and then quenched with 100 µL of 20 µM VRL (internal standard) in 
acetonitrile.  The samples were stored at -80°C prior to analysis by LC/MS. 
To quantify the CYP3A4 activity, testosterone (final concentration 200 µM, 
0.75% methanol) was added in methanol to the incubation buffer.  An appropriate 
volume of cell lysate was added to the testosterone solution (200 µL) with NADPH (1 
mM) for a pre-sonicated cell density of 0.3 x 106 cells/mL.  The suspension was 
incubated in a shaking water bath for 10 min, quenched with 200 µL of ethyl acetate, 
and stored at -80°C prior to analysis by HPLC as described in Methods, pg. 37, with 
slight modifications.  Because the incubation volume was only 200 µl, the 
chromatographic separation of the metabolites was achieved on a smaller diameter C18 
column (Inertsil ODS-3, 2.0 x 150 mm, 5-µm particle size; MetaChem Technologies, 
Inc) at an eluent flow rate of 0.2 mL/min. 
3. Michaelis-Menten Kinetics of M1 Formation 
For one lot of cryopreserved hepatocytes (EHI), the Michaelis-Menten kinetic 
parameters were estimated for intact cells and cell lysate (NADPH supplemented).  
VCR at approximately 100, 50, 25, 12.5, 6.3, and 3.1 µM was incubated with the 
appropriate cell preparation (1.5 x 106 cells/mL).  The incubations were quenched with 
20 µM VRL in acetonitrile after 90 min (intact cells) or 13 min (cell lysate).  The no cell 
controls or NADPH negative incubations were also performed at each concentration of 
VCR and quenched after 90 or 13 min, respectively.  The samples were stored at -80°C 
prior to HPLC analysis.   
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4. Radiolabeled Vincristine 
The HPLC eluent fractions of purified 3H-VCR (10 µCi) were divided between 
microcentrifuge tubes and evaporated to dryness at room temperature.  Except when 
noted, the conditions for the incubations with cryopreserved hepatocytes (Celcius In 
Vitro Technologies, lot EHI) were the same as described previously in Methods, pg. 48.  
3H-VCR (8 µM, approximately 1 x 107 dpm/tube, 50 µL final volume) was dissolved in 
media, transferred to individual wells in a 96-well plate, and incubated with intact cells 
or intact cells with ketoconazole (10 µM) for 4 h.  The 3H-VCR at the same 
concentration was also incubated with a cell lysate preparation in microsomal incubation 
buffer with and without NADPH for 30 min.  For the intact cell incubation without 
ketoconazole, the media and cells were separated by centrifugation, and 
radiochromatograms were generated from both fractions.  All incubations were 
quenched with an equal volume of acetonitrile and stored at -80°C prior to analysis.   
To generate radiochromatograms, the samples were thawed and centrifuged at 
1800 g for 10 min.  The supernatant was diluted with an equal volume of 0.2% formic 
acid and directly injected on a C18 column (Inertsil ODS-3, 3 x 150 mm, 5-µm particle 
size; MetaChem Technologies, Inc.).  Separation of analytes was achieved using 
gradient conditions previously described (Methods, pg. 35) at an eluent flow rate of 0.4 
mL/min.  The samples were fractionated into 96-well Scintiplate-96 plates at 15 sec/well 
using a Gilson 215 Liquid Handler.  The plates were dried using a GenerVac Personal 
Evaporator and counted using a Perkin Elmer 1450 LCS and Luminescence Counter 
(MicroBeta TriLux).                          
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5. Quantification of M1 and Vincristine by LC/MS 
All hepatocyte samples containing VCR were thawed, vortexed, and centrifuged at 1800 
g for 10 min.  The supernatant was diluted with an equal volume of 0.2% formic acid.  
For the experiments described in Methods, pg. 48, the M1 and VCR concentrations were 
quantified by LC/MS analysis (ThermoQuest; ThermoFinnigan, San Jose, CA) in 
positive electrospray ionization (ESI+) mode using selected ion monitoring of VCR (m/z 
413), M1 (m/z 397), and VRL (m/z 390).  Xcalibur software (version 1.0, 
ThermoFinnigan, San Jose, CA) was utilized for data acquisition and processing.  The 
VCR/M1 standard and the chromatography conditions were identical to those used 
during LC/MS/MS analysis of plasma (below).   
J. CYP3A5 Genotyping 
DNA samples isolated from the Indiana University human liver bank samples and 
cryopreserved hepatocytes were genotyped for the CYP3A5*3 and CYP3A5*6 allelic 
variants using allele-specific PCR methods and primers described previously116 with 
SYBR-green detection.117  A TaqMan allelic discrimination assay (Applied Biosystems, 
Germany) was used to determine the CYP3A5*7 allelic variant.118  The genotypes were 
determined by the Clinical Pharmacology Pharmacogenetics Core Laboratory. 
K. Prediction of CYP3A5 Contribution to Vincristine Metabolism 
The fraction of cytochrome P450 metabolism mediated by CYP3A5 (f3A5) was estimated 
using the following relationship:  
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The intrinsic clearances (CLint) of CYP3A4 and CYP3A5 were calculated using the 
estimated Michaelis-Menten parameters of M1 formation with cDNA-expressed 
enzymes (Vmax/Km).  The intrinsic clearances were used to estimate contribution because 
the therapeutic concentrations of VCR are well below the Km.  The protein contents (CP) 
of CYP3A4 and CYP3A5 were estimated by the median immunoquantified values as 
determined by Western blot in HLMs with high CYP3A5 expression (n = 10) described 
in Methods, pg. 39.   
The contribution of CYP3A5 to the formation of M1 was estimated for 
individual HLMs with high CYP3A5 expression (n = 10).  Using only CYP3A5 low 
expressing HLMs (n = 12), the relationship was defined by linear regression (without 
weighting) between the CYP3A4 selective activities (or protein contents) and the 
maximum rates of M1 formation.  With this correlation, using the CYP3A4 selective 
activity (or protein content), the maximum rate of M1 formation mediated by CYP3A4 
(Vmax,3A4) was calculated for each high CYP3A5 expresser; the remaining M1 activity 
(Vmax,3A5) was assumed to be mediated by CYP3A5.  Thus, the fraction of metabolism 
mediated by CYP3A5 (f3A5)HLM was calculated using the following equation: 
Eqn. 4 
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L. Prediction of Vincristine Hepatic Clearance 
For individual livers, a corresponding hepatic blood clearance of VCR (CLH) was 
estimated using the well-stirred model:119   
Eqn. 5 
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The well-stirred model assumes that the unbound drug concentration in the plasma is in 
rapid equilibrium and equal to the unbound intracellular hepatocyte concentration; this 
concentration is directly related to the rate of drug elimination.119  Also, the liver is a 
well-stirred compartment such that the concentration of drug in the liver is equal to the 
concentration in the venous blood.119  For VCR, a plasma fraction unbound (fu,p) of 
0.5148 and a blood-to-plasma ratio (ρ) of 1.211 were used.  Hepatic blood flow (QH) of 
1500 mL/min for a 70 kg man was assumed.  Intrinsic clearance (CLint) was calculated 
using the estimated Michaelis-Menten parameters, Vmax/Km, from the in vitro model.  
The in vitro/in vivo scaling assumed a liver mass of 1.5 kg, a microsomal mass of 45 mg 
per 1 g of liver, and a microsomal mass of 1 mg per 3 x 106 hepatocytes.120 
M. Quantification of Vincristine in Human Plasma and Urine 
1. Synthesis of M1 from Vincristine 
The major metabolite of VCR, M1, was not commercially available as a reference 
standard.  To quantify M1 in plasma, a stock solution containing M1 and VCR was 
prepared by incubating VCR with cDNA-expressed CYP3A5.  Vincristine sulfate in 
methanol (100 µl, 0.2 mg/mL) was evaporated at room temperature and dissolved in 
buffer (100 mM Na2HPO4 with 5 mM MgCl2, pH 7.4).  VCR (20 µg/mL), cDNA-
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expressed CYP3A5 (50 pmol/mL), and NADPH (0.5 µM) were incubated for 30 
minutes at 37°C (1 mL total volume).  The incubation was quenched with methylene 
chloride (8 mL) and 200 µl of 10% trichloroacetic acid (TCAA).  After the organic 
extract was dried at room temperature, the residue was reconstituted in 0.2% formic acid 
in water/methanol (80:20, v/v).  The resulting VCR and M1 stock solution was stored at 
4°C.  Just prior to each use, the concentrations of VCR and M1 in the stock solution 
were quantified by HPLC.  Analyte separation was achieved on an analytical C18 
column (Inertsil ODS-3, 3.0 x 150 mm, 5-µm particle size; MetaChem Technologies 
Inc., Torrance, CA).  The mobile phase consisted of 0.2% formic acid (mobile phase A) 
and methanol (mobile phase B).  The analytes were eluted using the following gradient 
conditions: 0–7 min 20% B, 7–42 min linear increase to 56% B, 42–52 min 80% B, and 
52–60 min 20% B.  Standard curves were generated from two independent stock 
solutions of vincristine sulfate in methanol (0.2 mg/mL), and the average values were 
used to calculate the unknown concentration of VCR in the stock solution.  M1 was 
previously shown to have the same extinction coefficient as VCR.121  Therefore, the M1 
concentration was calculated as a fraction of the VCR concentration using area ratios.  
All samples were assayed in triplicate. 
2. Purification of Internal Standard 
To optimize the sensitivity of the assay by LC/MS/MS, VLB was purified by HPLC 
prior to use because trace amounts of VCR were present in the raw material.  The HPLC 
conditions were the same used to quantify M1 and VCR (Methods, pg. 53).  The 
purified VLB, approximately 10 µg, was collected in mobile phase, diluted with water 
to a final volume of 10 mL, and stored at 4°C.    
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3. Standards, Quality Controls, and Sample Preparation for Urine 
For quantification of VCR and M1 in urine, calibration standards were prepared using a 
stock solution of VCR and M1 (Methods, pg. 53).  The stock solution was serially 
diluted (1:4) with 0.2% formic acid in water and methanol (80:20, v/v) to prepare 6 
working solutions daily.  The calibration standards were prepared by adding the 
following solutions to 100 µL of blank urine: 10 µL of the appropriate working solution; 
80 µL of 0.2% formic acid in water and methanol (50:50, v/v); and 10 µL of purified 
VLB in 5% methanol.  Two QC working solutions were prepared daily by independent 
serial dilutions of the stock solution (1:1 and 1:99).  With these working solutions, the 
QC standards were prepared using the identical procedure as described for the 
calibration standards.  For the clinical samples, the urine was centrifuged to remove any 
precipitates.  The preparation was identical to the calibration standards with one 
exception; 10 µL of 0.2% formic acid in water and methanol (80:20, v/v) was added to 
100 µL of urine instead of 10 µL of working solution.  For all samples, 50 µL of each 
solution was directly injected and analyzed by LC/MS/MS.           
4. Plasma Assay Development 
a) Extraction Solvent and pH 
A protein precipitation method was first evaluated without an extraction step.  VCR (0.1 
µM) and VRL (0.1 µM) were quantified in plasma (150 µL) after precipitation with 
10% TCAA (30 µL).  The sample was centrifuged at 1800 g for 10 min, and the 
supernatant (20 µL) was diluted with an equal volume of 0.2% formic acid and analyzed 
by LC/MS.  After this method was unsuccessful, extraction procedures were pursued.  
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Screening experiments were performed to determine the optimum solvent choice 
and pH for the extraction of VCR and M1 from buffer.  VCR (1 µM) was incubated in 
buffer (100 mM Na2HPO4 with 5 mM MgCl2, pH 7.4) with cDNA-expressed CYP3A5 
(50 pmol/mL) and NADPH (0.5 mM) at 37°C for 9 min.  The incubations (300 µL) 
were quenched with an equal volume of solvent, either acetonitrile or an immiscible 
organic solvent (ethyl acetate, hexanes, t-methylbutylether, or methylene chloride).  To 
reduce the pH of extraction for certain incubations, 10% trichloroacetic acid (70 µL) 
was added.  Extraction at a high pH was not tested because M1 was known to degrade to 
M3 readily in the presence of NaOH.  In all cases, VRL was used as an internal 
standard.  For the incubations that were quenched with acetonitrile, the solids were 
removed by centrifugation; the supernatant was evaporated; and the residue was 
dissolved in mobile phase A for direct HPLC injection.  For the other incubations 
quenched with immiscible solvents, the organic layer was evaporated, and the residue 
was dissolved in mobile phase A for HPLC analysis.  To determine relative recoveries 
of VCR, M1, and VRL using the various immiscible solvents, the UV areas were 
compared to the acetonitrile control.  In addition, to evaluate degradation of VCR, the 
VCR N-oxide was quantified.  
VCR (1 µM) was spiked into blank human plasma (500 µL) and extracted with 
toluene (1 mL) or methylene chloride (1 mL).  The organic phases were evaporated at 
room temperature, and the residues were reconstituted in mobile phase A (0.2% formic 
acid and methanol, 20:80, v/v) for analysis by HPLC and LC/MS.  The recoveries of 
VCR were estimated by HPLC; the VCR-related impurities were compared between the 
samples using LC/MS in full scan mode.  The experiment was repeated with increased  
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volumes of toluene and methylene chloride (4 mL each) and the addition of 100 µL of 
10% TCAA.   
b) Internal Standard 
For the VCR plasma assay, two possible internal standards, vinblastine (VLB) and 
vinorelbine (VRL), were investigated.  VCR (40 ng/mL) and each internal standard (40 
ng/mL) were extracted from plasma (0.5 mL) with methylene chloride (3.5 mL) and in 
some cases 100 µL of 10% TCAA.  Prior to separation of the methylene chloride, the 
two-phase solution in the phase separator apparatus was either agitated by manual 
shaking (10 sec) or by mechanical shaking (10 min).  The extraction recoveries for all 
analytes were quantified by LC/MS.   
c) Adsorption  
 VCR, VRL, and VLB solutions (0 to 50% methanol) were formulated using water stock 
solutions in different materials of construction (glass or polypropylene).  The analyte 
concentrations were quantified by LC/MS.  For another experiment, VCR in methanol 
(30, 10, 3, 1, 0.3, 0.1 ng) was evaporated in polypropylene tubes alone and in the 
presence of VLB (20 ng).  The residue was dissolved in mobile phase A (0.2% formic 
acid: water, 80:20, v/v), and the recovery was quantified by LC/MS for VCR.       
d) Dissolution of Concentrate 
Because the residue after the methylene chloride extraction was not easily dissolved in 
mobile phase A, the recoveries of VCR (20 ng) and VLB (20 ng) were quantified by 
LC/MS using two different dissolution approaches.  The pellet was first dissolved using 
methanol (25 µL), and the tube was vortexed for 10 sec.  The final composition was 
adjusted with 100 µL of 0.2% formic acid.  Alternatively, after mobile phase A (125 
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µL) was added, the pellet was scraped from the tube with a pipette tip, and the tube was 
vortexed for 10 sec.    
e) Optimization of LC/MS Conditions 
A solution containing VCR in mobile phase A was infused directly to the mass 
spectrometer (ThermoQuest; Thermo Electron Corporation, Waltham, MA) in positive 
ESI mode to optimize the detection settings for the maximum signal, the VCR dicharge 
ion at m/z 423.2.  The signal to noise ratio was also evaluated for the VCR monocharge 
and dicharge ions by LC/MS for the neat stock solution and the extracted standards with 
VCR.  Separation of analytes was achieved using a C18 column (Inertsil ODS-3, 2.1 x 
150 mm, 5-µm particle size; MetaChem Technologies Inc., Torrance, CA) at a flow rate 
of 0.2 mL/min.  The methanol concentration during the gradient elution was adjusted to 
allow baseline separation of M1, VCR, and internal standard without interference from 
peaks in the blank plasma.  For LC/MS/MS analysis, a solution containing VCR and M1 
and a separate solution with VLB were infused in mobile phase B to determine the 
optimal detection conditions.      
5. Standards and Quality Control Samples for Plasma 
A stock solution of VCR at 1.2 ng/µL and M1 at 0.62 ng/µL as described above 
(Methods, pg. 53) was used to prepare calibration and QC samples for plasma 
extraction.  Working solutions were prepared the day of the experiment by diluting the 
stock solution with 0.2% formic acid in water and methanol (80:20, v/v).  Calibration 
standards at nominal concentrations of 24, 8, 2.4, 0.8, 0.24, 0.08, 0.024, and 0.012 for 
VCR and 12, 4, 1.2, 0.4, 0.12, 0.04, and 0.012 ng/mL for M1 were prepared by spiking 
20 µL of the appropriate working solution into 500 µL of pooled blank plasma.  
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Separate working solutions were used to prepare three concentrations of QC samples by 
adding appropriate amounts of working solution to pooled blank plasma, and 500 µL 
aliquots were frozen at -20°C until use.  The nominal concentrations of the QC samples 
were 19, 0.92, and 0.047 ng/mL for VCR and 9.5, 0.47, and 0.024 ng/mL for M1.  For 
routine analysis, QC samples were prepared daily from the same stock solution as the 
calibration standards but with independent dilutions of the stock solution. 
6. Final Extraction Conditions for Plasma 
To 500 µL of plasma, 10 µL of purified VLB in water (1 ng/µL), 100 µL of 10% 
trichloroacetic acid in water, 20 µL of 0.2% formic acid in water and methanol (80:20, 
v/v), and 8 mL of methylene chloride were added.  The sample was vortexed for 30 sec, 
centrifuged at 1800 g for 10 min, and then transferred to a phase separator (Biotage, 
Uppsala, Sweden).  The organic layer was collected and evaporated at room temperature 
using a Savant concentrator (Thermo Electron Corporation, Waltham, MA).  The 
residue was reconstituted in 125 µL of 0.2% formic acid in water and methanol (80:20, 
v/v), and the solution (50 µL) was injected on the analytical column for LC/MS/MS 
analysis.      
7. Instrumentation and Chromatographic Conditions 
The analytes were detected using an API 4000 LC/MS/MS spectrometer (Applied 
Biosystems, Foster City, CA) in line with an 1100 HPLC system (Agilent Technologies, 
Palo Alto, CA) including a degasser, quaternary pump, and autosampler.  The data were 
acquired and processed using Windows® 2000 platform-based Analyst software, 
version 1.4.1.  Separation of analytes was achieved using a C18 column (Inertsil ODS-3, 
2.1 x 150 mm, 5-µm particle size; MetaChem Technologies Inc., Torrance, CA) at a 
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flow rate of 0.2 ml/min.  The mobile phase compositions were 0.2% formic acid in 
water/methanol (80:20, v/v, mobile phase A) and 0.2% formic acid in water/methanol 
(20:80, v/v, mobile phase B).  Starting at 0% B, the gradient conditions were as follows: 
0–0.5 min linear increase to 10% B, 0.5–6.5 min linear increase to 18% B, 6.5–10.5 min 
linear increase to 100% B, 10.5–14.5 min 100% B, and 14.5–20 min 0% B.   
A flow injection analysis was performed on each analyte to maximize sensitivity 
(Table 1). The analytes were optimized at a source temperature of 650°C, under unit 
resolution for quadrupoles 1 and 3, and the optimal gas pressures were as follows: 
collision gas 12 psi, curtain gas 31 psi, ion source gas (1) 40 psi, ion source gas (2) 
45 psi.   
8. Method Validation for Plasma  
Plasma calibration standards (n = 8 for VCR and n = 7 for M1) were used to generate 
standard curves on four separate occasions.   The VCR to internal standard area ratios 
were fit using linear regression with a weighting factor of 1/x.  The M1 standard curve 
used a power fit without weighting.  The fit was considered acceptable if the mean 
calculated values of the calibration standards over the four batches for each value were 
≤ 15% of the nominal values or ≤ 20% for the low limit of quantification.  Values for 
calibration standards were excluded from the standard curve if the calculated accuracies 
were < 55% or > 145% of the nominal concentration.  At least six points were used to 
generate each standard curve.  
Intra-day accuracy and precision were evaluated at three concentrations (0.012, 
0.8, and 24 ng/mL for VCR and 0.012, 0.40, and 12 ng/mL for M1) by analyzing five 
replicates at each concentration independent of the standard curve samples.  QC samples 
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were assayed on four separate days to calculate inter-day accuracy and precision.  The 
intra-day and inter-day accuracies were accepted if the calculated values were ≤ 15% of 
the nominal concentration or ≤ 20% for the low limit of quantification.  The precision of 
intra-day and inter-day samples was acceptable if the percent coefficient of variation 
(%CV) was ≤ 15% or ≤ 20% for the low limit of quantification.   
The specificity was evaluated using blank plasma pooled from three human 
donors.  The following drugs were tested for assay interference: cyclosphosphamide, 
methotrexate, dactinomycin, and asparaginase.  For each compound, the maximum 
therapeutic plasma concentrations were used to calculate the appropriate amounts of 
drug formulation to dissolve in 0.2% formic acid in water/methanol (80:20, v/v).  The 
maximum plasma concentrations used in this study follow: cyclophosphamide, 1000 
µg/mL; methotrexate, 45 µg/mL; dactinomycin, 50 ng/mL; and asparaginase, 1 IU/mL.  
The solutions, one per drug, were assayed using the same conditions as the plasma 
samples. 
The recoveries of VCR and M1 were determined by comparing the analyte to 
internal standard area ratios of unextracted samples to the ratios of the extracted 
samples.  For the unextracted samples, the VCR and M1 in mobile phase were added 
directly to the extracted residue of a plasma sample with only internal standard.   
The VCR and M1 concentrations of the stock solution were evaluated at the 
beginning and end of the validation experiments using HPLC analysis.  The post-
preparative stability studies used QC sample re-injections at the end of the run time (n = 
6 for each QC concentration, ≥ 10 h storage at room temperature).  The freeze-thaw and 
short-term stabilities of VCR and M1 in plasma were evaluated in triplicate using high 
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(19 ng/mL for VCR and 9.5 ng/mL for M1) and low concentrations (47 pg/mL for VCR 
and 24 pg/mL for M1).  For the freeze-thaw stability studies, the plasma samples were 
thawed three times at room temperature and refrozen for at least 12 h between thaws.   
The short-term (pre-preparative) stability studies evaluated VCR and M1 in plasma after 
15 h of room temperature storage.  In all cases, the analytes were considered stable if the 
concentrations were within 20% of the untreated sample concentrations.  The reported 
p-values between the treated and the QC control groups were determined using the 
Student’s t test.        
For routine analysis, the standard curve and six QC samples (three 
concentrations in duplicate) were assayed.  The standard curve was accepted if at least 
four out of six of the calculated concentrations of the QC samples were within 20% of 
the nominal values, with at least one QC sample passing at each concentration.    
9. Method Application 
To determine the pharmacokinetic profiles of VCR and M1, a prospective study 2006–
2007 was conducted in pediatric subjects undergoing treatment for rhabdomyosarcoma 
at Riley Hospital (Indianapolis, IN) and Children’s Memorial Hospital/Northwestern 
University (Chicago, IL).  The typical regimen included concurrent treatment with VCR 
(1.5 mg/m2), dactinomycin, and cyclophosphamide.  The study was approved by the 
Institutional Review Boards of Indiana University-Purdue University and Children's 
Memorial Hospital, and the patients were enrolled after written informed consent.  
Blood samples pre-dose and approximately 15 min, 1 h, 2 h, 4 h, 6 h, and 24 h post 
VCR dose were collected in heparinized tubes.  The plasma was separated within 30 
min and stored at -80°C until analysis.  The plasma samples were extracted in duplicate,  
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and the VCR and M1 concentration data were fit by non-linear regression using a two-
compartment model (WinNonlin 4.0, Pharsight, Mountain View, CA). 
A different study was conducted at Riley Hospital (Indianapolis, IN; 2002–2004) 
for patients that were treated with VCR for a variety of malignancies including 
rhabdomyosarcoma and neuroblastoma.  Urine and/or whole blood samples (pre-dose 
and various time points up to 24 h post-dose) were collected from the pediatric patients.  
The study was approved by the Institutional Review Board of Indiana University-Purdue 
University, and the patients were enrolled after written informed consent.  VCR and M1 
were quantified in the plasma and urine samples. 
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IV. Results 
A. Metabolite Identification with cDNA-expressed Cytochrome P450s  
For preliminary experiments with VCR and cDNA-expressed CYPs, the incubations 
were quenched with base and extracted with ethyl acetate.  These conditions were 
chosen to potentially improve the extraction efficiency of Vinca alkaloids (pKa ~ 7.4).  
At the time, the chemical stability was unknown for the major metabolite M1.  As we 
later discovered, the sodium hydroxide added during the extraction chemically 
transformed M1 to M3.  In addition, the initial chromatography conditions at a neutral 
pH did not allow baseline separation of M1 and VCR.  Once these issues were 
discovered, the post-incubation sample preparation and chromatography conditions were 
optimized to quantify M1 without degradation to M3.  The next section describes the 
initial kinetic data with the base extraction method and explains the process used to 
discover the relationship between M1 and M3. 
1. HPLC Analysis with Neutral pH Eluent and Base Extraction 
After VCR was incubated with cDNA-expressed cytochrome P450 3A5 (rCYP3A5) as 
described in Methods (pg. 30), VCR and one major metabolite (M3) were detected by 
HPLC analysis (Fig. 2; Methods, pg. 31).  The UV baseline noise may have masked the 
formation of other VCR minor metabolites because UV detection is not selective for 
VCR-related compounds.  Thus, metabolite profiling was completed using radiolabeled 
VCR (Methods, pg. 30).  The 3H-VCR was first purified by HPLC because the 
radiochemical purity of VCR was poor (approximately 60%).  VCR at multiple 
concentrations (0.1 to 100 µM, 106 dpm) was incubated with rCYP3A5.  The potential 
metabolites were identified by comparing the radiochromatograms of the incubation 
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extracts with and without NADPH (Fig. 3).  As shown previously by UV detection (Fig. 
2), M3 was the dominant metabolite (21 min).  Another minor metabolite M2 was 
observed at 17 min.  The M3 molar concentrations were estimated using the total 
radioactivity of the eluent fractions containing M3 by retention time.  The rates of M3 
formation with rCYP3A5 displayed saturable kinetics with a Km value of approximately 
10 µM (Fig. 3f).  
The rates of M3 formation for rCYP3A5 and rCYP3A4 were quantified using 
the identical incubation conditions (5 µM VCR, 50 pmol CYP/mL, 15 min incubation 
time; Methods, pg. 31).  As compared to the rate of M3 formation with rCYP3A5, the 
rate of M3 formation with rCYP3A4 was approximately 10-fold lower; M3 was 2.2% of 
the initial VCR UV area for rCYP3A4 versus 23% for rCYP3A5.  Additional 
experiments were performed to identify initial velocity conditions for the kinetic 
analysis of rCYP3A4 and rCYP3A5 with VCR.  However, the rates of M3 formation 
were not reproducible between experiments.  For example, 15 min incubations with 
rCYP3A5 resulted in 13% M3 formation (% of initial VCR area by UV); for the 
identical experiment three weeks later, the M3 formation was 28%.  A potential cause of 
these inconsistencies was discovered after the incubation extracts were assayed by 
LC/MS using an acidic mobile phase (Fig. 4; Methods, pg. 32).  Using this assay, three 
metabolite peaks (M1, M2, and M3) were detected in the rCYP3A5 incubations.  Only 
two peaks (M2 and M3) were previously discovered by HPLC with a neutral pH eluent 
(Fig. 3).  The identities of the peaks were determined by collecting the individual 
metabolite peaks from the acidic chromatography system (Fig. 5a) and then assaying the 
purified metabolites on the neutral pH system (Fig. 5b–f; Methods, pg. 31).  The 
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retention times of M2 and M3 increased approximately 18 min for the acidic 
chromatography system, compared to the neutral pH chromatography (Fig. 5a,d).  Using 
the acidic chromatography system, another metabolite, M1, eluted 2 min before VCR 
(Fig. 7a).  By neutral pH chromatography, the M1 eluted approximately one min after 
VCR and had an unusually broad peak shape (Fig. 7c).  In addition, when purified M1 
was injected, another smaller peak was detected with the same retention time as M3; a 
small amount of M3 was likely produced by M1 degradation during the purification 
process.  The close retention time of M1 to VCR and the broad peak shape of M1 
explain why M1 in the presence of VCR was not previously detected by neutral pH 
chromatography (Fig. 5b).       
After M1 was discovered as a metabolite, a series of experiments were 
performed to understand the relationship between M1 and M3.  First, the effects of the 
extraction and base addition on the incubations were evaluated.  VCR incubations with 
cDNA-expressed enzymes were quenched with acetonitrile to precipitate the protein, 
and the supernatant was directly assayed by HPLC and LC/MS.  Interestingly, M3 was 
not present; the only metabolites detected were M1, the major metabolite, and M2 (Fig. 
6).  Consistent with this result, M3 was not detected after the same solution was 
extracted with ethyl acetate but without sodium hydroxide.  To demonstrate that M3 was 
a product of M1 base treatment, HPLC-purified M1 was treated with sodium hydroxide 
and then extracted with ethyl acetate.  The extract and the untreated control solution 
were assayed by HPLC.  As determined by UV detection and by radioactive counting in 
another experiment, the major compound in the extract was M3 (Fig. 7); the conversion 
of M1 to M3 was nearly quantitative.  In contrast, the conversion of M1 to M3 was not 
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quantitative using the previously described extraction procedure (Fig. 5a; Methods, pg. 
31).  Thus, for VCR incubations previously extracted with ethyl acetate and base, the 
rates of M1 formation were underestimated by measurement of M3 alone.  The 
formation of M3 may have been a function of a variety of post-incubation conditions 
including temperature, agitation, and storage time.  Instead of studying these variables in 
detail, alternate sample preparation and analytical methods were developed to quantify 
M1.   
2. HPLC Analysis with Acidic pH Eluent and Acetonitrile Quench 
Using an acidic eluent and methanol gradient (Methods, pg. 32), baseline separation was 
achieved for the major products of VCR metabolism by rCYP3A5 (Fig. 6): M1 (21 
min), VCR (23 min), and M2 (35 min).  M3, a compound formed from M1 under basic 
conditions, had a retention time of 38 min (peak not shown).  Radiochromatograms were 
also generated from incubations of 3H-VCR (10 µM) with rCYP3A4 and rCYP3A5 
(Fig. 8).  The major metabolite for both rCYP3A4 and rCYP3A5-mediated metabolism 
of VCR was M1.  This peak was not present in VCR incubations with the insect 
microsome controls.  Other potential minor metabolites (M2, M4, and M5) were 
detected in all samples.  For M2, only the rCYP3A5 reaction produced levels higher 
than the control, approximately 10% of M1 by UV area.  Although another earlier 
eluting compound, M4 (19.3 to 19.7 min), was present in larger quantities than the 
control, the total amount was only 2% of the total radioactivity for both rCYP3A4 and 
rCYP3A5 incubations.  M5 (21.0 to 21.3 min) was detected in the control but was not a 
discrete peak in the other incubations because the M1 peak retention time (20.5 to 20.7 
min) was too close to M5 to allow resolution by radiochromatography.  In contrast, with 
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the HPLC assay used to determine the kinetic parameters with UV detection, M5 could 
be distinguished from M1 by retention time.  For all radiochromatograms (Fig. 8; 
Methods, pg. 30), the radioactivity counted from 10 to 45 min was at least 95% of the 
total radioactivity in the samples; no additional peaks with retention times before 10 min 
or after 45 min were identified. 
B. Structural Determination of Vincristine Metabolites by LC/MS/MS and NMR 
1. M2 
The MS spectrum of the minor metabolite M2 revealed a primary protonated molecular 
ion peak at m/z 839, a mass 14 Da higher than that of the VCR ion peak (Methods, pg. 
35).  The N-formylvindoline (NFV) segment of the molecule was unchanged from VCR 
as determined by MS/MS fragmentation showing a product ion at m/z 471, the 
protonated NFV segment.  Accurate mass measurement of M2 was used to determine 
the molecular formula, C46H54N4O11.  These results indicated that M2 was likely the 
same molecule previously described from the oxidation of VCR with horseradish 
peroxidase or ceruloplasmin (Fig. 9).9   To test this hypothesis, VCR was incubated with 
horseradish peroxidase and hydrogen peroxide using a similar procedure (Methods, pg. 
34).  Two compounds that displayed retentions times different from VCR were isolated 
by HPLC.  The compound that eluted at an earlier retention time than VCR was not 
conclusively identified by 1H NMR although the retention time was similar to the early 
eluting VCR epoxide (M4).  The second compound eluted at the same retention time as 
the compound M2 generated by CYP3A5-mediated metabolism of VCR, and a direct 
comparison by LC/MS/MS and 1H NMR confirmed that that the compounds were 
identical.  In the proposed mechanism for the formation of M2, the carbon α to the 
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piperidine nitrogen of VCR is oxidized followed by the fission of the C-13 and C-14 
bond (Fig. 9).9  Similar biotransformation pathways catalyzed by horseradish peroxidase 
have been described previously with other Vinca alkaloids including leurosine and 
vinblastine.122,123  The MS/MS product ions and the complete NMR characterization of 
M2 are reported elsewhere.9,121 
2. M1 and M3  
The primary metabolite generated by the metabolism of VCR with rCYP3A5 and 
rCYP3A4 is M1, a compound with a primary protonated molecular ion peak at m/z 793.  
MS/MS analysis revealed a structural change to the DHC segment of the molecule (Fig. 
1).  However, with a VCR mass loss of 32 Da, the possible chemical structures of M1 
were not obvious.  The structural identification of this compound by 1H NMR was 
challenging because M1 was not stable during standard sample preparation methods.  
Specifically, evaporation in methanol to remove residual water for 1H NMR degraded 
M1 so that direct analysis in methanol was not possible.  To determine whether alternate 
sample preparations would be suitable, VCR was incubated with rCYP3A5 to generate 
M1, and the resulting incubation solution was extracted with various solvents including 
hexanes, ethyl acetate, and methylene chloride (Methods, pg. 55).  The effect of acid on 
recovery and degradation was evaluated using trichloroacetic acid, and methylene 
chloride extraction with acid treatment most effectively concentrated M1 and VCR 
without degradation (Fig. 10).  This extraction procedure was used to purify larger 
quantities of M1 (Methods, pg. 34), and the concentrated extract was analyzed by 
LC/MS/MS (Methods, pg. 35).  In addition to an ion at m/z 793, an ion at m/z 811 was 
observed with a molecular formula of C45H55N4O10 as determined by accurate mass 
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measurements (Fig. 11).  Based on this observation, the ion at m/z 793 was hypothesized 
to be a source-induced fragment ion caused by dehydration of the primary compound at 
m/z 811, a compound with a mass 14 Da less than VCR.  The M1 extract was also 
dissolved in deuterated methanol for structural analysis by 1H NMR.  This approach was 
unsuccessful because, as before, the M1 degraded in methanol.   
Because direct structural analysis was not possible, a chemical modification 
approach was utilized to define the structure of M1.  As reported earlier, base treatment 
of M1 results in the chemical transformation to a stable derivative M3.  The mass of the 
primary protonated molecular ion for M3 was m/z 779 with a molecular formula of 
C44H50N4O9 by accurate mass measurements.  MS/MS analysis with a product ion of 
469 revealed that the NFV segment of VCR was chemically intact (Fig. 1).  Extensive 
analyses by NMR as described elsewhere121 indisputably verified the structure of M3 
(Fig. 9).  Based on the structure of M3 and the proposed mechanism for the formation of 
M2, the biotransformation pathway and structure of M1 were deduced (Fig. 9).  To form 
M1 and M2, VCR is initially oxidized at the position α to the piperidine nitrogen.  
However, instead of cleavage at the C-13 to C-14 bond to form M2, fission of the N-12 
to C-13 bond initiates the formation of M1.  As a secondary amine, the compound M1 is 
likely reactive under basic conditions causing an intramolecular amidation to form M3, 
a mass loss of 32 Da.   
To further confirm the structure of M1, additional chemical modifications of M1 
were attempted by chemically targeting the reactive secondary amine (Methods, pg. 34).  
Attempts to directly formylate the M1 secondary amine with formic acid were 
unsuccessful.  However, using acetic anhydride, the secondary amine on M1 was readily 
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acetylated.  M1-acetate was detected by LC/MS as a major product with a DHC segment 
modification and a molecular ion peak at m/z 853, a mass gain of 42 from M1.  In 
addition, the retention time of M1-acetate was approximately 17 min later than M1, a 
dramatic shift likely caused by modification to a protonatable amine group.  Altogether, 
these results confirm the proposed molecular weight (m/z 811) and structure of M1 (Fig. 
9).    
3. M4 and M5 
The compounds M4 and M5 are present as impurities in commercially available 
vincristine sulfate.  M4 may also be a minor metabolite produced during the rCYP3A5-
mediated metabolism of VCR (Fig. 6).  M5 as an impurity can interfere with the 
quantification of M1 by UV detection because the retention times are similar.  The 
MS/MS data support a chemical modification to the DHC segment compared to VCR.  
The structures of M4 and M5 are likely isomeric epoxides because the protonated 
molecular ion peaks of M4 and M5 are identical at m/z 823, 2 Da less than the VCR ion 
peak.  The vinblastine equivalent compound for one of the diasteromers has been 
previously identified as leurosine, a natural product isolated from the plant, 
Catharanthus roseus.122  1H NMR analysis was not used to characterize M4 and M5 
because they were not identified as major metabolites (Fig. 6).   
C. Enzyme Kinetics of Vincristine Metabolism with cDNA-expressed CYPs 
1. CYP Human and Rat CYP Panel 
VCR was incubated with a panel of cDNA-expressed human CYPs (Methods, pg. 27).  
As determined by parent drug disappearance and M1 formation, the metabolism of VCR 
was primarily mediated by rCYP3A4 and rCYP3A5 (Fig. 12).  The VCR disappearance 
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was normalized to insect microsome controls (n = 4).  The M1 values were not corrected 
because M1 was not detected in the control.  Using one-way ANOVA analysis, the VCR 
disappearance was different from the control for the following CYP enzymes: rCYP3A4 
(p < 0.001), rCYP3A5 (p < 0.001), rCYP3A7 (p < 0.01), and rCYP2E1 (p < 0.05).  
However, only rCYP3A4 and rCYP3A5 depleted the substrate by more than 10%.  M1 
formation accounted for 70% and 50% of parent drug loss in the rCYP3A5 and 
rCYP3A4 incubations, respectively.  The formation of M2, a minor metabolite, 
accounted for 7% parent loss with rCYP3A5 and 2% loss with rCYP3A4.  The 
formation of M4, another minor metabolite, accounted for 1% parent loss with 
rCYP3A5 and 4% loss with rCYP3A4. 
For rCYP3A1 and rCYP3A2 incubations (Methods, pg. 28), the rates of M1 
formation and vincristine depletion were not detectably different from the insect cell 
control incubations.  Thus, rat CYP enzymes do not readily metabolize VCR.   
2. Competitive Inhibition of CYP3A4 with Vincristine and Vinblastine 
The rates of formation of M1 from VCR and the formation of the M1-equivalent for 
vinblastine (identification by LC/MS/MS, data not shown) were used to estimate the 
competitive inhibition dissociation constants for VCR and vinblastine with rCYP3A4 
and rCYP3A5 (Methods, pg. 28).  A competitive inhibition model was used to 
simultaneously fit all concentrations of VCR and vinblastine by non-linear regression.  
Vinblastine was a much more potent inhibitor of rCYP3A4 activity than VCR; the 
estimated Ki values for rCYP3A4 were 2 µM and 38 µM with vinblastine and VCR, 
respectively (Fig. 13).  VCR did not selectively inhibit rCYP3A5 compared to 
rCYP3A4; the estimated Ki values were 39 µM and 38 µM for inhibition of rCYP3A5 
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and rCYP3A4, respectively.  However, the Ki value for rCYP3A5 had a high degree of 
uncertainty (CV = 54%).            
3. Competitive Inhibition of M1 Formation with Cyclosporin A 
To determine whether CsA was a selective chemical inhibitor of CYP3A4 activity, VCR 
was incubated with rCYP3A4 (or rCYP3A5) and CsA (Methods, pg. 28).  The rates of 
M1 formation with VCR (10 µM) were quantified using a range of inhibitor 
concentrations at different methanol concentrations.  For the initial experiments with 
2.4% methanol and 10 µM CsA, rCYP3A4 activity was completely inhibited while at 
the same concentration of inhibitor, only 15% of the rCYP3A5 activity was inhibited.  
Although CsA was a selective inhibitor of rCYP3A4 using these conditions, the high 
methanol concentration inhibited the formation of M1 in the vehicle controls.  Thus, 
alternative conditions were investigated at lower methanol concentrations.  For 
incubations without methanol (Fig. 14a), complete inhibition of rCYP3A4 activity was 
not possible.  The residual activities of rCYP3A4 at high apparent concentrations of 
CsA were likely a result of the CsA not dissolving completely in the incubation buffer.  
Consistent with this hypothesis, when the methanol concentrations were increased to 
0.3%, CsA again completely inhibited the rCYP3A4 activity whereas the rCYP3A5 
activity was only reduced 15% (Fig. 14b).   
4. Kinetics of M1 and M2 formation with rCYP3A4 and rCYP3A5 
VCR at various concentrations was incubated with rCYP3A4 (or rCYP3A5) and 
supplemented cytochrome b5 (Methods, pg. 30).  The rates of M1 and M2 formation 
were quantified in duplicate over two sets of experiments approximately 30 min apart 
(Fig. 15).  The rates of M1 formation (major metabolite) and M2 formation (minor 
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metabolite) demonstrated saturable kinetics with rCYP3A4 and rCYP3A5.  While the 
Km values for M1 and M2 formation were similar with rCYP3A4 and rCYP3A5, the 
Vmax values were 6 to 10-fold higher with rCYP3A5.  For this experiment, some scatter 
was noticed between the duplicate values, especially for the M1 values.  The rates of M1 
formation determined from the second set of experiments were consistently lower than 
the first indicating that the enzyme preparation with supplemented cytochrome b5 was 
probably not stable.   
The role of enzyme preparation on the kinetics of M1 formation was determined 
for rCYP3A4 and rCYP3A5 (Fig. 16).  The Km and Vmax values were estimated for 
rCYP3A4 and rCYP3A5 with and without cytochrome b5 (Table 1).  For both rCYP3A4 
and rCYP3A5 incubations, the presence of cytochrome b5 consistently increased the 
Vmax values; the highest Vmax values were estimated with co-expressed cytochrome b5.  
The intrinsic clearance values (Vmax/Km) with rCYP3A5 were consistently higher than 
those with rCYP3A4 for all preparations (9 to 14-fold higher for rCYP3A5).  The Km 
values were not statistically different for preparations without cytochrome b5 and co-
expressed cytochrome b5.  The kinetic parameters were not estimated for M2 or M4 
because at the lowest concentrations of VCR, the compounds could not be consistently 
quantified by HPLC.  However, for the rCYP3A4 and rCYP3A5 reactions, the M2 and 
M4 concentrations were higher than the control concentrations at the highest VCR 
concentration (48 µM).  Correcting for the amounts in the controls, M2 was less than 
10% of the M1 values for both rCYP3A5 and rCYP3A4 reactions.  M4 was 
approximately 5% of M1 for rCYP3A5 incubations and 15% of M1 for rCYP3A4  
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reactions.  The concentrations of M5 for both rCYP3A4 and rCYP3A5 reactions were 
not measurably higher than the concentrations in the controls. 
5. Prediction of CYP3A5 Contribution to Vincristine Metabolism 
The kinetic data from the cDNA-expressed CYPs can be used to estimate the CYP3A5 
contribution to the metabolism of VCR with a few assumptions (Eqn. 3).  First, to use 
the intrinsic clearance values (Vmax/Km), the therapeutic unbound concentration of VCR 
(< 0.1 µM) must be lower than the measured Km (approximately 20 µM).  The rates of 
M1 formation should account for all the VCR metabolism by CYP3A4 and CYP3A5.  
For the protein concentrations of CYP3A4 and CYP3A5 as determined by Western blot 
(Methods, pg. 39), all the CYPs need to have the same percentage of active holoprotein.  
Finally, only CYP3A4 and CYP3A5 are assumed to metabolize VCR. 
The CYP3A5 contribution for CYP3A5 high expressers was calculated as a 
fraction of the total activity using the selectivity data from each enzyme preparation:  
0.91 (no cytochrome b5); 0.92 (supplemented cytochrome b5); and 0.88 (co-expressed 
cytochrome b5).  Regardless of the preparation method, the CYP3A5 contribution to 
VCR metabolism was substantial, approximately 90%.     
D. Characterization of CYP3A4 and CYP3A5 in Human Liver Microsomes 
1. CYP3A5 Genotype 
The bank of HLMs (n = 56) was genotyped for CYP3A5*3, *6, and *7; these alleles 
were previously associated with low or null expression of CYP3A5.  Without these 
defective alleles, the HLMs by elimination were assumed to have active CYP3A5*1 
alleles.  One liver, IUL-40, was homozygous and 11 livers were heterozygous for 
CYP3A5*1 (Table 2).   
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2. Protein Expression  
CYP3A4 and CYP3A5 concentrations in select livers (n = 12 for CYP3A5*1 livers, n = 
10 for CYP3A5*3/*3 livers) were quantified by Western blot (Fig. 17; Methods, pg. 39).  
To effectively quantify the CYP content in the HLMs, the CYP standards were co-
loaded with an equal amount of protein from an HLM without detectable expression of 
the CYP.  When the standards were loaded without this HLM, the CYP intensity of the 
standard alone was much higher than the standard with the co-loaded HLM (Fig. 17a).  
The CYP standard alone also ran slower on the gel than the standard with a co-loaded 
HLM.  As a result, all the standards were loaded with an appropriate amount of “blank” 
microsomal protein.  For the CYP3A5 standard curves, IUL-52 (CYP3A5*3/*3) was the 
HLM typically loaded with the standards (Fig. 17b).  The standards and unknowns were 
separated by at least 4 lanes with standards on lanes 1 and 15.  These conditions were 
chosen to account for errors that can naturally occur during a Western blot procedure 
including uneven transfers and uneven development of the nitrocellulose.  To estimate 
the concentrations of the CYPs in the unknown samples, the intensities of all 6 
standards were fit by linear regression (Fig. 17c), and the unknown values were 
estimated by interpolation.  The duplicate values for all unknown HLMs were within 
15% of each other on the same blot.  The HLMs were assayed for both CYP3A4 and 
CYP3A5 content (Table 2).  For CYP3A5 high expressers with only one CYP3A5*1 
allele, the CYP3A4 and CYP3A5 protein contents (Table 2) were not correlated (r2 = 
0.07).  
Because CYP3A5 was not available for purchase as a purified enzyme, two 
different types of CYP reference standards were used—purified CYP3A4 enzyme and 
 77
CYP3A5 Supersomes.  To determine the percentage of CYP3A5 as holoprotein, the 
relative intensities of the purified CYP3A4 and the CYP3A5 Supersomes were 
compared by Western blot using a CYP3A non-specific antibody (Fig. 18; Methods, pg. 
39).  This type of comparison assumed that the antibody was equally immunoreactive 
with both CYPs.  For this particular lot of Supersomes (lot 22), the CYP3A5 values 
were similar to the CYP3A4 values.  As a result, the CYP3A5 Supersomes standard was 
used to quantify the CYP3A5 content in the HLMs without a purity correction (Table 2). 
Compared to the CYP3A5*3/*3 livers, the CYP3A5 protein concentrations were 
higher for 10 livers with at least one CYP3A5*1 allele (p < 0.001).  However, for two 
livers (IUL-57 and IUL-71), the CYP3A5 protein concentrations were comparable to 
other HLMs with the CYP3A5*3/*3 genotype (Fig. 19).  As a result, IUL-57 and IUL-
71 were classified as CYP3A5 low expressers contrary to genotype (Table 2).  Although 
low CYP3A5 expression could be explained by general enzyme degradation, for these 
two livers, the CYP3A4 protein concentrations and the CYP3A4 activities were typical 
of the CYP3A5*3/*3 HLMs.  At this time, the exact cause for the discrepancy between 
CYP3A5 genotype and expression is unknown.   
3. CYP3A4 Activity Assays  
The itraconazole hydroxylase activity, testosterone 6β-hydroxylase activity, and 
CYP3A4 content by Western blot were quantified for select HLMs with low and high 
CYP3A5 expression (Table 2).  To estimate the maximum velocities for the itraconazole 
hydroxylase activities, the HLMs were incubated with itraconazole at target 
concentrations of 0.5 or 1 µM, concentrations much higher than the Km (54 nM, Fig. 20; 
Methods, pg. 37).  Although the target concentration of ITZ was higher than the Km, the 
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actual concentrations as measured by LC/MS were initially variable; the concentrations 
declined over time until the ITZ stock solution was reformulated (Fig. 21a).  Given that 
ITZ is a highly lipophilic drug, the initial decline in ITZ concentration was likely caused 
by adsorption of ITZ to the polypropylene container.  For later incubations, to maintain 
a high ITZ concentration, the ITZ stock solution was freshly formulated for each set of 
reactions (Fig. 21b).  These later reactions were used to quantify the CYP3A4 activities 
of the HLMs (Table 2).   
As another measure of CYP3A activity, the testosterone 6β-hydroxylase 
activities for the HLMs were also quantified (Table 2; Methods, pg. 37).  The 
testosterone 6β-hydroxylase activity was correlated to CYP3A4 content and 
itraconazole activity (r2 = 0.77 and 0.98, respectively) but did not differ between 
CYP3A5 high and low expressers (Fig. 22).  Thus, CYP3A5 did not significantly 
contribute to testosterone 6β-hydroxylation.   
E. Vincristine Metabolism with Human Liver Microsomes 
1. Metabolite Profiles by HPLC 
The formation rates of VCR metabolites, including compounds previously described 
from recombinant enzyme incubations (M1, M2, M3, and M4), were quantified for 
select HLMs (n = 22; Methods, pg. 41).  By comparing the chromatograms to controls 
lacking NADPH, M1 was identified as the major metabolite.  M4 was a minor 
metabolite with rates of formation 10% or less than those of M1.  Representative 
chromatograms for incubations with IUL-73 (a CYP3A5 high expresser) and the 
corresponding negative control are shown in Fig. 23.  The chemical structures of M1 
and M4 were confirmed by LC/MS/MS (data not shown).   
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2. Kinetics of M1 Formation 
For all HLMs, VCR metabolism as determined by M1 formation displayed Michaelis-
Menten kinetics (Fig. 24).  The Vmax and Km values were estimated by non-linear 
regression (Table 2).  The Km values were corrected for microsomal protein (Methods, 
pg. 45).  The Vmax values for the CYP3A5 high and low expresser groups were not 
directly compared because the CYP3A5 low expressers were not selected randomly and 
therefore did not represent the population.  An alternative approach was used to 
compare Vmax values between the groups (Methods, pg. 53).  The Km values between the 
groups were directly compared because the Km values of the CYP3A5 low expresser 
group were not correlated to Vmax values (r2 = 0.26).  The Km values for CYP3A5 high 
and low expressers (18.4 ± 5.2 µM and 20.5 ± 5.2 µM, respectively) were not 
statistically different (p = 0.49).  The Km values of M1 formation using HLMs (average 
19.6 µM) and rCYP3A5 and rCYP3A4 with co-expressed cytochrome b5 (16.7 and 19.9 
µM, respectively) were in good agreement.  The Km values of the recombinant CYPs 
were not corrected for non-specific binding because the incubations had low protein 
concentrations (Cp ≤ 0.55 mg/ml) corresponding to a fu ≥ 0.92 using Eqn. 2 and the 
estimated values of K from HLMs. 
3. Selective Chemical Inhibition of M1 Formation 
To quantify the contribution of hepatic drug metabolizing CYPs in VCR metabolism, 
the rates of M1 formation were determined with selective chemical inhibitors in pooled 
HLMs at 15 µM VCR (Fig. 25; Methods, pg. 42).  The rates of M1 formation in 
incubations with omeprazole, quinidine, ketoconazole, VLB, and VRL were 
significantly lower than the control incubations (p < 0.05).  Only known CYP3A 
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substrates, VLB and VRL, and the CYP3A inhibitor, ketoconazole, inhibited the M1 
formation rate by more than 25%.  The rate of VCR disappearance was significantly 
reduced by ketoconazole, VLB, and VRL (p < 0.05, data not shown).   
As shown previously (Fig. 14), CsA is a potent, selective inhibitor of rCYP3A4 
and was therefore used to selectively inhibit CYP3A4 in HLMs (Methods, pg. 43).  For 
the initial screening experiment with a select number of HLMs, CsA more effectively 
inhibited the formation of M1 with CYP3A5 low expressers; the degree of inhibition 
was dependent on the CYP3A4 activity of the HLM (Fig. 26b).  However, the vehicle 
controls with 4.8% methanol were also inhibited (Fig. 26a).  Interestingly, methanol also 
selectively inhibited CYP3A4; the CYP3A5 low expressers were selectively inhibited 
by methanol alone (approximately 20% more inhibition with low expressers).  In 
addition, the inhibition response of the HLMs to 4.8% methanol was highly variable.   
One methanol-sensitive HLM (IUL-42, 70% inhibition) was selected to 
determine the maximum concentration of solvent without loss of activity (Methods, pg. 
45).  At various acetonitrile and methanol concentrations, the activity of IUL-42 was 
quantified; 7% of the activity was inhibited at an organic concentration of 0.5% (Fig. 
27).  The inhibition was independent of solvent choice. 
As a result of this study, the concentration of methanol chosen for the next CsA 
inhibition experiments was 0.3%.  The inhibition of M1 formation by CsA was 
determined for HLMs with low (Fig. 28a) and high expression of CYP3A5 (Fig. 28b).  
The M1 rates of formation for CYP3A5 low expressers were not completely inhibited 
by CsA; the remaining activities as estimated by the modified Michaelis-Menten 
equation (Eqn. 1) were 27% for IUL-6 and less than 10% for IUL-78 and IUL-55.  The 
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percents of activity remaining after CsA inhibition for the CYP3A5 high expressers 
(IUL-79, -59, and -73, Table 3) were in the same rank order as would be predicted by 
their CYP3A4 protein content and activity (Table 2).  As determined by CsA inhibition, 
the percent contributions of CYP3A5 to M1 formation were likely underestimated 
because rCYP3A5 was somewhat inhibited (15%) by CsA (Fig. 14).   
4. Prediction of CYP3A5 Contribution to Vincristine Metabolism 
The Vmax values of M1 formation from VCR for CYP3A5 low expressers were 
correlated with CYP3A4 activity and protein content: testosterone 6β-hydroxylase 
activity (r2 = 0.89, Fig. 29a); itraconazole hydroxylase activity (r2 = 0.91, Fig. 29b); and 
CYP3A4 protein content (r2 = 0.75, Fig. 29c).  The CYP3A5 low expressers were 
assumed to have an insignificant amount of CYP3A5 activity as compared to CYP3A4 
activity.  For the HLMs with CYP3A5 low expression, regression lines and 
corresponding 95% prediction intervals for the M1 Vmax values were calculated using 
each measure of CYP3A4 (activity or protein content).  Using these prediction intervals, 
the Vmax values from the CYP3A5 high expressers were compared to the CYP3A5 low 
expressers.  Regardless of CYP3A4 measure, the Vmax values of all the CYP3A5 high 
expressers were above the 95% prediction intervals established by the CYP3A5 low 
expressers. To determine the specific contribution of CYP3A5 to M1 formation at Vmax 
for CYP3A5 high expressers, the CYP3A4 contributions were subtracted from the Vmax 
values.  For each CYP3A5 high expresser, the CYP3A4 contribution was the 
corresponding best-fit Vmax value of the CYP3A5 low expressers at a specific CYP3A4 
measurement (activity or protein content).  The resulting CYP3A5 contributions (% of 
total activity, Table 3) for the CYP3A5 high expressers were in good agreement with 
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each other, regardless of the CYP3A4 value (activity or protein content) used to 
determine the CYP3A4 contribution to M1 formation.  The average contribution of 
CYP3A5 to the formation of M1 for CYP3A5 high expressers at Vmax was 81% of the 
total activity (Eqn. 4).  Thus, with CYP3A5 high expressers at Vmax, VCR metabolism to 
M1 was primarily mediated by CYP3A5.  This result was similar to the CYP3A5 
contribution predicted using cDNA-expressed enzymes, approximately 90%.   
The CYP3A5 contributions to the rate of M1 formation using intrinsic 
clearances, rather than Vmax values, were also quantified because therapeutic 
concentrations of VCR are less than 1 µM, well below the Km.  However, as indicated 
earlier, the Km values of M1 formation for CYP3A5 high and low expressers were not 
statistically different (p = 0.49).  As a result, the calculated CYP3A5 contributions for 
CYP3A5 high expressers using Vmax values were similar to the CYP3A5 contributions 
using intrinsic clearances (data not shown).   
The CYP3A5 activities of M1 formation for the high CYP3A5 expressers, 
calculated by subtraction of the CYP3A4 contribution using ITZ hydroxylase activities, 
were correlated to the CYP3A5 protein content (r2 = 0.95, Fig. 30).  The correlation was 
highly influenced by IUL-40 because its CYP3A5 protein content was much higher than 
those of the other HLMs (Table 2), yet even without including IUL-40 in the analysis, 
the CYP3A5 activities were correlated to the CYP3A5 protein content (r2 = 0.63).  The 
CYP3A5 M1 activities using testosterone 6β-hydroxylation to calculate the CYP3A4 
contribution were almost identical to the CYP3A5 activities calculated using 
itraconazole hydroxylation as a CYP3A4 standard (Table 3).  Thus, the CYP3A5 
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activities derived using testosterone 6β-hydroxylation were also correlated to CYP3A5 
protein content (r2 = 0.96).   
The specific activities of M1 formation for CYP3A4 and CYP3A5 in HLMs 
were calculated using the protein contents as quantified by Western blot and the 
maximum rates of M1 formation.  For the CYP3A5 high expressers, the ITZ 
hydroxylase activity was used to calculate the CYP3A4 contribution to the rate of M1 
formation as described earlier.  The specific activities were 7-fold higher for CYP3A5 
(Fig. 31) and consistent with the values obtained using cDNA-expressed CYP3A4 and 
CYP3A5 (Table 1).  
5. Prediction of Vincristine Hepatic Clearance for CYP3A5 High and Low 
Expressers  
The hepatic clearance of VCR was estimated for each HLM using the well-stirred model 
(Eqn. 5).  An alternate more complex physiological model, the parallel-tube model, does 
not assume that the concentration of drug is the same throughout the liver.124  However, 
the well-stirred model was appropriate because VCR is a low to medium extraction ratio 
drug and not highly bound to blood cells and plasma proteins.  Thus, with these 
conditions, the well-stirred model would predict similar hepatic clearances to the 
parallel-tube model.124  M1 was assumed to be the only metabolite formed from VCR, 
and the rate of M1 formation was assumed to be equal to the rate of VCR disappearance.  
The testosterone 6β-hydroxylase activities of CYP3A5 low expressers were correlated 
to the rate of M1 formation (Fig. 29a).  Thus, for the HLMs that were not initially 
selected for incubation with VCR (all CYP3A5 low expressers not listed in Table 2), the 
M1 maximum rates of formation from VCR were estimated by linear interpolation using 
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the testosterone 6β-hydroxylase activities.  The average Km (20.5 µM) of the CYP3A5 
low expressers was used for each HLM not incubated with VCR.  The intrinsic and 
hepatic clearances of the HLM bank classified by CYP3A5 expression are presented in 
Fig. 32.  For the two groups, the intrinsic and hepatic clearances were statistically 
different (p < 0.001) with the median of CYP3A5 high expressers 7- and 5-fold higher 
than low expressers, respectively.  Median values were used to compare the CYP3A5 
low and high expressers because the data from both groups were not normally 
distributed. 
F. Binding 
1. Microsomal 
Using pooled HLMs, the fraction unbound of VCR was estimated by ultrafiltration 
(Methods, pg. 45).  The binding was quantified for the lowest concentration of VCR 
used during the HLM kinetic experiments (5 µM).  For the binding experiments, buffer 
controls without protein were intended to correct for non-specific binding to the 
apparatus.  However, for these negative controls, the VCR fraction unbound was 
consistently lower than the fraction unbound with protein (values plotted on y-axis, Fig. 
33a).  Thus, the negative controls in buffer could not be used to correct for non-specific 
binding.  Pre-treatment of the device with 1% BSA, as described previously,48 improved 
the recovery of the buffer control to 77% versus 66% but did not completely remove the 
non-specific binding of VCR to the apparatus.  An alternate approach (Eqn. 2) was used 
to estimate the fraction unbound caused by non-specific binding (fu,nsb = 0.76 ± 0.05) 
and the parameter K (0.161 ± 0.05 ml/mg) with non-linear regression.  These values  
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were used to calculate the fraction unbound (fu) at any protein concentration (Cp) and 
then to correct the Km values for the HLMs (fu = 0.67 to 0.90, Fig. 33).   
2. Plasma 
The fraction unbound of VCR in plasma was estimated at 1 µM, a concentration 
approximately 10-fold higher than the maximum therapeutic concentration (Methods, 
pg. 46).56  Like the buffer controls for the microsomal binding experiments, the PBS 
controls were unable to correct for non-specific binding to the apparatus (values plotted 
on y-axis, Fig. 33b).  Thus, a dilution approach with PBS was used to estimate the 
fraction unbound in human plasma from one donor (Eqn. 2).  The parameters fu,nsb and K 
were determined from the apparent binding measured with undiluted plasma (100%) and 
with diluted plasma at three concentrations (50, 20, and 10%).  The estimated fraction 
unbound caused by non-specific binding (fu,nsb) was 0.64 ± 0.02, and the parameter K 
was 0.0064 ± 0.0008 (% of undiluted plasma)-1.  The fu,nsb value was used to estimate the 
fraction unbound (fu) for two other plasma donors.  The final fraction unbound of VCR 
for the three donors (fu = 0.595 ± 0.007) was similar to other reported values of 0.41 and 
0.51.47,48  Using the median value of 0.51 in the well-stirred model (Eqn. 5), the hepatic 
clearances were estimated for each HLM (Table 2).   
3. Whole Blood 
Freshly heparinized whole blood at 37°C was used to estimate the blood-to-plasma ratio 
of VCR at 100 nM, a concentration close to the maximum therapeutic concentration 
(Methods, pg. 46).  At this concentration, radiolabeled VCR was utilized because the 
VCR was below the HPLC limit of quantification.  For this experiment, the estimated 
blood-to-plasma ratio was 1.14 to 1.20.   
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An additional experiment also estimated the blood-to-plasma ratio of VCR and 
M1 at typical to low therapeutic concentrations (0.2 and 4.6 ng/mL for VCR, 0.1 and 2.3 
ng/mL for M1).  However, because the primary purpose of the experiment was evaluate 
the effect of ascorbic acid on VCR and M1 stability in whole blood, the experiment was 
performed at room temperature.  The VCR and M1 concentrations in the plasma were 
quantified by LC/MS/MS (Methods, pg. 59).  The blood-to-plasma ratios were similar at 
both VCR concentrations (1.08 and 1.10).  Likewise, the blood-to-plasma ratios of M1 
were similar at both M1 concentrations (0.72 and 0.80).    
G. Human Hepatocytes 
1. Vincristine Degradation in Media 
Initial incubations with cryopreserved hepatocyte (lots SD012 and SD017) and VCR 
resulted in the formation of VCR degradation products with no evidence of metabolism 
(Fig. 34; Methods, pg. 48).  For both the no cell controls and the hepatocyte inbubations, 
the fractions of ions as the epoxide 1 or epoxide 2 (typical degradation products) 
increased as the concentration of VCR was reduced (Fig. 34a,b).  The binding of VCR 
to the hepatocytes may have protected the VCR somewhat from degradation because the 
degradation was the highest in the no cell controls.  The M1 concentrations with 
hepatocytes were similar to the M1 concentrations of the no cell controls (Fig. 34c).  
This observation was consistent for screening incubations with other lots of hepatocytes 
(lots 652, Hu418; data not shown).  The formation of M1 in the no cell controls was 
unexpected because M1 was not previously observed in buffer or plasma standards.  To 
verify that M1 was formed in the media standards, the degradation of 15 µM VCR at 
37°C was quantified by LC/MS in plasma, buffer, and media after 0 and 4 h (Fig. 35a).  
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Consistent with the previous incubation results, the media formed substantial amounts 
of M1, unlike the plasma and buffer standards.  Although the M1 concentration in media 
was the highest at the 4 h time point, M1 formation was also apparent at the 0 time 
point.  The effects of other incubation variables (oxygen purging and shaking) on the 
degradation of 10 µM VCR were evaluated (Fig. 35a; Methods, pg. 47).  Although the 
shaking during the 4 h incubation had little effect, oxygen purging increased the 
concentration of VCR degradation products, in particular epoxide 1.   
2. Selection of Cryopreserved Hepatocytes 
To potentially differentiate the rates of M1 formation caused by degradation from the 
rates caused by metabolism, high CYP3A activity hepatocytes were chosen and 
incubated at high cell concentrations (1.5 x 106 cells/mL; Methods, pg. 47).  Based on 
data from previous microsomal studies, livers with high CYP3A5 expression were 
expected to have the highest rates of M1 formation.  Unfortunately CYP3A5 pre-
genotyped hepatocytes were not available commercially.  As an alternative, African-
American hepatocytes were purchased (n = 9, 70% probability of CYP3A5 
expression).75  The hepatocytes were genotyped for CYP3A5 polymorphisms using 
DNA extracted from the residual cells.  By CYP3A5 genotype, the CYP3A5 expression 
for three lots (REL, CHD, and MRS) could not be predicted because the livers had 
multiple CYP3A5 SNPs which could prevent expression on one or both chromosomes.  
These livers were later categorized by phenotype using VCR activity (Table 4).  Of the 
9 African-American livers, 7 were categorized as CYP3A5 high expressers, and 2 livers 
(with inconclusive genotypes) were CYP3A5 low expressers.  For this study, one 
additional Caucasian liver (AIT, CYP3A5*1/*3) was purchased from the same vendor. 
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3. Testosterone 6β-hydroxylase Activity 
For all lots, the testosterone 6β-hydroxylase (CYP3A) activity was reported for the 
intact cells by the vendor.  To provide additional information on the CYP3A activity, we 
quantified the testosterone 6β-hydroxylase activity for the cell lysates (sonicated 
hepatocytes) supplemented with NADPH (Methods, pg. 48).  The activities of the cell 
lysates were highly variable between lots with a 100-fold range in values (Table 4).  The 
CYP3A cell lysate activities were not correlated to the reported intact cell activities.  
4. Vincristine Depletion and M1 Formation for CYP3A5 High Expressers 
The metabolism of VCR was investigated using both intact hepatocytes and cell lysates 
(Table 4; Methods, pg. 48).  For livers with a conclusive CYP3A5*1 genotype, for 
example EHI, VCR was almost exclusively metabolized to M1 as determined by HPLC 
(Fig. 36).  Using radiolabeled VCR with both cell preparations, M1 was also identified 
as the major metabolite (Fig. 37; Methods, pg. 50).  With the cell lysate, M1 formation 
by retention time accounted for approximately 50% of the total radioactivity not VCR 
(Fig. 37a).  For the intact cells, the rate of M1 formation in the media was inhibited 
approximately 70% by ketoconazole, a CYP3A inhibitor (Fig. 37c).  The VCR/M1 
concentration ratios were approximately the same in the media and cell fractions (Fig. 
37b). 
To estimate the rates of metabolism, M1 and VCR concentrations were 
quantified by LC/MS at multiple time points up to 4 h.  The rate constants for VCR 
depletion (k) were estimated by non-linear regression assuming a first-order reaction 
(Fig. 38b).  Similarly, the rate constants for M1 formation were also estimated assuming 
that M1 was the terminal product and the only metabolite of VCR.  For these two 
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methods, the rate constant estimated from VCR depletion was typically higher than the 
rate constant estimated from M1 formation.  However, in all cases, the M1 formation 
accounted for at least 42% of the VCR depletion (range =  42 to 131%) as shown by the 
differences in intrinsic clearances calculated using the rates of M1 formation and VCR 
depletion (Table 4).   
When the M1 formation rate constants were estimated for the lysates, the 
assumption of first-order kinetics was not valid for two lots of hepatocytes (FKM, SCA; 
Fig. 38a).  Although the mechanism is currently unknown, for these two lots, M1 was 
rapidly formed from VCR and then degraded and/or metabolized at later time points.  
With hepatocyte lot SCA, the initial VCR concentration was reduced 90% by an 
apparent first-order reaction over 40 min.  The M1 concentration correspondingly 
increased early in the reaction but later stabilized, even as the VCR concentration 
continued to decline.  As a result, for lots FKM and SCA, the rate constants for M1 
formation were estimated using the 10 min time point only.  Interestingly, for lots FKM 
and SCA, the concentrations of VCR and M1 were effectively modeled by non-linear 
regression using a kinetic model with two rate constants: k1 (the first-order constant for 
VCR depletion and M1 formation) and k2 (first-order constant for M1 depletion) (Fig. 
38a).       
5. Prediction of Intrinsic Clearance for CYP3A5 High Expressers 
Using the estimated rate constants for CYP3A5 high expressers, the intrinsic clearances 
of VCR were predicted with the intact cells and the cell lysates (Table 4).  For most lots, 
the intrinsic clearances for the two cell preparations were dramatically different from 
each other; the cell lysate predicted values at least 10-fold higher than those predicted 
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with intact cells.  In addition, the values from the cell lysate were more variable than 
those from intact cells.  As compared to the intrinsic clearances predicted with human 
liver microsomes (Table 2), the cell lysate values were similar for CYP3A5 high 
expressers.  The cell lysate activities for M1 formation and TST 6β-hydroxylation were 
somewhat correlated (r2 = 0.67).  The cell lysate activities for TST 6β-hydroxylation did 
not predict the rate of M1 formation with intact cells (r2 = 0.03).  Interestingly, although 
the values were similar to each other, the highest activity hepatocytes for M1 formation 
with intact cells were lots with the CYP3A5*1/*1 genotype (median value = 101 versus 
59 mL/min for CYP3A5*1/*0 livers, Table 2).      
6. Effects of Inhibitors on M1 Formation  
To determine whether M1 formation was mediated by CYP3A enzymes, ketoconazole 
was used as a selective CYP3A inhibitor (Fig. 39a).  For each lot of hepatocytes, the 
cells were incubated with VCR for 4 h with and without ketoconazole.  The M1 
concentrations of the incubations with ketoconazole were 8 to 38% of the positive 
control incubations without inhibitor (Table 5).  The concentrations of M1 were not 0% 
of the positive control because M1 was formed in the controls as discussed earlier.  
However, the CYP-mediated formation of M1 was completely inhibited by 
ketoconazole; the final concentrations of M1 with ketoconazole were comparable to 
those of the sonicated cell controls for lot EHI, a typical CYP3A5 high expresser (Fig. 
39a).  For hepatocyte incubations with radiolabeled VCR (lot EHI), the concentration of 
M1 by retention time was 30% of the positive control, a value approximately 2-fold 
higher than the remaining M1 concentration after ketoconazole inhibition for the same 
lot of hepatocytes (17%, Fig. 37c).  However, the radiochromatogram value should be 
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somewhat higher than the value determined by LC/MS because M1 and EPOX1, a 
degradation product, co-elute by HPLC.       
Two other chemical inhibitors were also co-incubated with VCR: CsA (a 
selective CYP3A4 inhibitor) and LSN335984 (a selective P-gp inhibitor).  CsA at 25 
µM was chosen because the drug at this concentration was previously used to inhibit the 
formation of M1 by CYP3A4 in HLMs.  For all hepatocyte lots incubated with CsA, the 
rates of M1 formation were unaffected (Table 5).  This result would be expected if CsA 
did not enter the cells or if CYP3A4 did not metabolize VCR.  The Pgp inhibitor 
LSN335984 was initially chosen to reduce the rate of VCR efflux from the hepatocytes 
and thus potentially increase the intracellular, unbound concentration of VCR.  For 
screening experiments with hepatocyte lot EHI, 5 µM LSN335984 (a typical 
concentration for cell culture transporter experiments) was metabolized faster than VCR 
and did not affect the rate of M1 formation (data not shown).  To prevent the depletion 
of LSN335984 from the media, the concentration of LSN335984 was increased to 50 
µM although the non-selective inhibition on CYP enzymes at this concentration was 
unknown.  For the remaining hepatocyte incubations, the rates of M1 formation with 50 
µM LSN335984 were partially inhibited, not increased as was predicted if the 
intracellular concentration of VCR was increased (Table 5).  Although the mechanism is 
unknown, the reduced rates of M1 formation may have been caused by inhibition of 
CYP3A5 by LSN335984.     
7. Michaelis-Menten Kinetics of M1 Formation  
To better understand the differences in rates of M1 formation between intact cells and 
cell lysates, the Michaelis-Menten kinetic parameters were estimated for Lot EHI using 
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both cell preparations (Methods, pg. 49).  The Km of the cell lysate was 3-fold lower 
than the Km of the intact cells; the Vmax of the cell lysate was 3-fold higher than that of 
intact cells (Fig. 40).  Altogether, the intrinsic clearance of the cell lysate (Vmax/Km) was 
9-fold higher than that of the intact cells.  For the intact cell system, the rate of VCR 
diffusion through the cell membrane may be relatively slow compared to the rate of 
metabolism.  In this case, because the intra-cellular concentration of VCR would be less 
than the extracellular concentration, the apparent Km would be higher than the value 
predicted using HLMs.  However, a Vmax change is not likely caused by transport 
effects, provided the transport is not saturable.    
8. Prediction of Intrinsic Clearance for CYP3A5 Low Expressers 
VCR depletion and M1 formation were not observed using specific lots of intact 
hepatocytes: 652, CHD, Hu418, MRS, SD012, and SD017 (Table 4).  For these lots, 
categorized as CYP3A5 low expressers, the M1 concentration during the incubations 
surprisingly decreased (inset, Fig. 39b).  Perhaps the decline was caused by M1 
degradation and/or metabolism as described earlier with lysate incubations.   
Although the intact cells of CYP3A5 low expressers did not metabolize VCR, 
the CYP3A4 activities were typical of other CYP3A5 high expressers as determined by 
the testosterone 6β-hydroxylase activities of the intact cells from the vendor (lots CHD 
and MRS) and of the cell lysate (lot MRS, Table 4).  The CYP3A5 low expressing 
hepatocytes used during the screening experiments also effectively metabolized a probe 
CYP3A substrate, verapamil (data not shown).  In direct contradiction with the intact 
cell results, the cell lysate of MRS effectively metabolized VCR to M1 (Table 4).  At 
this time, we do not understand why the hepatocytes without CYP3A5 expression did 
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not metabolize VCR.  Nevertheless, the predicted intrinsic clearance of VCR for 
CYP3A5 low expressers is essentially zero.  This prediction contradicts the human liver 
microsome data and the hepatocyte lysate data.   
H. Assay Development for the Quantification of M1 and Vincristine in Plasma 
The methods for VCR quantification were chosen to optimize VCR stability and 
recovery.   Direct precipitation methods were first used to quantify VCR in plasma.  For 
one method, the plasma was quenched with an approximately equal volume of methanol 
and froze the sample to facilitate protein precipitation.  Although this procedure 
effective isolated VCR from the protein, by the nature of the procedure, the method 
naturally diluted the plasma and did not enable a large percentage of the sample to be 
injected on column.  Using an alternate procedure, 10% trichloroacetic acid (TCAA) 
was added to the plasma to precipitate the protein.  This method effectively precipitated 
the protein while only adding a small volume of acid to the plasma.  Unfortunately the 
chromatography that resulted from these samples was unacceptable because the peak 
shapes of VCR and VRL were broad.   
At this point, conditions for an extraction procedure were explored including 
solvent choice, solvent volume, and pH.  Previously, the extraction of VCR, M1, and 
VRL was evaluated in a screening experiment with various solvents (Fig. 10, Methods, 
pg. ).  For this experiment, methylene chloride with TCAA addition effectively 
extracted VCR, M1, and VRL from buffer without degradation.  Based on this 
experiment, methylene chloride was a logical choice.  Toluene was also considered as 
an extraction solvent for the plasma assay because aromatic solvents have historically 
been used in the extraction of Vinca alkaloids from the periwinkle plant.1  In moving 
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forward with plasma extractions for VCR, toluene and methylene chloride were both 
tested.  For toluene, although the extraction recovery was reasonable at a neutral pH 
(49% with 2 volumes of solvent), VCR degraded to the N-oxide.  At a low pH, the 
extraction recovery was less than 2%.  The methylene chloride extraction efficiencies 
for VCR were consistent with the previous experiment in buffer (46 to 59% with 4 
volumes of solvent + TCAA).  In addition, the VCR N-oxide was not detected by 
LC/MS.  Therefore, for extraction of VCR in plasma, methylene chloride was chosen as 
the solvent. 
The internal standard (VLB or VRL) was chosen based on recovery with 
methylene chloride.  VCR with the internal standards was extracted with 2 volumes of 
methylene chloride.  The effects of acid addition and mechanical shaking were 
determined by quantifying the relative recoveries of VCR and the internal standard 
(Table 6).   For all the extraction condition, the recovery of VLB was significantly 
higher than VRL.  Thus, for the VCR extraction procedure, VLB was chosen as the 
internal standard.  Acid addition and mechanical shaking did increase the recoveries of 
VCR and VLB; these conditions were included in the final VCR extraction procedure. 
Now that the conditions for the extraction were somewhat optimized for 
recovery, standard curves with VCR were generated for therapeutic concentrations of 
VCR (0.2 to 100 ng/mL).  Unfortunately, the LC/MS responses of VCR were not linear 
because the VCR working solution adsorbed to the container.  Specific experiments 
were designed to choose an appropriate material of construction (glass or 
polypropylene) and to choose the correct solution composition (0 to 50% methanol) for 
the serial dilutions (Fig. 41).  For the most lipophilic compound, VRL, regardless of 
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tube material, the recoveries continued to increase even at the highest two 
concentrations, 30 and 40% methanol.  The recoveries of VCR and VLB were the least 
sensitive to methanol concentration in polypropylene tubes.  For VCR, recoveries in 
polypropylene tubes were similar at 20, 30, and 40% methanol.  As a result, for later 
extractions with plasma, the VCR standard curves were generated from working 
solutions in 20% methanol, diluted in polypropylene tubes.   
Polypropylene tubes were also chosen for the dissolution of the methylene 
chloride extract in 0.2% formic acid: methanol (80:20).  The recoveries of VCR and 
VLB were 10 to 15% higher in polypropylene tubes compared to glass tubes (silanized 
or not).  The most consistent recovery of the analytes (80% for VCR) was accomplished 
by scraping the pellet from the polypropylene wall.  Other techniques (methanol 
dissolution) resulted in 5 to 10% less recovery.  The internal standard VLB was also 
required for high recovery of VCR because VLB acted as a carrier for VCR at low 
concentrations (Fig. 42a). 
Finally, using the initial gradient conditions (Fig. 41), the standard curves 
generated by LC/MS were unable to quantify concentrations of VCR below 0.4 ng/mL 
(Fig. 42b).  An extended gradient method was chosen to eliminate the baseline noise 
from the blank plasma.  Although the baseline noise was not present in the LC/MS/MS 
assay, the assay was developed to work using both LC/MS and LC/MS/MS detection. 
I. Validation of M1 and Vincristine Quantification in Plasma 
1. Liquid chromatography and mass spectrometry 
ESI in positive mode was chosen for the analysis of VCR, M1, and vinblastine (internal 
standard).  Previously for Vinca alkaloids, ESI was shown to have the greatest 
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sensitivity when compared to EI or APCI.15,125  Q1 scans of VCR, M1, and vinblastine 
revealed that the dicharge ions were the most intense precursor ions.  As expected from 
our previous work,121 the dehydrated dicharge ion for M1 at a m/z of 397.2 was the 
dominant Q1 ion.  The two Q3 product ions for each compound with the most intense 
signals were selected for automated MRM optimization (Fig. 43, Table 7).  The Q3 ions 
for each compound with the highest signal-to-noise (S/N) ratio were used to quantify the 
analytes in standards and clinical samples (400 ms dwell times).  The alternate Q3 ions 
for VCR and M1 (100 ms dwell times) were used to verify compound identities.   
Representative chromatograms of a high QC standard are presented in Fig. 44.  
Baseline separation in the standard samples was achieved for all compounds using a 
series of linear gradients (Fig. 44).  The M1 and VCR chromatograms of a 
representative blank plasma sample and the standards at the low limit of quantification 
are presented in Fig. 45a,b.  No interference was detected in the blank plasma sample 
for any monitored ions.  The chromatograms of an extracted patient plasma sample at 
the last time point (20 h post VCR dose) are also presented (Fig. 45c).  For this sample, 
M1 and VCR concentrations were within the limits of quantification.                          
2. Validation data 
The standard curves were generated using analyte/internal standard area ratios (Fig. 46).  
The VCR standard curve (0.012 to 24 ng/mL) was fit using a linear regression model 
with 1/x weighting (slope = 0.154 ± 0.011, mean r2 = 0.993).   The M1 standard curve 
(0.012 to 12 ng/mL) required a power fit (y = mxγ) to consistently fit the data (m = 0.045 
± 0.005, γ = 1.01 ± 0.01, mean r2 = 0.994).  The average calculated concentration values  
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(n = 4) for the calibration standards at each concentration met the accuracy requirements 
of the validation for the models chosen (90 to 115% for VCR and 93 to 110% for M1).   
VCR and M1 were extracted from plasma using 10% trichloroacetic acid and 
methylene chloride.  The recoveries of VCR and M1 averaged 62% and 58%, 
respectively, with no differences between low, medium, and high concentrations (Table 
8).  The limits of detection and quantification for VCR and M1 are summarized in Table 
9.  The concentration limit of detection (cLOD) in plasma was defined as the lowest 
plasma concentration tested with a S/N ratio of at least 3.  The concentration limit of 
quantification (cLOQ) was the lowest plasma concentration tested for which the intra-
day accuracy (80 to 120%) and precision (%CV ≤ 20) standards were met (n = 4) and 
for which the S/N ratio was at least 5.  The mass limit of detection (mLOD) and the 
mass limit of quantification (mLOQ) were defined as the mass of drug on column at the 
cLOD and cLOQ, respectively.  The intra-day and inter-day accuracy and precision data 
are presented in Table 10 with three concentrations of each compound tested.  The 
acceptance criteria as described in the methods section were met for both VCR and M1.    
The stability of VCR and M1 in the stock solution at 4°C was evaluated at the 
beginning and end of the validation experiments by HPLC with UV detection.  The 
VCR and M1 concentrations after 14 days were 96% and 98%, respectively, of the 
original values.  The post-preparative stability of VCR and M1 was also quantified by 
injecting the QC samples (high, medium, and low concentrations, n = 6 total) 10 to 26 h 
after the first injections.  This process was repeated for three standard curves, and the 
average accuracies of the reinjected samples for each concentration were calculated.  No  
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degradation was detected for VCR (90 to 97% accuracy) or M1 (93 to 98% accuracy) at 
any concentration. 
 The stability of VCR and M1 in plasma after 15 h at room temperature and after 
three freeze-thaw cycles was determined using QC samples of high (19 ng/mL VCR, 9.5 
ng/mL M1, n = 3) and low (0.047 ng/mL VCR, 0.024 ng/mL M1, n = 3) concentrations.  
The VCR concentrations after 15 h at room temperature were on average 85.3% (high) 
and 81.8% (low) of the control group (untreated QC samples), but the differences were 
not statistically significant (p = 0.08, high and p = 0.06, low).  The VCR concentrations 
were also unaffected by multiple freeze-thaw cycles at high (92.2% accuracy, p = 0.35) 
and low (89.5% accuracy, p = 0.25) concentrations.  Unlike VCR, M1 was not stable in 
plasma after 15 h; the M1 concentrations at both high and low concentrations were only 
20% of the untreated QC sample concentrations.  However, the freeze-thaw stability 
studies showed no statistical differences in M1 concentrations between the previously 
thawed and untreated QC samples for high (84.2% accuracy, p = 0.20) and low (98.4% 
accuracy, p = 0.88) concentrations.  To understand the processing stability of VCR and 
M1, stability studies at room temperature for VCR and M1 at therapeutic concentrations 
were conducted using freshly heparinized whole blood.  The recovery of VCR and M1 
after 3 h was within 15% of the control (15 min) value.  Thus, although M1 degrades in 
plasma, standard processing times (< 3 h) should be acceptable for routine processing 
and freezing of the plasma samples.  The selectivity of the assay was evaluated using 
blank plasma from healthy human donors (n = 3), and no interference was detected for 
M1, VCR, or vinblastine.  The drugs potentially coadministered with VCR were also 
assayed individually to evaluate interference, and no interfering peaks were detected. 
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J. M1 and Vincristine Concentrations in Patient Samples 
1. Urine 
The urine samples from the 2002–2004 clinical studies were assayed for M1 and VCR 
concentration (Fig. 47).  In addition, two samples of the VCR clinical formulation were 
directly assayed by LC/MS/MS to determine the administered VCR/M1 plasma 
concentration ratio.  Compared to the VCR/M1 plasma concentration ratio of the clinical 
formulation, the patient sample metabolite ratios were similar but highly variable.  For 
the urine samples from the two patients with high CYP3A5 expression, the VCR/M1 
ratios were not different from those of other patients (200 vs. 10 to 1000 for all 
patients).  For two urine samples collected at different time points (patient 14), the 
VCR/M1 ratios were drastically different (100-fold lower concentration after 3 h).  A 
high VCR/M1 ratio would be expected during the initial distribution phases of VCR, 
while the VCR concentration is highest in the blood before it completely distributes to 
the tissues.  To predict the exposure of patients to VCR or plasma VCR/M1 
concentration ratios of a patient, the VCR/M1 concentration ratios in urine would be 
most useful if the samples were collected during the terminal elimination phase of VCR.     
2. Plasma from 2002–2004 Clinical Studies 
Over 100 plasma samples were collected from pediatric patients receiving VCR 2002–
2004.  These samples were assayed for VCR and M1 content after the assay was 
validated in 2007.  Compared to the standard curve samples, the VCR chromatograms of 
the patient samples included three additional peaks (Fig. 48); by retention time, these 
compounds were tentatively identified as epoxide 1 (M4), epoxide 2 (M5), and VCR-
NO.  For one representative sample, the VCR-NO signal intensity as quantified by 
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LC/MS was 10-fold higher than the VCR signal intensity (Fig. 49).  Thus, the VCR in 
these clinical samples had degraded.   
3. Plasma from Rhadomyosarcoma Patients, 2006–2007 
Samples from patients (n = 4) treated for rhabdomyosarcoma were assayed in duplicate 
for VCR and M1 up to 24 h after treatment.  The lowest VCR and M1 concentrations 
(0.47 ng/mL and 16 pg/mL, respectively) were above the LOQ for all plasma samples, 
and the concentration of M1 at any time point was 1.7 to 22.3% of the VCR 
concentration (Fig. 51).  The plasma concentration versus time profiles of VCR and M1 
are shown in Fig. 50.  Using a two-compartment model with elimination from the 
central compartment, the fitted parameters of VCR for two patients and the average 
values of the parameters for all patients are listed in Table 11.  The average terminal half 
life of 27 h and clearance of 491 mL/min/m2 for VCR are consistent with previously 
published pharmacokinetic data in adults.56,126  However, for almost all the model fitted 
parameters, the uncertainty was somewhat high, approximately 30% for plasma 
clearance, because the model was required to extrapolate past the last time point at 24 h.  
More importantly, the two-compartment model chosen to fit the data may not be correct 
at later time points.  In fact, adult pharmacokinetic studies with VCR past 24 h routinely 
used a three-compartment model to describe the data.44,52  For the patients in our study, 
the plasma time points described less than 50% of the AUC.  A better estimation of 
exposure and clearance would be achieved if additional plasma samples were collected 
at later time points (48, 72 h).  
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V. Discussion 
A. Key Pathways of Metabolism and Major Metabolites of Vincristine 
The primary objective of this study was to understand the role of CYP3A5 in the 
metabolism of vincristine.  This information could then be used to predict how CYP3A5 
genotype in patients may influence the systemic clearance of vincristine.  To begin to 
understand the role of CYP3A5, some fundamental questions about the metabolism of 
vincristine needed to be answered.  What cytochrome CYP enzymes metabolize 
vincristine?  What are the primary metabolites of vincristine?  Previously published 
evidence from multiple in vivo and in vitro studies suggested that vincristine is 
metabolized by CYP3A enzymes.16  However, even though vincristine is one of the 
most studied chemotherapeutic agents, fundamental metabolism data was not available 
for vincristine with cytochrome CYP enzymes.  To this point, other research scientists 
have commented on the “frustrating paucity” of information related to Vinca alkaloid 
metabolism.127  This apparent void in the literature is likely caused by multiple factors 
including model selection for metabolism and analytical techniques. 
For the first in vitro studies, we chose to use commercially available cDNA-
expressed CYP enzymes produced from baculovirus-infected insect cells.  In pre-
clinical drug development, these enzymes are the industry standard because the 
activities between lots of enzyme are consistent.  In addition, the substrate selectivity 
can be evaluated for individual CYP enzymes.  For this study, cDNA-expressed 
CYP3A4 and CYP3A5 were incubated with vincristine.  In the incubated mixtures, one 
primary metabolite (M3) was first observed at a later retention time than vincristine by 
HPLC (Fig. 5d).  However, when LC/MS detection was used, the metabolic profiles of 
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these same incubates were different.  Two metabolites were detected, one at an earlier 
retention time than vincristine (M1) and one at a much later time (M3) (Fig. 4).  After a 
series of experiments, a relationship between M1 and M3 was realized; M1 degraded to 
M3 in the presence of base (Fig. 7).  Thus, M1 was the only major metabolite of 
vincristine because M3 formation was an artifact of post-incubation base treatment (Fig. 
6).  To quantify M1 by UV detection, the initial HPLC conditions had to be optimized to 
enable baseline separation of M1 and vincristine (Fig. 5a).  In addition, to prevent the 
formation of M3, base was no longer added to the incubations.  In retrospect, UV 
analysis was a poor choice for the initial metabolic profiling of vincristine.  
Alternatively, LC/MS ion monitoring would have detected M1 from the beginning.  In 
fact, we were fortunate that sodium hydroxide was added to the initial vincristine 
incubations; without the base-catalyzed conversion of M1 to M3, vincristine depletion 
and metabolite formation would not have been observed by HPLC at all.  Perhaps other 
investigators who previously studied the CYP metabolism of vincristine were misled, as 
we were initially, by non-selective methods of detection (electrochemical or UV).127    
Isolation and identification of the primary metabolite M1 was particularly 
challenging because it is chemically unstable.  Direct mass measurement of M1 by 
LC/MS was not straightforward because the compound readily lost water in the source 
(m/z 811 → 793).  The actual mass was not apparent until high concentrations of M1 
were infused (Fig. 11).  In addition, M1 degraded during normal procedures for 
metabolite isolation, including evaporation with water or methanol.  Thus, to chemically 
identify M1, stable derivatives of M1 were synthesized and characterized: M3, the base-
catalyzed product, and M1-acetate.  The structure of M3 was conclusively determined 
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by LC/MS/MS and NMR analysis.  For the acetylated product (M1-acetate), the Q1 
mass by LC/MS/MS (m/z 853) was consistent with acetylation of the proposed M1 
compound (m/z 811).     
Using the information from the M1 derivatives and the exact mass of M1, the 
chemical structure of M1 was deduced (Fig. 9); the compound is a unique secondary 
amine with modifications on the vincristine Catharanthine moiety.  The proposed 
mechanism of formation begins with the CYP-mediated hydroxylation of the carbon α 
to the piperidine ring nitrogen.  The piperidine ring reversibly opens between the 
nitrogen and the hydroxyl group.  The resulting aldehyde is then oxidized to a 
carboxylic acid; the acid is eliminated to yield M1.  These oxidations (best categorized 
as N-dealkylation and oxidative deformylation) are typical CYP-mediated reactions.63  
Although it was previously recognized that the two heterocyclic amines of vincristine 
were vulnerable to oxidation by cytochrome CYP enzymes, the structure of M1 is 
radically different from any previously proposed metabolites of vincristine.127  These 
structures were predicted without consideration of sequential oxidation possibilities.  
Other CYP3A substrates are reported to undergo sequential metabolism including 
itraconazole and docetaxel.34,128  In fact, the major metabolite of vincristine with 
horseradish peroxidase is M2, a compound formed by two sequential oxidations.9      
M2 was detected as a minor metabolite of vincristine using cDNA-expressed 
CYP3A5 (Fig. 6, approximately 10% of M1 by area); CYP3A4 and human liver 
microsomes did not produce M2.  The chemical structure of M2 was confirmed by 
LC/MS/MS to be the same as a product from a different enzyme system, horseradish 
peroxidase.9  We used this enzyme to more efficiently synthesize microgram quantities 
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of M2 for NMR analysis.  Just like M1, the first step in M2 synthesis is the 
hydroxylation of the carbon α to piperidine nitrogen (Fig. 9).  However, unlike M1, the 
carbon-carbon bond of the diol is cleaved leaving a formyl group on the piperidine 
nitrogen.  This type of oxidation is rarely observed with CYP enzymes.  Specifically, 
during the last step, mitochondrial P450scc oxidizes cholesterol to pregnenolone by 
cleaving the C-C bond of the diol.129  When selecting sites of oxidation on the 
vincristine-intermediate diol, CYP3A4 and CYP3A5 preferentially oxidize the aldehyde 
to produce M1.  Interestingly, for other non-CYP enzymes such as peroxidases and 
copper oxidases, M2 is the only vincristine metabolite reported.9,127  
Based on the CYP metabolism of vincristine, other Vinca analogues are also 
likely metabolized by CYP3A enzymes.  In particular, Vinca alkaloids with identical 
Catharanthine moieties to vincristine, such as vinblastine and vindesine, may be 
metabolized to an M1-equivalent molecule.  In fact, the CYP3A-mediated M1 
equivalent for vinblastine has been discovered by our laboratory (data not shown, 
manuscript in progress).  Other investigators have observed one primary metabolite (M) 
of unknown chemical identity from the incubation of radiolabeled vinblastine and 
vindesine with human liver microsomes.106,107  Using sodium perchlorate/perchloric acid 
(acidic pH) and an extended methanol gradient, these compounds by HPLC eluted later 
than their parent drug (+ 4 min).  Based on our HPLC data with vincristine at an acidic 
pH (Fig. 5a), the metabolites by retention time appear most like M2 or M3-equivalent 
compounds.  However, the incubations were not pretreated with a strong base, a 
requirement for the production of vincristine M3 from M1.  Without LC/MS data, we 
cannot know with certainty what compounds were observed in these studies.   
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Other Vinca alkaloids such as vinorelbine are likely to have a different metabolic 
pathway from vincristine because the hydroxyl group β to the piperidine nitrogen is not 
present (Fig. 1).  After the initial hydroxylation, this hydroxyl group is required for the 
subsequent oxidation reactions to produce M1 and M2.  Published data is consistent 
with this assessment; vinorelbine is metabolized to multiple compounds primarily by 
CYP3A4.109  Unlike with vincristine, one dominant metabolite has not been identified 
for vinorelbine.  The results from our laboratory (not shown) are in agreement with this 
finding.          
Once M1 was identified as a primary metabolite of CYP3A4 and CYP3A5, the 
relative roles of other hepatic (and a few non-hepatic) CYP enzymes were assessed.  
After each enzyme was incubated with vincristine, the vincristine depletion and M1 
formation were quantified (Fig. 12).  CYP3A4 and CYP3A5 were the only two enzymes 
with more than 20% depletion of vincristine.  Interestingly, with 90% vincristine 
depletion, CYP3A5 was the most active enzyme.  Vincristine was a statistically 
significant but poor substrate of other enzymes: CYP3A7 (a fetally expressed CYP3A 
enzyme) and CYP2E1.  Consistent with previous experiments, the depletion of 
vincristine corresponded to an increase in M1 concentration; 50 to 70% of the 
vincristine depletion was accounted for as M1.   
We demonstrated that cDNA-expressed CYP3A4 and CYP3A5 enzymes are the 
primary drug metabolizing enzymes for vincristine.  However, the results from cDNA-
expressed enzymes need to be carefully interpreted in combination with data from other 
in vitro models.  The cDNA-expressed enzymes lack all the cofactors and proteins 
found in a human hepatocyte.  In addition, compared to human liver microsomes, 
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recombinant enzymes contain higher concentrations of co-expressed redox coenzymes 
(NADPH-cytochrome P450 reductase and cytochrome b5).  The concentration of 
cytochrome b5 can significantly alter the kinetics of a reconstituted system; in some 
cases, even the metabolic profile of a substance can change.70   
As an alternative to cDNA-expressed enzymes, human liver microsomes are 
often used to evaluate CYP metabolism of drugs.  In this study, a select number of 
human liver microsomes from the Indiana University Liver Bank were incubated with 
vincristine and NADPH.  These human livers were phenotyped for CYP3A5 content.  A 
liver of each type (one high and one low CYP3A5 expresser) was used to identify any 
vincristine metabolites.  As with the cDNA-expressed enzyme system, the only major 
metabolite formed with human liver microsomes was M1 (Fig 23).   
M1 formation was confirmed to be primarily mediated by CYP3A4 and/or 
CYP3A5 using selective chemical inhibitors of CYP enzymes (Fig. 25).  The activity 
was reduced 80% with the addition of ketoconazole, a typical CYP3A selective 
inhibitor.  Other CYP3A substrates, vinblastine and vinorelbine, also competitively 
inhibited M1 formation.  The inhibition by the Vinca alkaloids was not surprising 
because in a different study, vincristine inhibited the metabolism of vinblastine.107  The 
rates of formation for M1 were somewhat reduced, approximately 20%, when CYP2D6 
and CYP2C19 were chemically inhibited.  This reduction in activity by quinidine and 
omeprazole may have been caused by non-selective effects of the chemical inhibitors on 
CYP3A4 or CYP3A5.  For example, the Km of omeprazole hydroxylation with CYP3A4 
is equal to the concentration used in this experiment.130  In addition, the selectivity of 
chemical inhibitors is unknown for CYP3A5.  Thus, the reduction in activity by 
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quinidine and omeprazole may be an artifact of the method.  In any case, the CYP3A 
enzymes were the primary drug metabolizing enzymes of vincristine.  
To understand the relative roles of CYP3A4 and CYP3A5 in human liver 
microsomes, the activity of CYP3A4 was selectively inhibited by cyclosporin A (Fig. 
26b).  As predicted by the cDNA-expressed enzyme system (Fig. 14), the rates of M1 
formation for CYP3A5 low expressers were more inhibited by cyclosporin A than those 
for high expressers (Fig. 26b, Fig. 28).  The degree of inhibition for both high and low 
expressers was predicted by 6β-testosterone hydroxylase activity, a CYP3A4 activity 
probe (Fig. 22b).  This correlation was expected for CYP3A5 high expressers because 
the residual activity after CYP3A4 inhibition should be CYP3A5-mediated.  However, 
for human liver microsomes without CYP3A5 activity, this relationship is less obvious.  
Perhaps for the microsomes with lowest CYP3A4 activity, the other less active CYP 
enzymes (or even the small amount of CYP3A5, Table 2) are primarily responsible for 
the metabolism of vincristine, albeit at an extremely slow rate.       
Although some useful data were obtained from the initial cyclosporin A 
inhibition experiments (Fig. 26b), the organic solvent concentration was high (4.8% 
methanol).  As a result, the basal activities of high and low CYP3A5 expressers were 
unequally inhibited in the vehicle controls (Fig. 26a).  While all the microsomes showed 
variable response to the methanol, the CYP3A5 low expressers were the most sensitive 
to methanol inhibition.  This data imply that the CYP3A4 activity with vincristine is 
more sensitive to methanol concentration than the CYP3A5 activity.  As previously 
reported, hepatic CYP enzymes in microsomes are not equally inhibited by organic 
solvents.131  Our data for CYP3A4 and CYP3A5 are consistent with this observation.  
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Later cyclosporin A inhibition experiments used lower concentrations of methanol 
(0.3%, Fig. 28); this concentration did not significantly affect the basal activity the 
microsomes (Fig. 27).  
To provide additional evidence of CYP3A4-mediated metabolism for vincristine, 
the CYP3A4 activities of the human liver microsomes were characterized with selective 
probe substrates, itraconazole and testosterone (Table 2, Fig. 29).  For CYP3A5 low 
expressers, a strong correlation was observed between CYP3A4 activities (ITZ and 
TST) and the rates of M1 formation (r2 = 0.89 and 0.91).  Although the protein content 
of CYP3A4 also correlated to the rates of M1 formation (r2 = 0.75), less of the 
relationship was explained by CYP3A4 protein expression as compared to CYP3A4 
activity.  As previously reported, CYP3A4 activity is commonly correlated to but not 
completely explained by CYP3A4 protein content; typical r2 values for CYP3A4 are 
0.74 to 0.78.80,132  In our study, the testosterone 6β-hydroxylase activity was also 
correlated to CYP3A4 protein content with an r2 value of 0.77.  Other than protein 
content, several factors likely influence the activity of CYP3A4 including variable heme 
coupling, assay uncertainty, and variable expression of coenzymes.  In any case, the 
majority of the variability in the rates of M1 formation was accounted for by CYP3A4 
activity and protein content.  Thus, CYP3A4 is a major drug metabolizing enzyme of 
vincristine for CYP3A5 low expressers. 
The roles of CYP3A4 and CYP3A5 were also evaluated for CYP3A5 high 
expressers.  Compared to CYP3A5 low expressers with equivalent CYP3A4 activities, 
the high expressers more rapidly metabolized vincristine to M1 (Fig. 29).  All values for 
CYP3A5 high expressers were outside of the 95% confidence interval established by 
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CYP3A5 low expressers.  Hence, CYP3A5 expression is a significant factor in the 
metabolism of vincristine.  In addition, the CYP3A5 protein content was correlated to 
the predicted CYP3A5 activity with vincristine (Fig. 30, r2 = 0.95).  This analysis and 
the data from the selective chemical inhibition experiment (Fig. 28b) provide strong 
evidence of CYP3A4 and CYP3A5 involvement in vincristine metabolism for CYP3A5 
high expressers.  
For the last in vitro model, cryopreserved hepatocytes were used to evaluate the 
metabolic profile of vincristine.  Unlike the two other in vitro models, hepatocytes 
contain physiological concentrations of enzymes, coenzymes, and NADPH.  Of 
particular importance, the previous models were unable to evaluate the potential roles of 
phase II enzymes.  In previously published studies, investigators hypothesized that 
secondary metabolism (possible phase II) of vincristine may be responsible for the 
formation of three metabolites.10  From our previous work with cDNA-expressed 
enzymes and microsomes, we anticipated that vincristine would be metabolized by 
hepatocytes to at least one compound, M1, by CYP3A4 and CYP3A5 (if present). 
We first incubated vincristine with hepatocytes of unknown CYP3A5 genotype.  
To our surprise, the hepatocytes produced no apparent metabolites of vincristine (Fig. 
39b).  In fact, for these incubations, the concentrations of M1 were high at time zero (2 
to 3% of vincristine) and then decreased with time; an increase in concentration was not 
detected for any vincristine-related compounds.  This observation was true using 
multiple concentrations of vincristine (0.1 to 50 µM) and cells concentrations up to 1.5 x 
106 cells/mL. 
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Initially, the high concentration of M1 at time zero was a concern, particularly at 
low concentrations of vincristine (Fig. 34).  As shown in Fig. 35, unlike plasma or 
buffer solutions, a small percentage of vincristine in media readily degraded to M1 at 
time zero (2 to 3%).  Thus, the high concentrations of M1 and other degradation 
products (especially epoxide 1) at time zero were artifacts of the model.  Although we 
do not have an explanation for the degradation, we were able to account for the 
formation of M1 at time zero; the initial concentrations of M1 were quantified by 
LC/MS and subtracted from the values at later time points.  This correction was possible 
because the concentrations of M1 were high at time zero but did not detectably change 
over 4 h for the sonicated cell controls (Fig. 39).  In addition, for the remaining 
incubations, the vincristine concentrations were always 4 µM or higher to minimize 
degradation.   
Vincristine metabolism was not detected using the following cryopreserved 
hepatocyte lots: 652, Hu418, MRS, SD012, and SD017.  Various control experiments 
were performed to ensure that the activity of CYP3A4 and the viability of the cells were 
normal.  In addition, to verifying that vincristine was not adsorbed to the wells or cells, 
the free concentrations of vincristine were quantified in the media.  In the absence of an 
alternate explanation, we hypothesized one of two possibilities; either CYP3A4 was not 
able to metabolize vincristine, or vincristine was not entering the cells.   
The latter explanation was partially discounted after hepatocytes with high 
CYP3A5 expression were incubated with vincristine.  Multiple lots of African-
American hepatocytes were tested until a CYP3A5 high expresser (CYP3A5*1/*1) was 
discovered.  The hepatocytes from this donor (EHI) were able to metabolize vincristine 
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to M1 (Fig. 36a).  Yet, the rates of M1 formation were much lower than those predicted 
using the IU human liver microsomes (Table 2).  To further understand this observation, 
in paired experiments with intact cells, hepatocytes were sonicated to release their 
intracellular contents.  For the same lot of hepatocytes, vincristine was then incubated 
with both intact cells in media and sonicated cells in buffer supplemented with NADPH 
(Table 4).  For the sonicated cell preparation, the activity was 4 to 69-fold higher than 
the intact cells.  Thus, although vincristine is able to enter the cells, the concentration of 
vincristine inside the cells may be lower than that in the media.  Alternatively, the CYP 
enzymes inside the intact cells may be less efficient in metabolizing vincristine.  In any 
case, for all experiments for intact and sonicated cells, the formation of M1 almost 
completely accounted for the depletion of vincristine (> 80% recovery by UV, Fig. 36a).  
The formation of M1 in the intact cells was substantially reduced with the addition of 
ketoconazole, confirming the role of CYP3A4 and/or CYP3A5 in the metabolism of 
vincristine (Fig. 37c).  However, taking into consideration the lack of detectable activity 
with CYP3A5 low expressers, the CYP3A4-mediated metabolism of vincristine may be 
insignificant in hepatocytes.  In support of this hypothesis, the rates of M1 formation for 
CYP3A5 high expressers were not inhibited by cyclosporin A, a selective CYP3A4 
inhibitor. 
In a previously published study with vincristine and hepatocytes, vincristine was 
readily metabolized to at least three compounds.10  In our studies, using CYP3A5 high 
expressing hepatocytes, vincristine was metabolized relatively slowly to only one major 
metabolite (Fig. 36).  It is unknown why the previously published hepatocyte data 
conflict with our results.  However, based on our experience with hepatocytes, the 
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metabolism described previously may have been vincristine degradation.  First, we do 
not know the stabililty of the radiolabeled vincristine using their incubation conditions 
because the authors did not present an appropriate “no cell” or “sonicated cell” control.  
The N-oxide, two diasterameric epoxides, and M2 are common vincristine impurities 
and degradation products.  In addition, the concentrations of vincristine (0.5 µM) were 
much lower than in our experiments (4 µM).  As indicated earlier, vincristine is highly 
susceptible to degradation by epoxidation at low concentrations in media (Fig. 34a).  
The investigators also did not present evidence to specifically implicate CYP 
metabolism, such as inhibition with ketoconazole.  As for the CYP3A5 genotype of the 
hepatocytes, the study was conducted in France, a primarily Caucasian population with 
a low frequency (< 20%) of CYP3A5 high expressers.  Based on our experience with 
cryopreserved hepatocytes, the metabolism of vincristine is not detectable using a 
typical CYP3A5 low expresser (Table 4).  Although the investigators may have only 
published the positive results from numerous donors, the probability is low that these 
French investigators tested a high CYP3A5 expresser the first time.  Finally, although 
the authors indicated that they were pursuing the chemical identification of the 
metabolites, no publications on the topic followed.  Presumably, either the results were 
not reproducible (because of CYP3A5 expression), or the compounds were difficult to 
isolate and identify as described previously.            
After evaluating vincristine with three in vitro metabolism models, we opted not 
to thoroughly pursue other types of models.  In a screening experiment, we did incubate 
rat liver microsomes and rat cDNA-expressed CYP3A enzymes (CYP3A1 and 
CYP3A2) with vincristine.  The formation rates of M1 and the rates of depletion for 
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vincristine were extremely slow or not detectable.  Based on this data, the rat model is 
not representative of vincristine metabolism in humans.  Other investigators have 
utilized in vivo rat and mice models to study vincristine disposition.127,133  One group 
discovered three potential metabolites in the bile of rats.  However, these compounds 
may have been degradation products (see above hepatocytes discussion).1  Consistent 
with our results, another group was unable to find any vincristine metabolism with rat 
liver microsomes.14  These investigators also did not observe metabolism with mouse 
liver microsomes.  However, we do not have any in vitro data to support this 
observation.   
The human in vitro models of metabolism all confirmed that vincristine was 
metabolized by CYP3A4 and/or CYP3A5 to one primary metabolite M1.  The next 
approach was to identify and quantify metabolites in human plasma or urine samples.  
Unfortunately, because of the low therapeutic dose (2 mg maximum) and high volume 
of distribution, the plasma vincristine concentrations are extremely low, less than 0.2 
ng/mL after 24 h.  As a result, we were unable to detect any Vinca-related metabolites 
with a mass spectrometer in scan mode.  Perhaps this approach would have been more 
successful for vinblastine, a compound administered at a higher clinical dose.   
To quantify vincristine and M1 in plasma, we developed and validated a more 
sensitive LC/MS/MS assay using selected reaction monitoring.  Previously developed 
assays were either not selective or not sensitive enough to detect vincristine (or M1) in 
plasma.  Of the previously published methods, the most discriminating methods utilized 
LC/MS or LC/MS/MS technology and could detect vincristine concentrations as low as 
0.2 ng/mL with a lowest mLOQ of 15 pg.126,134-136  The LC/MS/MS method by Skolnik 
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et al.135 is modestly better (2-fold) than an alternative LC/MS method by Schmidt et 
al.126 (Table 8).  Compared to these assays, our LC/MS/MS assay is 10-fold more 
sensitive than the lowest reported mLOQ.  The sensitivity of our assay using LC/MS 
detection (data not shown) is consistent with the reported mLOQ by Schmidt et al.126  
Comparing our LC/MS/MS assay to the method by Skolnik et al.,135 the apparent 
sensitivity differences can be explained by two possibilities.  First, in our assay, we 
purified the vinblastine internal standard by HPLC prior to use.  In our experience, all 
commercially available vinblastine contains trace amounts of vincristine.  Without 
purification, the cLOQ of vincristine in the current assay would not have been better 
than 0.1 ng/mL.  Second, the current assay monitored the dicharge ions of vincristine 
and vinblastine which resulted in greater sensitivity than the monocharge ions by 
LC/MS or LC/MS/MS.  Although we did not test the ionization of vincristine with 
exactly the same mobile phase, monitoring of dicharge ions may improve the sensitivity 
of the assay by Skolnik et al.135   
This same group recently published an updated LC/MS/MS method for 
vincristine quantification.137  The improved method has a cLOQ of 50 pg/mL, a major 
improvement over the previous method (500 pg/mL).  To achieve this sensitivity, the 
investigators changed the internal standard to vinorelbine because the vinblastine 
standard degraded to an interfering compound.  In our hands, vinblastine did not 
degrade but contained vincristine as a trace impurity.  In addition, for their new method, 
the eluent composition was optimized to improve ionization by LC/MS/MS.  Their 
method continued to monitor the monocharged Q1 ion of vincristine, unlike our method.  
Even so, the overall sensitivity of the method is similar to ours with a mLOD of 0.8 pg 
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(Table 8).  Based on this value, their assay could achieve a mLOQ value of less than 2 
pg but was only validated to a mLOQ of 4 pg, a value almost 4-fold higher than our 
assay.         
Although the method by Lee et al.137 can quantify low vincristine concentrations 
in plasma, our method also quantifies M1, the major in vitro metabolite of vincristine.  
M1 is more sensitive to degradation than vincristine in plasma and during sample 
preparation.121  The previously published assays isolated vincristine by solid-phase 
extraction and then evaporated the methanol and/or methanol eluent.126,135,137  Using this 
procedure based on our experience, M1 would likely degrade.  The inverse is also true; 
M1 could be generated by this method.  Vincristine dissolved in methanol will degrade 
to low levels of M1 by evaporation alone (data not shown).  Methylene chloride 
evaporation or processing steps with other solvents that do not require evaporation 
minimize M1 degradation and formation in our experience.   
After the method for vincristine quantification was validated for plasma, a 
modified procedure without an extraction step was used to assay urine samples by 
LC/MS/MS.  Other detection methods, for example LC/MS in scan mode, were unable 
to detect M1, even using concentrated samples.  By selected ion monitoring, the 
concentrations of M1 were quantified in the urine.  Low concentrations of Vinca 
compounds in the urine were expected because most of the Vinca-related compounds 
are excreted in the bile.  Other researchers have encountered similar difficulties; only 
one type of Vinca-related compound, a deacetylated derivative, has been isolated and 
conclusively identified from the urine.13,14  These compounds represented less than 1% 
of the parent drug by radioactivity.  Although the investigators call the deacetylated 
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Vinca alkaloids “metabolites,” these compounds may actually be metabolites, 
degradation products, or impurities in the formulation.  In our experience, multiple 
impurities are present in the clinical formulation and the analytical grade vincristine, 
including desacetylvincristine, M2, and M1.   
The vincristine and M1 concentrations were quantified for the clinical 
formulation of vincristine and for several patient urine samples.  Compared to the ratios 
of VCR/M1 in the clinical formulation, the concentration ratios in most patient urine 
samples were similar (Fig. 47).  Like the deacetylated Vinca alkaloids isolated in 
previous studies, it is unclear using the urine data alone whether M1 is a metabolite of 
vincristine or an impurity in the formulation.  However, the data from patient 14 are 
consistent with the hypothesis that M1 is a metabolite; the VCR/M1 ratio in urine was 
substantially lower in a later time point sample.  The data are nevertheless inconclusive 
because the VCR/M1 ratio of the clinical formulation is unknown for this particular 
patient.  Also, more importantly, the disposition properties of M1 as compared to 
vincristine are unknown.  The volumes of distribution for M1 and vincristine are likely 
different as indicated by the blood-to-plasma ratios at room temperature (0.8 for M1, 1.1 
for vincristine).         
The concentrations of vincristine and M1 were quantified in human plasma 
samples from two clinical studies.  For samples from the first study, the vincristine was 
obviously degraded to epoxides and an N-oxide derivative (Fig. 48, Fig. 49).  Although 
the exact cause is unknown, samples from these studies prior to analysis were stored for 
more than 2 years at -20°C.  This type of degradation was not observed for samples 
from the second clinical study stored for 8 months or less at -80°C.   
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For the second study of patients, the M1 concentration paralleled that of 
vincristine for the terminal elimination phase (Fig. 50).  These data are strong evidence 
that M1 formation from vincristine is rate limiting in vivo.  However, the data presented 
do not prove that M1 is a major metabolite in vivo.  We were unable to search for other 
vincristine-related compounds by LC/MS because the plasma concentrations were too 
low.  Previous radiolabeled vincristine clinical studies determined that the majority of 
vincristine-related compounds are eliminated in the bile.  Fecal samples could be used to 
scan for unknown metabolites although previous investigators had trouble with 
vincristine stability in the feces control samples.11   
Even if M1 is a major metabolite of vincristine in vivo, the M1 contents in urine 
and feces will not likely account for a large percentage of the administered vincristine 
because M1 is not chemically stable in plasma.  In the stability studies performed for the 
method validation, 80% of M1 degraded after 15 h at room temperature.  In addition, 
during hepatocyte lysate incubations in sodium phosphate buffer, M1 was also rapidly 
metabolized and/or degraded.  Multiple degradation products of M1 were observed after 
radiolabeled vincristine was incubated with hepatocyte lysate (Fig. 37a).  M1 was a 
definite precursor to one of these compounds (retention time = 22 min).  This compound 
by LC/MS/MS (data not shown) was identical to M1 but without a methyl ester group 
on the Catharanthine moiety.  Admittedly, these experimental results could be artifacts 
of the in vitro experimental conditions.  However, in past radiolabeled vincristine 
studies, vincristine was metabolized or degraded to multiple compounds in the feces and 
bile with ~50% of the parent drug remaining.  A modern radiolabeled study with 
vincristine using LC/MS technology would provide the data necessary to complete a 
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material balance with vincristine and perhaps identify additional metabolites or 
degradation products. 
B. Contribution of CYP3A5 to Vincristine Metabolism 
Once M1 was conclusively identified as the major metabolite formed by CYP3A4 and 
CYP3A5-mediated metabolism of vincristine, the contribution of CYP3A5 to the 
formation of M1 could be estimated.  CYP3A5 contribution was quantified using data 
from the in vitro models with cDNA-expressed enzymes and human liver microsomes. 
The first approach to quantifying the contribution of CYP3A5 to M1 formation 
with vincristine was using cDNA-expressed enzymes, both CYP3A4 and CYP3A5.  The 
other CYP enzymes were not examined because in an experiment with a panel of 
enzymes, CYP3A4 and CYP3A5 were the only enzymes with substantial substrate 
depletion and M1 formation (Fig. 12).  The CYP3A4 and CYP3A5 enzymes were 
available commercially with and without co-expressed cytochrome b5, a coenzyme 
present in vivo that typically increases the reaction rate but may also alter the affinity of 
the enzyme for the substrate.  Each enzyme was examined using three preparations: 
without cytochrome b5, with supplemented cytochrome b5, and with co-expressed 
cytochrome b5.   For CYP3A4 and CYP3A5, the rates of M1 formation at different 
concentrations of vincristine were used to estimate the Michaelis-Menten kinetic 
parameters (Fig. 16).  Regardless of preparation with or without cytochrome b5, the 
maximum rates of M1 formation were 6 to 9-fold higher for CYP3A5 compared to 
CYP3A4; the Km values were not statistically different between the enzymes (Table 1).  
Overall, the intrinsic clearances (Vmax /Km) were 9 to 14-fold higher for CYP3A5 than 
CYP3A4.  This high degree of selectivity for CYP3A5 was unexpected because almost 
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all reported substrates of CYP3A are equally or preferentially metabolized by 
CYP3A4.71,88,95,96  One clinically relevant CYP3A5-selective substrate is tacrolimus 
which has a modest 2-fold selectivity for CYP3A5.97  As a consequence, individuals 
with at least one CYP3A5*1 allele (high CYP3A5 expression) require a higher dose to 
maintain therapeutic trough concentrations.102  For other substrates, for example 
midazolam, CYP3A4 and CYP3A5 have equal intrinsic clearances in vitro.95,96,98  
However, high expression of CYP3A5 does not result in clinically significant 
differences (even if statistically different) in clearance of midazolam.82,93,100,101 
The relative role of CYP3A5 in the metabolism of vincristine can be estimated 
as a fraction of the total CYP3A activity using cDNA-expressed enzyme kinetic data 
(Eqn. 3).  For this calculation to be correct, the Western blot assay must be able to 
accurately quantify the relative amounts of active CYP enzymes, specifically CYP3A4 
and CYP3A5.  The literature values of CYP3A4 and CYP3A5 contents are highly 
variable between liver banks.86  These discrepancies are probably caused by differences 
in Western blot methods including enzyme standards.  Purified CYP3A4 (Invitrogen) 
was chosen as our standard; the CYP3A5 standard was one lot of Supersomes (no 
cytochrome b5, Gentest).  To account for any incomplete heme incorporation in the 
CYP3A5 standard, the CYP protein concentrations of each CYP3A4 and CYP3A5 
standard were compared by Western blot with a non-specific CYP3A antibody (Fig. 18).  
The CYP3A5 lot we chose to use as a standard (lot 22) had no measurable apoprotein by 
Western blot.  However, in our experience, the apoprotein content in Supersomes is 
highly variable between lots (data not shown).  To account for the apoprotein in most 
lots, the CYP protein concentration as compared to the manufacturer value needs to be 
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increased.  Without correction, the CYP contents may be underestimated for unknown 
human liver microsome samples.  Consistent with this assessment, a recent meta-
analysis reported that the absolute concentrations of the CYP3A4 and CYP3A5 enzymes 
are lower in human liver microsomes when Supersomes are used for standards.86     
To calculate the CYP3A5 contribution by Eqn. 3, the average CYP3A5 protein 
content was determined by Western blot assay of human liver microsome samples from 
the Indiana University Liver Bank.  For individuals heterozygous for CYP3A5*1 and 
classified as CYP3A5 high expressers (Table 1), approximately 40% of the CYP3A 
protein content was CYP3A5.  Completing the calculation (Eqn. 3) using the estimated 
intrinsic clearances for CYP3A4 and CYP3A5 (Table 1), the average CYP3A5 
contribution to vincristine metabolism is 88 to 92 %, the vast majority of the 
metabolism for CYP3A5 high expressers. 
However, the contribution of CYP3A5 varies between individuals (50 to 93%) 
based on CYP3A4 and CYP3A5 content.  Consistent with other human liver microsome 
banks, the CYP3A4 content (10-fold) is more variable than the CYP3A5 content (3-
fold).81  The differential variability between CYP3A4 and CYP3A5 expression is likely 
caused by several factors.  First, CYP3A4 expression is more easily induced by PXR 
substrates than CYP3A5.84  Although the patient histories are unknown for the IU liver 
bank, PXR ligands such as phenytoin are frequently administered to patients.79  In 
addition, as compared to CYP3A5, CYP3A4 is generally more susceptible to 
mechanism-based inhibition.  For example, using cDNA-expressed enzyme models, 
mechanism-based inhibitors erythromycin and saquinavir only inactivate CYP3A4.88,138  
In vivo, selective competitive inhibition of CYP3A4 with drugs such as itraconazole 
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may also reduce the CYP3A4 contribution to metabolism.  For vincristine, severe 
neurotoxicity caused by vincristine overdose was observed with concurrent 
administration of intraconazole.28  If the itraconazole toxicity was caused by inhibition 
of metabolism, individuals with high CYP3A5 expression may be protected from this 
type of drug-drug interaction.             
The CYP3A5 contribution to vincristine metabolism was also calculated using a 
bank of human liver microsomes.  By genotype, twelve livers in the Indiana University 
liver bank were predicted to be expressers of CYP3A5.  The actual number of CYP3A5 
high expressers was ten as determined by Western blot phenotyping.  Although the 
cause of this discrepancy is unknown, the two livers with low CYP3A5 expression may 
have a rare genetic polymorphism.  Our laboratory plans to sequence the CYP3A5 genes 
of the individuals to determine if any additional functionally relevant SNPs are present.  
An additional ten livers were chosen with low CYP3A5 expression and a range of 
CYP3A4 activities as determined by testosterone 6β-hydroxylase activity.  The 
Michaelis-Menten parameters of M1 formation from vincristine were estimated for each 
human liver microsomal sample (n = 22, Fig. 24, Table 2).  The Km values (corrected for 
binding) were not correlated to the CYP3A4 activities of the microsomes.  Thus, even 
though the CYP3A5 low expressers were not selected randomly, the Km parameters 
were directly compared between the groups.  No statistical differences in Km values 
were detected between the CYP3A5 high and low expressers.  This result was expected 
because the Km values for cDNA-expressed CYP3A4 and CYP3A5 were not statistically 
different (Table 1).     
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For CYP3A5 low expressers, the maximum rates of M1 formation were highly 
correlated with the testosterone 6β-hydroxylase activities (r2 = 0.91).  This relationship 
was used to estimate the Vmax values of M1 formation for the remaining untested human 
liver microsomes in the bank (n = 34).  With all the Vmax values, the two groups of 
microsomes with high and low CYP3A5 expression were compared; the CLint median 
value was 7-fold higher for the CYP3A5 high expressers versus low expressers with 
some overlap between the groups (Fig. 32).  The intrinsic clearances of a few CYP3A5 
low expressers were phenotypically similar to those of CYP3A5 high expressers.  These 
CYP3A5 low expressers were predicted to have relatively high CYP3A4 activities.  To 
test this hypothesis, the CYP3A4 activity was selectively inhibited with cyclosporin A.  
For cDNA-expressed enzymes, CYP3A4 activity for M1 formation is completely 
inhibited with 25 µM of cyclosporin A.  However, using the same conditions, only 15% 
of the CYP3A5 activity is inhibited.  As predicted by the recombinant system, the 
CYP3A5 high expressers were less inhibited by cyclosporin A than the low expressers 
(Fig. 26b).  This experiment needs to be interpreted with caution because the methanol 
alone inhibited M1 formation in the vehicle controls (Fig. 26a).  Nevertheless, from Fig 
26b, the CYP3A5 high expressers retained at least 60% of their original activity after 
cyclosporin A inhibition.  The CYP3A5 contribution to M1 formation was likely higher 
than 60% because cyclosporin A non-selectively inhibited cDNA-expressed CYP3A5.      
The calculation of CYP3A5 contribution to M1 formation by human liver 
microsomes is not as straightforward as with the cDNA-expressed enzymes.  With 
human liver microsomes, the contribution of CYP3A5 cannot be determined directly 
because the CYP3A4 and CYP3A5 are co-expressed.  Previous investigators have 
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looked for statistical differences in microsomal activities between the groups of 
CYP3A5 high and low expressers.71  In contrast, we chose to use three different 
normalization approaches to calculate the contribution of CYP3A5 for each CYP3A5 
high-expressing microsomal sample.  First, for CYP3A5 low expressers, the 
itraconazole hydroxylase activities (highly selective for CYP3A4) of the microsomes 
were correlated with the Vmax of M1 formation.  This correlation was used to predict the 
CYP3A4-mediated Vmax of M1 formation for CYP3A5 high expressers.  The CYP3A5 
contribution for each CYP3A5 high expresser was the difference of the actual Vmax and 
the calculated CYP3A4-mediated Vmax.  A similar normalization approach was used to 
calculate the CYP3A4-mediated Vmax of M1 formation using testosterone 6β-
hydroxylase activities.  Testosterone 6β-hydroxylase is thought to be mediated primarily 
by CYP3A4 with some contribution (10%) by CYP3A5.95  At least for the incubation 
conditions used in this study, the testosterone 6β-hydroxylase activities were highly 
correlated with the itraconazole hydroxylase activities and CYP3A4 protein content 
(Fig. 22); these relationships were independent of CYP3A5 expression.  Thus, the 
testosterone 6β-hydroxylase activities were only dependent on CYP3A4 activity.  For 
the last normalization, the CYP3A4 protein content was used to estimate the CYP3A4 
activity of CYP3A5 high expressers.  Interestingly, regardless of the normalization 
approach, the average estimated CYP3A5-mediated metabolism of vincristine for 
CYP3A5 high expressers was consistently 80% (Table 3).  The CYP3A5 contribution to 
metabolism for an individual liver (43 to 93%) was dependent on the CYP3A4 activity.  
As predicted by these two in vitro models, the contributions of CYP3A5 to vincristine 
metabolism are on average between 80 to 90% for CYP3A5 high expressers.  For other 
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published human liver microsome studies with CYP3A substrates, the estimated 
CYP3A5 contribution to metabolism was 30 to 40%.71  Thus, vincristine is a unique, 
CYP3A5-selective substrate. 
  To provide additional evidence of CYP3A5 selectivity, the specific activities of 
CYP3A4 and CYP3A5 in M1 formation were calculated for human liver microsomes 
and compared to the cDNA-expressed enzyme activities (Fig. 31).  The selectivity was 
similar for all the models regardless of cytochrome b5 expression. The enzyme specific 
activities for the microsomes were somewhere between Vmax values for the cDNA-
expressed enzymes with supplemented cytochrome b5 and co-expressed cytochrome b5 
(Table 1).  However, the specific activities for the microsomes were calculated based on 
both holoprotein and apoprotein as determined by Western blot.  Thus, the variability in 
heme incorporation lowered the specific activities of the enzymes.  Correcting for the 
CYP3A heme incorporation (69%),86 the CYP3A4 and CYP3A5 specific activities for 
the human liver microsomes are almost identical to the values of cDNA-expressed 
CYP3A4 and CYP3A5 with co-expressed cytochrome b5 (3 and 19 pmol M1/min/pmol 
CYP versus and 3 and 22 pmol M1/min/pmol CYP).  We conclude that the high 
contribution of CYP3A5 to the metabolism of vincristine (80 to 90%) in vitro is a result 
of a relatively high CYP3A5 specific activity.   
C. Effect of CYP3A5 Expression on the Clearance of Vincristine 
The role of CYP3A5 in the clearance of most CYP3A substrates is not well understood.  
To estimate the role of CYP3A5 expression in the clearance of vincristine, we used 
kinetic data from multiple in vitro models to complete in vitro/in vivo scaling.  The 
predicted hepatic clearances were compared for CYP3A5 high and low expressers.  
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These values were then compared to published clearance values of adult patients treated 
with vincristine. 
To estimate intrinsic clearances with human liver microsomes and hepatocytes, 
the in vitro Vmax/Km ratio was scaled by microsomal protein content and cell 
concentration as appropriate.  For hepatocytes, the intrinsic clearance was estimated by 
M1 formation rates at one vincristine concentration below the Km.  The liver donors 
were categorized into high and low CYP3A5 expressers.  For this study, CYP3A5 
phenotype by Western blot was used to characterize the human liver microsomes; for 
the hepatocytes, CYP3A5 genotype was used exclusively.  CYP3A5 phenotyping is 
preferred to CYP3A5 genotyping because the CYP3A5*1 genotype-phenotype 
relationship is not absolute.  The CYP3A5 genotype was determined by elimination of 
three common gene SNPs; other less common SNPs may alter the expression of 
CYP3A5.  In fact, CYP3A5 genotype did not accurately predict CYP3A5 expression in 
2 out of 12 human liver microsomes in this study.  In addition, if more than one type of 
SNP is identified for one individual, the CYP3A5 expression cannot be predicted 
because the chromosomal locations of the two SNPs are unknown.  Three African-
American livers in our hepatocyte study fell in this category (Table 4).          
To complete the in vitro/in vivo scaling for all in vitro models, the well-stirred 
model for hepatic clearance was utilized (Eqn. 5).  This model was chosen because 
vincristine is a low to intermediate extraction ratio drug with unbound therapeutic 
concentrations well below the Km.  The model requires an estimation of the fraction 
unbound of drug in the plasma, whole blood, and microsomes.  The fraction unbound in 
plasma (0.6) and the blood-to-plasma ratio (1.2) estimated in this study were in good 
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agreement with the previously published results (0.5 and 1.2 respectively).11,47  Rapid 
equilibrium between plasma proteins and erythrocytes was assumed although it was 
reported that the binding of vincristine to platelets and blood cells is not quickly 
reversible.139  The calculated clearance may be overestimated in this case because 
regardless of the intrinsic clearance, the hepatic clearance can never equal hepatic blood 
flow.  However, this effect is likely minor because vincristine is a low to medium 
extraction ratio drug.      
Based on previously published in vitro/in vivo scaling data, the intrinsic 
clearances estimated using human liver microsomes typically underpredict in vivo 
intrinsic clearances by 9-fold.140  To compensate for the under-prediction, an empirical 
scaling factor is often used.  However, for vincristine, the human liver microsome data 
of CYP3A5 low expressers accurately predicted the clearance from the pharmacokinetic 
studies in Caucasian populations.  Using the human liver microsome model, the median 
hepatic clearances of CYP3A5 high expressers were 5-fold higher than low expressers 
with extraction ratios of 0.5 and 0.1 respectively (Fig. 32b).  These values were in good 
agreement with the adult literature for hepatic clearance of vincristine (50 to 300 
mL/min, 0.03 to 0.2 equivalent extraction ratios).44,52  However, the clearances 
estimated in the clinical studies may have been underestimated because the vincristine 
plasma assays were not selective for the parent drug.52 
Compared to the human liver microsome kinetic data, the human hepatocyte data 
predicted a much lower in vivo clearance for vincristine.  Based on the rates of M1 
formation for the most active hepatocyte lot, the extraction ratio was only 0.04.  Thus, 
after correcting for binding, the intrinsic clearances predicted by hepatocytes were well 
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below hepatic blood flow and effectively equal to the hepatic clearances.  For the 
CYP3A5 low expressers, the predicted intrinsic clearances were zero because vincristine 
metabolism was not observed.  To verify the cells from CYP3A5 low expressers were 
capable of M1 formation, the rates of M1 formation for one lot (MRS) were estimated 
using a hepatocyte lysate preparation supplemented with NADPH.  The rates of M1 
metabolism were typical of CYP3A5 low expressing human liver microsomes.    
The estimated hepatic clearances using human hepatocytes are inconsistent with 
the reported clearance of vincristine for adults and approximately 10-fold lower than the 
predicted values from human liver microsomes.  Like with human liver microsomes, 
other investigators have reported a 5-fold systemic underprediction of in vivo intrinsic 
clearance using cryopreserved hepatocytes.141  Although an underprediction of in vivo 
clearances was expected using human hepatocytes, the hepatocyte kinetic data were 
expected to more closely match the human liver microsome data.  In particular, the 
CYP3A5 low expressers with high CYP3A4 activity (lot MRS) were predicted to have 
intrinsic clearances similar to those of typical CYP3A5 high expressers.  The published 
studies that have compared the predicted clearances of hepatocytes and microsomes are 
conflicting and confounded by the variability of the preparations.  For example, one 
study reported that the midazolam intrinsic clearance estimated with human liver 
microsomes was 5-fold higher compared to the hepatocyte estimated value.  However, 
like all these type of studies, the lots of cryopreserved hepatocytes and the microsomes 
were not from the same liver, and the numbers of different lots tested were small (n = 3 
to 7).  In another study, when compared to human liver microsomes, the cryopreserved 
hepatocytes predicted at least a 3-fold higher intrinsic clearance for midazolam.  Again 
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the variability between lots may in part explain the discrepancy between the reports.  
We designed our experiments to remove this variable by preparing cell lysates from the 
same lots of hepatocytes.  For the various lots of cryopreserved hepatocytes, the intrinsic 
clearances of CYP3A5 high expressers were 4 to 69-fold lower than those predicted 
using paired cell lysate preparations (Table 4).  From this data, we concluded that 
hepatic clearance with cryopreserved hepatocytes may be a function of intrinsic 
clearance and hepatic transport. 
The uptake of vincristine by hepatocytes is primarily diffusion rate limited while 
the export is mediated by active transporters in the canalicular membrane, specifically 
P-pg and MRP2.10,12,49  To understand the potential role of active transport in our 
hepatocyte study, we coincubated vincristine with transporter inhibitors: cyclosporin A 
(P-gp and MRP2) and LSN335984 (P-gp).  The rates of M1 formation were unaffected 
or slightly reduced by the inhibitors, perhaps as a result of CYP3A inhibition (Table 5).  
Thus, assuming the transporter function of hepatocytes is representative of in vivo 
transport, active transport in hepatocytes may not be an important determinant of the 
vincristine intracellular concentration.   
To demonstrate the rates of M1 formation were influenced by vincristine 
transport, the Michaelis-Menten kinetic parameters of M1 formation were estimated for 
one lot of hepatocytes (EHI); both intact cells and cell lysate preparations with NADPH 
were incubated with vincristine (Fig. 40).  The Km value for the intact cells was 3-fold 
higher than that of the cell lysate.  Therefore, at least for this lot of hepatocytes, 
membrane transport was possibly responsible for approximately 50% of the reduced 
intrinsic clearance.  The 3-fold change in Vmax values accounted for the remaining 50% 
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reduction.  This result was unexpected because the Vmax values can only change if the 
CYP activity is reduced.  At this time, we have no explanation for why the CYP activity 
with vincristine would be lower for intact hepatocytes versus the cell lysate preparation 
from the same lot.  Additional studies will be required to understand this effect.   
Assuming the hepatocyte model is representative of the in vivo cells, one 
possibility is that drug metabolism and consequently CYP3A5 genotype play a minor 
role in the overall clearance of vincristine.  Case reports of drug/drug interactions with 
vincristine and itraconazole are consistent with CYP3A and/or P-gp inhibition.35  
Perhaps almost all the vincristine is concentrated in the bile by active transport and 
eliminated unchanged.  For example, the clearance of fexofenadine is primarily biliary 
and controlled by OATP drug uptake transporters and P-gp.  Reported drug/drug 
interactions with fexofenadine and ketoconazole can be only be explained by inhibition 
of transport, not CYP3A inhibition, because 95% of fexofenadine is eliminated 
unchanged in the bile or urine.  Vincristine and/or vincristine-related compounds are 
also concentrated in the bile (at least 20-fold higher than the plasma) presumbly by P-pg 
and MRP2.  However, the percentage of vincristine unchanged in the feces was reported 
to be less than 60%, not 95% like fexofenadine.11  As discussed earlier, the actual 
percentage of the vincristine dose excreted unchanged may be higher (because of parent 
degradation during the in vitro assay) or lower than 60% (because the parent drug and 
metabolites may have co-eluted by HPLC).  Also, for any value not close to 100% like 
fexofenadine, more information about the product composition would be required to 
separate the roles of degradation, biliary excretion, and metabolism.  Because the 
therapeutic concentration is low for vincristine, the biological samples, particularly fecal 
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material, would be difficult to analyze and complete a material balance without a 
radiolabel.  Even with a radiolabel, the degradation products of vincristine and M1 
would be difficult to distinguish from one another because M1 degrades in plasma to 
multiple compounds of unknown composition.   
Although transport may play a role in the clearance of vincristine, hepatic 
metabolism by CYP3A enzymes may also be clinically significant.  The clearances of 
certain drugs, such as midazolam, are almost entirely mediated by CYP3A enzymes.96  
The role of CYP3A enzymes is evident in vivo by clearance changes with co-
administration of chemical inhibitors (itraconazole) and inducers (rifampin).93  The 
clearance changes of midazolam can be attributed to CYP3A inhibition or induction 
because midazolam is not a ligand of any known transporters.36  In contrast, because 
vincristine and other CYP3A substrates such as docetaxel are substrates of P-gp, in vivo 
chemical inhibition and inducer studies are more difficult to interpret.  For example, the 
docetaxel clearance in vivo was reduced only 1.7-fold versus 6-fold for midazolam with 
the same dose of ketoconazole.142  This result may possibly indicate that CYP3A 
enzymes are not clinically important in the disposition of docetaxel.  However, in 
clinical study using the selective P-pg inhibitor R101933, the docetaxel clearance was 
also not significantly affected.143  As an added complication, the inter-individual 
variability in CYP expression may change the relative contribution of biliary excretion 
and metabolism.  For example, the clearance of vincristine for individuals with high 
CYP3A5 expression may be primarily CYP3A5-mediated while the clearance for 
individuals with low CYP3A5 expression may be primarily biliary.   
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The most direct way to understand the role of CYP3A5 metabolism in 
vincristine clearance is to compare vincristine exposure of high and low CYP3A5 
expressers in vivo.  A clinical study with pharmacokinetic vincristine data can also be 
used to recommend dose adjustments for individualized therapy.  Historically, 
estimation of exposure in vincristine patients has been technically challenging because 
the concentrations in plasma are low.  In addition, because the terminal half life of 
vincristine is approximately 24 h, plasma samples over several days are required to 
accurately assess the exposure by AUC.  In our study, a vincristine assay using 
LC/MS/MS was developed that could accurately quantify vincristine in plasma at 
concentrations at least 3 terminal half lives past the initial dose.  At the time of this 
report, estimations of vincristine exposure by this method were limited to four patients 
with low CYP3A5 expression over 24 h (Fig. 50).  Additional patients with high 
CYP3A5 expression and longer sampling time points are required to determine whether 
high CYP3A5 expression reduces exposure to vincristine.  Patient recruitment for these 
prospective studies is in progress.  The results of these studies will hopefully provide a 
definitive answer to whether CYP3A5 genotype is clinically significant in vincristine 
therapy. 
D. Conclusions 
Using cDNA-expressed enzymes and human liver microsomes, vincristine is 
metabolized by cytochrome P450 enzymes CYP3A4 and CYP3A5 to one primary 
metabolite, M1; this secondary amine readily degrades in basic solutions and in plasma.  
In vitro, cDNA-expressed CYP3A5 selectively metabolizes vincristine to M1.  The rates 
of M1 formation are at least 7-fold higher with CYP3A5 than CYP3A4.  For CYP3A5 
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high expressing microsomes, the CYP3A5 contribution to M1 formation is substantial, 
approximately 81% of the total CYP activity.  With cryopreserved hepatocytes, the rates 
of M1 formation are much lower than those of human liver microsomes.  The M1 rates 
of formation may be limited by vincristine transport.  Further studies are required to 
understand why CYP3A5 low expressing hepatocytes do not metabolize vincristine.  In 
vivo, M1 is likely a product of vincristine because the plasma concentration of M1 
parallels that of vincristine during the terminal elimination phase.  Although the role of 
metabolism in the systemic clearance of vincristine is presently unknown, CYP3A5 
expression is predicted to increase metabolic hepatic clearance at least 5-fold.  Thus, for 
vincristine chemotherapy, CYP3A5 expression as predicted by CYP3A5 genotype may 
be an important determinant of inter-individual variability in clinical outcomes.  Further 
in vivo studies are required to understand the impact of CYP3A5 expression on 
vincristine pharmacokinetics.   
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Table 1.   Michaelis-Menten parameters for M1 formation with CYP3A4 and CYP3A5 
 
Vmax units = pmol M1/pmol CYP/min, Km units = μM, fitted values ± 1 standard deviation, CLint = Vmax /Km 
 
 No cytochrome b5  Supplemented cytochrome b5  (3:1 ratio)  Co-expressed cytochrome b5 
 CYP3A4 CYP3A5 p-value  CYP3A4 CYP3A5 p-value  CYP3A4 CYP3A5 p-value 
Vmax 0.90 ± 0.06 8.1 ± 0.4 <0.0001  1.49 ± 0.07 11.0 ± 1.0 <0.0001  2.97 ± 0.17 21.5 ± 0.9 <0.0001 
Km 19.7 ± 3.0 14.3 ± 1.7 0.14  25.7 ± 2.6 13.3 ± 3.2 0.009  19.9 ± 2.5 16.7 ± 1.6 0.30 
CLint 0.046 ± 0.004 0.57 ± 0.04 <0.0001  0.058 ± 0.003 0.83 ± 0.13 <0.0001  0.15 ± 0.01 1.29 ± 0.08 <0.0001 
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Table 2. Characterization of human liver microsomes by CYP3A5 genotype, CYP3A4 and CYP3A5 
protein content, and Vmax with vincristine (VCR), testosterone (TST), and itraconazole (ITZ) as substrates. 
Metabolites for Vmax are in parentheses. 
 
  Protein Content (pmol/mg)  Vmax (pmol/min/mg) 
 
VCR in vitro/in vivo scaling 
Liver CYP3A5 genotype 3A4 3A5  
ITZ 
(OH-ITZ) 
TST 
(6β-OH) 
VCR 
(M1)  
Km
a 
(µM) 
CLint 
b 
(mL/min) 
CLH
 c 
 (mL/min) 
CYP3A5 high expressers         
IUL-40 * 1 / * 1 103.8 89.4  121.3 7244 1262  14.0 6070 823 
IUL-32 * 1 / * 3 20.9 18.2  18.1 1021 172  18.2 636 169 
IUL-41 * 1 / * 3 14.7 20.5  52.5 2886 467  26.2 1200 291 
IUL-42 * 1 / * 3 23.7 16.1  26.4 1518 302  25.1 813 210 
IUL-59 * 1 / * 3 36.3 14.7  51.6 3274 302  14.6 1400 328 
IUL-66 * 1 / * 3 24.4 20.6  32.7 2223 327  17.0 1300 310 
IUL-73 * 1 / * 3 96.1 20.1  147.0 6564 521  15.9 2220 461 
IUL-74 * 1 / * 6 10.7 26.2  13.5 1958 470  16.1 1970 424 
IUL-79 * 1 / * 3 11.2 13.6  15.4 1291 201  17.0 803 208 
IUL-85 * 1 / * 3 85.5 24.8  39.4 4013 393  20.7 1280 305 
CYP3A5 low expressersd         
IUL-6 * 3 / * 3 19.0 0.8  33.8 3082 80.3  22.2 244 69.7 
IUL-49 * 3 / * 3 48.8 0.8  52.3 2511 68.3  23.8 193 55.9 
IUL-52 * 3 / * 3 14.8 0.0  8.4 1337 8.8  11.4 52.0 15.5 
IUL-55 * 3 / * 3 130.4 0.8  136.2 7260 245  29.8 555 150 
IUL-57 * 1 / * 3 40.6 0.8  41.1 3947 104  31.2 225 64.5 
IUL-65 * 3 / * 3 15.6 0.6  14.7 1139 18.3  10.7 115 33.8 
IUL-71 * 1 / * 7 10.9 1.1  41.9 2950 49.9  15.8 213 61.3 
IUL-72 * 3 / * 3 25.3 0.9  27.1 2100 40.1  20.6 132 38.4 
IUL-75 * 3 / * 3 78.2 2.3  108.2 4938 140  15.6 609 163 
IUL-78 * 3 / * 3 109.5 3.1  148.7 6993 198  19.2 695 183 
IUL-81 * 3 / * 3 71.7 2.0  65.2 3424 132  22.5 395 110 
IUL-86 * 3 / * 3 77.8 2.1  160.0 8851 288  23.0 844 217 
 
a Corrected for microsomal binding to vincristine. 
b Intrinsic clearance = CLint = Vmax ● 1500 g liver ● 45 mg microsomal protein/ g liver/ Km for a 70 kg man 
c Hepatic clearance = CLH = Q ● fu,p / ρ ● CLint / (Q + fu,p / ρ ● CLint) where fu,p = 0.51, ρ = 1.2, and Q = 1500 ml/min for a 70 
kg man 
d HLMs not selected randomly. 
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Table 3. Percent contribution of CYP3A5 to vincristine metabolism for CYP3A5 high expressers. 
Using values from the CYP3A5 low expressers as standards, the CYP3A4 contribution for each CYP3A5 
high expresser was calculated from the CYP3A4 content, testosterone 6β-hydroxylase activity, and 
itraconazole hydroxylase activity.  Metabolites are in parentheses.  The remaining CYP3A5 activity was 
quantified after selective inhibition of CYP3A4 with cyclosporin A.   
 
 % contribution by CYP3A5 to M1 formation  
Liver Protein content 
TST 
(6β-OH) 
ITZ 
(OH-ITZ) CsA
a 
IUL-40 83 86 84 ND 
IUL-32 75 87 83 ND 
IUL-41 93 80 82 ND 
IUL-42 84 84 86 ND 
IUL-59 75 75 72 71 
IUL-66 85 84 84 ND 
IUL-73 62 57 54 46 
IUL-74 95 92 95 ND 
IUL-79 88 83 88 79 
IUL-85 55 81 84 ND 
Avg ± SD 80 ± 13 81 ± 11 81 ± 10 NA 
 
a ND = not determined, NA = not applicable 
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Table 4. Characterization of cryopreserved hepatocytes by CYP3A5 genotype and CYP3A activity. 
Multiple lots of hepatocytes were genotyped for CYP3A5 expression and assayed for CYP3A activity 
using testosterone and vincristine as probe substrates.  For each lot of hepatocytes, the intrinsic clearances 
of vincristine were estimated with intact cells and NADPH-supplemented cell lysate; the rates of M1 
formation or the rates of vincristine depletion were used to estimate the intrinsic clearances.   
 
 
 
 
Testosterone 6β- 
Hydroxylase Activity 
(pmol/min/mg)a 
 VCR Intrinsic Clearance  (mL/min)a 
Lot Ethnicityb CYP3A5 genotype Cells
b Lysate  Cellsc  Lysate 
CYP3A5 high expressers    Formation Depletion  Formation Depletion 
AIT C * 1 / *3 246 4300  59 140  1755 1755 
EHI AA * 1 / * 1 744 3300  173 270  1620 1913 
FKM AA * 1 / *7 522 8700  59 133  4050 4500 
REL AA * 3 / *6 d 300 4700  41 97  563 1035 
RML AA * 1 / *1 456 10500  88 108  608 608 
SCA AA * 1 / *3e 564 25500  86 180  5625 6525 
ZIJ AA * 1 / *1 75 2200  95 72  968 1260 
ZYZ AA * 1 / *1e 297 260  106 108  405 473 
CYP3A5 low expressers         
652 U *3 / *3 U ND  0 0  ND ND 
CHD AA * 3 / * 7 d 84 ND  0 0  ND ND 
Hu418 U *3 / *3 U ND  0 0  ND ND 
MRS AA * 3 / * 7 d 2025 4300  0 0  293 855 
SD012 U ND U ND  0 0  ND ND 
SD017 U ND U ND  0 0  ND ND 
 
ND = not determined, U = unknown  
a CLint =  Initial rate of reaction / substrate concentration x (45 mg protein / g liver) x (3 x 106 cells/ mg protein) x 1500 g liver for a 70 kg 
man  
bReported by vendor, In Vitro Technologies. AA = African-American, C = Caucasian.  Other vendors (Xenotech for 652, Cellzdirect for 
others) did not provide ethnicity information. 
cValues reported as zero are not different from the sonicated cell controls.   
d Genotype data alone cannot predict the CYP3A5 phenotype. 
e Not genotyped for CYP3A5*6. 
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Table 5. Effects of chemical inhibition on M1 formation with cryopreserved hepatocytes. 
VCR and multiple lots of cryopreserved hepatocytes were incubated with and without chemical inhibitors 
(cyclosporine A, LSN335984, and ketoconazole) for 4 h.  The final concentration of M1 with inhibitor 
was expressed as a percentage of the control without inhibitor.      
 
 % of positive control at 4 h 
Lot CsA LSN KTZ 
CYP3A5 high expressers 
AIT 127 72 18 
EHI 95 66 17 
FKM 125 48 18 
REL 105 42 17 
RML 106 38 12 
SCA 148 77 38 
ZIJ 99 49 11 
ZYZ 68 45 8 
CYP3A5 low expressers 
CHD 108 81 93 
MRS 99 92 71 
 
CsA = 25 µM cyclosporin A; LSN = 50 µM LSN335984; KTZ = 10 µM ketoconazole 
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Table 6. Relative recoveries of vincristine, vinblastine, and vinorelbine from plasma. 
VCR, VLB, and VRL were extracted with methylene chloride (4 vol).  The signal intensities of the 
analytes were quantified by LC/MS.  The effects on recoveries were determined for acid addition (TCAA) 
and mechanical agitation.  The controls were not extracted.   
 
  VCR and VLB Extraction  VCR and VRL Extraction 
  VCR Intensity VLB Intensity  VCR Intensity VRL Intensity 
Control  3.5 x 106 12 x 106  3.0 x 106 17 x 106 
+ shake  0.75 x 106 0.5 x 106   1.1 x 106  < 0.1 x 106 
+ acid  1.5 x 106 5.5 x 106  2.4 x 106 0.5 x 106 
+ shake, + acid  2.2 x 106 8.0 x 106  3.0 x 106  2.2 x 106 
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Table 7. MS parameters for multiple-reaction monitoring of M1, vincristine (VCR), and vinblastine 
(VLB) dicharge ions. 
 
  M1  VCR  VLB 
Q1 → Q3 (m/z)  397.3 → 337.3 397.3 → 376.2  413.2 → 362.2 413.2 → 392.1  406.3 → 271.7 
Declustering 
potential (V) 
 
65 65 
 
65 65 
 
60 
Entrance 
potential (V) 
 
10 10 
 
10 10 
 
8 
Collision energy (V)  30 20  30 20  40 
Exit potential (V)  12 12  10 10  10 
Dwell time (ms)  100 400  400 100  100 
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Table 8. Extraction efficiency for vincristine and M1 in human plasma.  
 
 Low Medium High 
Vincristine    
Nominal concentration (ng/mL) 0.120 0.792 24.0 
VCR/IS area ratio not extracteda (a) 0.017 (0.002) 0.11 (0.00) 3.07 (0.10) 
VCR/IS area ratio extracted (b) 0.010 (0.001) 0.069 (0.001) 1.92 (0.05) 
Recovery (%)b 61 64 62 
M1    
Nominal concentration (ng/mL) 0.0610 0.402 12.2 
VCR/IS area ratio not extracteda (a) 0.0039 (0.0004) 0.022 (0.001) 0.70 (0.02) 
VCR/IS area ratio extracted (b) 0.0022 (0.0008) 0.013 (0.001) 0.40 (0.03) 
Recovery (%)b 56 61 57 
 
a Vincristine and M1 in mobile phase A added after extraction and evaporation of methylene chloride.  n = 3 except for 
the low extracted samples where n = 2; numbers in parentheses are standard deviations or the range for the low 
extracted samples. 
b Recovery is defined as (b/a) x 100%. 
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Table 9. Limits of detection and quantification for vincristine and M1 for the current method and a 
comparison of vincristine limits from previously published methods. 
 
  Current method  Schmidt et al.126  Skolnik et al.135 
Method  LC/ESI-MS/MS  LC/ESI-MS  LC/ESI-MS/MS 
Analyte  M1 VCR  VCR  VCR 
mLOD (pg)  0.7 0.8  17  6 
mLOQ (pg)  1.4 1.5  33  15 
cLOD (pg/mL)  6 6  90  200 
cLOQ (pg/mL)  12 12  180  500 
 
mLOD; mass limit of detection, mLOQ; mass limit of quantification, cLOD; concentration limit of detection, cLOQ; 
concentration limit of quantification 
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Table 10.  Intra-day (n = 5) and inter-day (n = 4) precision and accuracy for vincristine and M1 in human 
plasma.  
 
 Intra-day  Inter-day 
 Low Medium High Low Medium High 
Vincristine        
  Nominal concentration (ng/mL) 0.0120 0.792 24.0  0.0468 0.924 18.6 
  CV (%) 16.8 4.9 5.0  13.8 8.8 11.9 
  Accuracy (%) 105.6 105.0 103.2  96.8 95.6 87.4 
M1        
  Nominal concentration (ng/mL) 0.0122 0.402 12.2  0.0234 0.462 9.30 
  CV (%) 12.9 12.3 2.2  16.3 6.5 14.8 
  Accuracy (%) 109.1 106.0 111.9  92.7 87.5 85.3 
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Table 11. Pharmacokinetic parameter estimates for patients (n = 4) treated with vincristine (1.5 mg/m2). 
The vincristine kinetic parameters were estimated for all 4 patients.  The data from two patients (patient 1 
and patient 2) are presented with the percent coefficient of variation values (% CV) for the model fit.  The 
mean for all patients is presented with the standard deviation (SD), the interpatient variability.  The data 
were modeled using a two-compartment model with 1/y2 weighting.   
 
Parameter Patient 1 (% CV) 
Patient 2 
(% CV) 
Mean (SD) 
n = 4 Minimum Maximum 
Clp (ml/min/m2) 778 (23) 389 (35) 490.8 (195.0) 354 778 
t1/2α (min) 25.2 (17) 24.0 (14) 18.6 (7.0) 11.3 25.2 
t1/2β (min) 1368 (36) 2719 (46) 1643 (733) 1070 2719 
VC (L/m2) 170 (20) 138 (17) 114 (49) 65 170 
V2 (L/m2) 1142 (20) 1249 (17) 891 (376) 439 1249 
 
Clp; plasma clearance, t1/2α; first compartment half life, t1/2β; second compartment half life, VC; central volume of 
distribution, V2; second compartment volume of distributio 
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Fig. 1.  Chemical structures of vincristine, vinblastine, and vinorelbine.  The two segments of vincristine 
(DHC and NFV) are separated by a dotted line.  
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Fig. 2.  Representative UV chromatograms of vincristine and its metabolites using a basic extraction and 
neutral pH chromatography.  Vincristine (5 µM) was incubated for 5 min with rCYP3A5 (50 pmol/mL) 
and NADPH (1 mM) at 37°C (a) or without enzyme and NADPH (b).  The solution was quenched with 
ethyl acetate and extracted using NaOH and additional ethyl acetate.  Internal standard was not added.  A 
putative metabolite M3, not in the control sample, was detected by UV absorbance approximately 1 min 
after the parent drug (VCR).  Note that the attenuation of plot (b) is 2-fold less than that of (a).  
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Fig. 3.  Radiochromatograms of M2 and M3 formation from vincristine with rCYP3A5.  The vincristine control without addition of NADPH is shown in panel 
(a). Different concentrations of 3H-vincristine at 0.1 (b), 1.0 (c), 10 (d), and 100 µM (e) were incubated with rCYP3A5 (50 pmol/mL) for 30 min with NADPH 
(1 µM).  From the areas of the radiochromatograms, the rates of M3 formation at initial velocity conditions were estimated assuming non-saturable first-order 
kinetics for the two lowest concentrations where the parent drug was depleted more than 20%.  The Michaelis-Menten kinetic parameters of M3 formation were 
estimated using non-linear regression (f). 
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Fig. 4.  Total ion chromatographs of vincristine incubated with rCYP3A5 with (a) and without NADPH (b).  The sample preparation included NaOH treatment 
and ethyl acetate extraction.  Three compounds (M1, M2, and M3) not present in the control were detected in the NADPH positive sample. 
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Fig. 5.  Identification of metabolites using alternate chromatography systems.  Vincristine (20 µM) was incubated with rCYP3A5 (50 pmol/mL) for 30 min and 
then extracted with ethyl acetate and NaOH.  The sample was split in two and assayed by HPLC using an acidic pH eluent (a) and using a neutral pH eluent (d). 
The product peaks were collected from the acidic HPLC system (a) and reassayed by HPLC using the neutral pH system to determine the corresponding 
retention times of vincristine (b), M1 (c), M2 (e), and M3 (f). 
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Fig. 6.  Representative UV chromatogram of CYP3A5-mediated metabolism of vincristine using an acidic 
pH eluent.  Vincristine (20 µM) was incubated for 30 min with rCYP3A5 (50 pmol/mL) and NADPH (0.5 
µM) at 37°C.  The solution was quenched with acetonitrile and diluted with an equal volume of 0.2% 
formic acid prior to analysis by HPLC.  The vincristine metabolites are labeled as follows: M1 (major), 
M2 (minor), and M4 (minor).  Vinorelbine (VRL) was used as an internal standard.   
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Fig. 7.  Base-promoted conversion of M1 to M3.  Eluent fractions containing HPLC purified M1 were split into two parts.  One part was evaporated at room 
temperature and analyzed directly by HPLC, plot (a).  For the second part, sodium hydroxide was added to complete the conversion of M1 to M3.  The solution 
was extracted with ethyl acetate, and the organic extract was evaporated.  The residue was assayed by HPLC, plot (b).   
M1
M3
a b
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Fig. 8.  Radiochromatograms of vincristine incubated with cDNA-expressed CYP3A4 and CYP3A5.  3H-vincristine (10 µM ) was incubated for 15 min with 
insect control microsomes, matched to CYP3A5 protein content (a), cDNA-expressed CYP3A4 with co-expressed b5, 50 pmol/ml (b) and CYP3A5 with co-
expressed b5, 100 pmol/ml (c).  At least 95% of the radioactivity is represented from 10 to 45 min, and no distinctive peaks different than the control are present 
outside of this time range.  All dpm values are normalized to total radioactivity recovered. 
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Fig. 9.  Proposed biotransformation pathways of vincristine catalyzed by CYP3A4 and CYP3A5.  
(a) formation of M2; (b) formation of M1 and M3.  Structures not labeled are putative intermediates. 
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Fig. 10.  Extraction recoveries of vincristine, M1, and vinorelbine.  VCR (1 µM) in sodium phosphate 
buffer was incubated with cDNA-expressed CYP3A5 (50 pmol/mL) and NADPH (0.5 mM) for 9 min at 
37°C.  The solution was split between tubes and extracted with an equal volume of dichloromethane 
(DCM), ethyl acetate (EtOAc), methyl t-butyl ether (MTBE), or hexanes.  For certain extractions, 
trichloroacetic acid (TCAA) was used to reduce the pH.  The control was quenched with acetonitrile and 
evaporated without extraction.  The dried residues for all samples were assayed by HPLC. 
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Fig. 11.  Evidence of MS source-induced dehydration for M1 and the proposed mechanism.  The full scan 
mass spectrum of M1 (top) has two primary ions at m/z 811 and 793.  The ions at m/z 406 and 397 are the 
dicharged molecular ion and the dicharged source-induced dehydration ion, respectively.  Based on the 
chemical structure of M1, a mechanism of dehydration was proposed (bottom).  
R = N-formylvindoline 
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Fig. 12. Vincristine disappearance and M1 formation for various CYPs.  All enzymes were tested in 
duplicate (25 or 50 pmol, 5 µM vincristine, 250 µl final volume).  Vincristine and M1 concentrations 
were compared to an internal standard and normalized to the average of an insect microsome control.  The 
enzymes were tested in the absence of cytochrome b5 with the exception of coexpressed b5 in CYPs 2J2, 
2E1, and 3A7.  Error bars represent data ranges (n = 2) for each P450.  Statistical differences from the 
control incubations were calculated for vincristine disappearance using one-way ANOVA analysis, *p < 
0.05, **p < 0.01, ***p < 0.001.  
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Fig. 13.  Competitive inhibition of CYP3A4 and CYP3A5 with vincristine and vinblastine.  Vincristine 
and vinblastine at various concentrations were coincubated with cDNA-expressed CYP3A4 (a,b) or 
CYP3A5 (c) at 50 pmol/mL.  Vincristine inhibition with vinblastine for CYP3A5 is not presented because 
the data did not fit the model.  The rates of M1 formation from vincristine and vinblastine were assayed 
simultaneously by HPLC.  Using a competitive inhibition model, Ki (± SD) was estimated for each CYP 
and inhibitor by non-linear regression.  The Vmax and Km values were estimated previously. 
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Fig. 14.  Competitive inhibition of CYP3A4 and CYP3A5 activities with cyclosporin A.  Vincristine (10 
µM) was coincubated with cDNA-expressed CYP3A4 and/or CYP3A5 at various concentrations of CsA 
in 0% methanol (a) and 0.3% methanol (b).  For plot (b), the control incubations were performed without 
CsA in 0.3% methanol.  The fitted lines were estimated using Eqn. 1.  For plot (a), the uninhibited 
fraction was set at zero.  
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Fig. 15.  Kinetics of M1 and M2 formation from vincristine with CYP3A4 and CYP3A5.  VCR at various concentrations was incubated with CYP3A4 or 
CYP3A5 supplemented with b5 (3:1).  For one set of experiments, the incubations were performed using one CYP enzyme preparation and 6 concentrations of 
VCR (circles).  The identical incubations were repeated approximately 30 min later with the same CYP enzyme preparation to provide duplicate values 
(triangles).  The rates of M1 (open symbols) and M2 (closed symbols) formation were quantified by HPLC.  Not all values were available because of poor 
chromatography.  The Michaelis-Menten parameters were estimated with a one-enzyme model using non-linear regression.    
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Fig. 16.  Effect of enzyme preparation on the kinetics of M1 formation with CYP3A4 and CYP3A5.  Vincristine was incubated with multiple enzyme 
preparations: enzyme with co-expressed cytochrome b5 (•), enzyme with supplemented b5 (3:1) (▼), and enzyme without b5 (■ or □). For the enzyme 
preparation with CYP3A5 and supplemented b5 , the duplicate incubations (□) used the enzyme preparation approximately 30 min after the first set of 
incubations; this data was excluded in the kinetic analysis.  Data was fit to a one-enzyme model to determine Michaelis-Menten parameters.  
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Fig. 17.  Quantification of CYP3A4 and CYP3A5 in human liver microsomes by Western blot.  The 
cDNA-expressed CYP3A5 standard (1 pmol) was assayed with and without a co-loaded standard, IUL-9 
(a).  IUL-9 and IUL-52 do not have immunodetectable CYP3A5.  A typical Western blot (b) was loaded 
with 3 concentrations of standards in duplicate, a blank, and a protein loading control (IUL-52).  The 
protein loading control was added to each of the P450 standards to match the protein content of the 
unknowns (20 µg in this case).  A standard curve was generated using the 6 standard values, and the P450 
concentrations of the unknown HLMs were calculated by linear interpolation.    
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Fig. 18.  Western blot comparison of CYP3A4 and CYP3A5 standards.  By assuming equal immunoreactivities of the enzymes, the purity of the CYP3A4 and 
CYP3A5 standards were directly compared using a non-specific CYP3A antibody. 
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Fig. 19.  Western blot of CYP3A5 for IUL-57 and IUL-71.  The immunoreactive CYP3A5 protein contents of  IUL-57 and IUL-71 were compared to those of 
CYP3A5*3/*3 livers.  IUL-52, an HLM with no detectable CYP3A5, was added to the CYP3A5 standards.  IUL-32 (CYP3A5*1/*3) was used as a positive 
control for CYP3A5 expression.  Each well was loaded with 150 µg of protein.  
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Fig. 20.  Michaelis-Menten kinetics of itraconazole hydroxylation with IUL-49.  ITZ at multiple 
concentrations (0.2% methanol) was incubated in duplicate for 3 min with IUL-49.  The kinetic 
parameters were estimated by non-linear regression.   
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Fig. 21.  Final itraconazole concentration as a function of stock solution preparation.  ITZ incubations 
with HLMs were performed on two independent days.  For the first day (a), the initial target concentration 
of ITZ was 500 nM (0.1% methanol).  Two working stock solutions in 50 mL plastic tubes were 
formulated for the 90 incubations.  For the second day (b), the initial target concentration of ITZ was 1000 
nM (0.2% methanol).  Working stock solutions were freshly formulated in glass for each batch of 
incubations (9 tubes per batch).        
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Fig. 22.  Correlation between CYP3A activities and CYP3A4 protein content in human liver microsomes.  A select number of HLMs (n = 22) were 
characterized by CYP3A4 content, testosterone 6β-hydroxylase activity, and itraconazole hydroxylase activity.  The testosterone hydroxylase activity was 
correlated to CYP3A4 protein content (a) and to itraconazole hydroxylase activity (b).  Microsomes are separated by CYP3A5 expression:  ● low expression and 
○ high expression, at least one CYP3A5*1 allele.  Two microsomes (IUL-57 and IUL-71) with a genotype of CYP3A5*1/*0 are plotted as CYP3A5 low 
expressers. 
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Fig. 23.  Representative UV chromatogram of vincristine biotransformation with human liver 
microsomes.  VCR was metabolized to one major metabolite (M1) after incubation with human liver 
microsomes, IUL-73, for 10 min with and without NADPH.  Vinorelbine (VRL) was the internal 
standard.  The peak at 31 min was not vincristine-related as determined by LC/MS/MS. 
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Fig. 24.  Michaelis-Menten curves for rates of M1 formation with CYP3A5*1 human liver microsomes.  
Vincristine (5 to 108 µM) was incubated with microsomal protein (0.5 to 1.2 mg/mL) from livers with at 
least one CYP3A5*1 allele.  The initial M1 rates of formation at each concentration of VCR were used to 
estimate the Michaelis-Menten kinetic parameters of each liver by non-linear regression.         
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Fig. 25. Rates of M1 formation normalized to control activity after chemical inhibition of hepatic CYPs in 
human liver microsomes.  Vincristine (15 µM) was incubated with pooled HLMs (2 mg/mL) in the 
presence of selective CYP chemical inhibitors for 15 min.  The control experiments were completed 
without inhibitors. *p < 0.01  
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Fig. 26.  Inhibition of vincristine metabolism by the addition of methanol (a) and cyclosporin A (b).  
Vincristine (10 µM) was incubated with a panel of CYPs and CsA (25 µM).  For the CYPs, the vehicle 
controls contained 4.8% methanol and were compared to the previously estimated rate of M1 formation at 
10 µM VCR in plot (a).  The competitive inhibition of CsA was determined by comparing the rates of M1 
formation from the vehicle control incubations to the CsA inhibited incubations (b).  The degree of CsA 
inhibition was evaluated as a function of CYP3A4 activity by plotting the 6β-testosterone hydroxylase 
activities on the x-axis.      
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Fig. 27.  Inhibition of M1 formation with methanol and acetonitrile for IUL-42.  Vincristine (20 µM) and 
IUL-42 (1.2 mg/mL) were coincubated in duplicate with various concentrations of methanol and 
acetonitrile.  The control incubations were performed without solvent (0% organic).         
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Fig. 28.  Selective inhibition of CYP3A4 by cyclosporin A for CYP3A5 low expressers (a), and CYP3A5 
high expressers (b).  Points represent individual values (IUL-6, 59, and 73) or the average of replicates 
(CYP3A4, CYP3A5, IUL-55, 78, and 79).  Non-linear regression was used to fit data points to Eqn. 1 
(dotted lines), except for IUL-79 because the data did not fit model. 
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Fig. 29.  Correlation of the maximum rates of M1 formation to 6β-OH testosterone hydroxylase activity (a), itraconazole hydroxylase activity (b), and CYP3A4 
protein content (c) in human liver microsomes.  The livers are separated by CYP3A5 expression: ▼ low expression, ○ heterozygous high expression 
(CYP3A5*1/*0), and ● homozygous high expression (CYP3A5*1/*1).  Two microsomes (IUL-57 and IUL-71) with a genotype of CYP3A5*1/*0 are plotted as 
CYP3A5 low expressers.  Data from low CYP3A5 expressers was fit by linear regression (solid lines) with 95% confidence intervals (dotted lines). 
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Fig. 30. Correlation of the corrected maximum rate of M1 formation to CYP3A5 content.  The M1 
formation mediated by CYP3A5 was quantified by subtracting the CYP3A4 contribution as determined 
by linear regression with the CYP3A5*3/*3 samples using itraconazole hydroxylase activities.  
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Fig. 31. Specific activities of CYP3A4 and CYP3A5 in the formation of M1 from vincristine at Vmax for 
CYP3A5 high expressers.  The CYP3A4 and CYP3A5 contributions to M1 activity are estimated by 
normalization to testosterone 6β-hydroxylase activities of CYP3A5*3/*3 livers.  The specific activities of 
CYP3A4 and CYP3A5 for each microsome are calculated using the CYP3A4 and CYP3A5 protein 
concentrations as determined by Western blot.  Using the median values of the microsomes (dotted lines), 
the CYP3A5 activity is 7-fold higher than the CYP3A4 activity.   
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Fig. 32.  Estimation of intrinsic (a) and hepatic (b) clearances by in vitro/in vivo scaling with human liver 
microsomes.  The clearances were predicted for CYP3A5 high expressers (n = 10) and low expressers (n 
= 46).  Using the M1 formation velocity from 12 HLMs, the distribution of clearance values for CYP3A5 
low expressers was determined by linear regression of the testosterone 6β-hydroxylase activity for the 
bank of HLMs (n = 46).  
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Fig. 33.  Protein binding of vincristine to human liver microsomes (a) and plasma (b).  VCR (5 µM) was incubated at 37°C with various concentrations of 
pooled HLMs.  The apparent fraction unbound was calculated by dividing the concentration of the ultrafiltrate to the unprocessed VCR concentration in 
microsomal incubation buffer.  The concentrations were quantified by HPLC.  VCR (1 µM) was incubated at 37°C with human plasma from one donor diluted 
with phosphate buffer saline (PBS).  The apparent fraction unbound was determined in triplicate for each concentration.  The fraction unbound caused by non-
specific binding (fu,nsb, the y intercept) and the binding parameter (K) for microsomes and plasma were estimated by non-linear regression using Eqn. 2.  The 
fraction unbound (fu) was calculated for the plasma and each concentration of protein (labeled above). 
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Fig. 34.  Metabolite profiling of vincristine with cryopreserved hepatocytes.  Cyropreserved hepatocytes (lot SD012, SD017) were incubated in 24-well plates 
over 4 h at 5 x 105 cells/mL with 0.2, 2, and 20 µM VCR.  The cell density at 50 µM VCR was 1 x 106 cells/mL.  No cell controls were not performed for the 
two lowest concentrations of vincristine. 
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Fig. 35.  Vincristine degradation in plasma, buffer, and media.  VCR (15 µM) was incubated at 37°C in plasma, buffer, and media for 0 and 4 h (a).  VCR (10 
µM) was incubated in media for 0 and 4 h with different processing conditions (b).  Before certain incubations, the media was bubbled with 95% oxygen.  The 
impact of the shaker on degradation was also evaluated.  The samples were assayed by LC/MS.    
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Fig. 36.  UV chromatograms of M1 formation and vincristine depletion with intact hepatocytes (a) and 
hepatocyte cell lysate supplemented with NADPH (b).  Vincristine (4 µM) was incubated with intact cells 
in media and a sonicated cell preparation from cryopreserved hepatocytes (lot EHI, 1.5 x 106 cells/mL) 
with NADPH.  The intact cell incubation was quenched after 0, 1.5, and 4 h.  The lysate preparation was 
quenched after 0, 10, 20, and 40 min.  Arrows indicate the growth of M1 and the depletion of VCR over 
time.  VRL is the internal standard.  The peak at 25 min (a) is not VCR-related. 
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Fig. 37.  Radiochromatograms of vincristine incubated with cryopreserved hepatocytes.  VCR (8 µM) was 
incubated with two preparations of cryopreserved hepatocytes: cell lysate (a) and intact cells (b and c).  
For plot (a), the cell lysate was incubated with (solid line) and without (dotted line) supplemented 
NADPH.  The media and cells were quenched with acetonitrile prior to analysis.  For plot (b), the media 
(solid line) and cells (dotted line) were separated by centrifugation prior to the quench.  For plot (c), the 
VCR was coincubated with (dotted line) and without ketoconazole (10 µM, solid line).  The media was 
separated from the cells for analysis.  
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Fig. 38.  Vincristine depletion and M1 formation with hepatocyte lysate of microsomal buffer.  For VCR depletion and M1 formation, the first-order rate 
constants (k or k1) were estimated by non-linear regression for multiple lots of hepatocytes including lot SCA (a) and ZYZ (b).  For highly active hepatocytes 
such as lot SCA, the rate of M1 formation did not fit the model at late time points.  An additional first-order rate constant for the degradation of M1 was 
calculated (k2) assuming all the VCR was metabolized to M1.  For lot FKM, the estimated k1 was 2.0 h-1, and the k2 was 2.5 h-1.  
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Fig. 39.  Vincristine depletion and M1 formation with cryopreserved hepatocytes from one CYP3A5 high expresser (a) and one low expresser (b).  Lots EHI (a) 
and MRS (b) were incubated with VCR (4 µM) alone (circles) and with ketoconazole (10 µM, squares).  As an additional control, the hepatocytes were 
sonicated prior to use (triangles).  The solutions were assayed for M1 (solid symbols) and VCR (open symbols) after various incubation times.     
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Fig. 40.  Michaelis-Menten kinetics of M1 formation with cryopreserved hepatocytes (a) and hepatocyte lysate (b).  VCR at various concentrations was 
incubated with lot EHI (1.5 x 106 cells/mL) for 90 min with intact cells and 13 min with the cell lysate.  The rates of M1 formation were quantified by HPLC.  
The Michaelis-Menten constants were estimated using a one-enzyme model by non-linear regression.  
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Fig. 41.  Adsorption of vincristine, vinblastine, and vinorelbine to glass (a) and polypropylene (b) as a 
function of methanol concentration.  VCR (0.1 µM) and VRL (0.1 µM) in water were formulated in glass 
or polypropylene tubes with 0, 10, 20, 30, and 40% methanol (dark to light lines).  VLB (0.1 µM) was 
similarly formulated with 0, 20, 37, and 50% methanol (dark to light lines).  The relative recoveries were 
measured by LC/MS. 
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Fig. 42.  LC/MS assay development issues – carrier effect of vinblastine with vincristine (a) and baseline 
interference using initial LC/MS gradient conditions (b).  After evaporation, VCR was dissolved in 0.2% 
formic acid:methanol (20:80) in polypropylene tubes with and without VLB (130 ng/mL).  For plot (a), 
the VCR abundance without VLB was expressed as a percentage of the abundance with VLB.  For plot 
(b), VCR was extracted from plasma using the final extraction procedure.  The residue was assayed by 
LC/MS using fast gradient conditions (see Methods).  
 186 
 
                                    
a
b
c
 
 
 
 
Fig. 43.  Product ion spectra of M1 (a), vincristine (b), and the internal standard—vinblastine (c).  The 
precursor ions were [M+2H]2+ for all compounds.   
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Fig. 44.  Representative chromatograms of M1 (a), vincristine (b), and vinblastine (c) extracted from a plasma standard.  Blank plasma was spiked with M1 at 4 
ng/mL, vincristine at 8 ng/mL, and vinblastine (internal standard).  The sample was extracted with methylene chloride and assayed by LC/MS/MS per the 
validated method.  The monitored product ions (and approximate retention times) are as follows: M1 m/z 397.3 → 376.2 (11.3 min); vincristine m/z 413.2→ 
362.2 (13.6 min); and vinblastine m/z 406.3→ 271.7 (14.0 min).   
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Fig. 45. Representative chromatograms of M1 and vincristine from blank plasma (a), a plasma standard at the LOQ (b), and a patient plasma sample (c).  The 
M1 and VCR LOQ was 12 pg/mL.  The patient plasma sample, subject 2, was collected 20 h after vincristine administration.  For the patient sample, the 
estimated concentrations of M1 and vincristine were 31 pg/mL and 430 pg/mL, respectively.  
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Fig. 46.  Typical standard curves for vincristine and M1 quantification in plasma.  To generate a standard curve, a stock solution of M1 and VCR was 
synthesized using cDNA-expressed CYP3A5.  The stock solution is diluted with 0.2% formic acid: methanol (80:20, v/v) and spiked into 500 µL plasma at 8 
concentrations (0.012 to 24 ng/mL VCR, 0.012 to 12 ng/mL M1, closed circles).  Three separate QC concentrations were assayed in dpulicate (open circles).
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Fig. 47.  Metabolite ratios (VCR/M1) in human urine.  The M1 and VCR was quantified in urine samples 
from 2002—2004 clinical studies.  Patients with at least one CYP3A5*1 allele are represented by grey 
bars.  Two samples of the neat IV formulation for VCR were also assayed (white bars).  
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Fig. 48.  Representative chromatogram of a plasma sample collected from the 2002—2004 clinical 
studies.  Patient plasma samples were extracted per the validated method in 2007.  Four separate peaks 
were evident by selected ion monitoring of VCR that correspond by retention time to EPOX1, EPOX2, 
VCR, and VCR-NO.
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Fig. 49.  LC/MS monitoring of vincristine and vincristine N-oxide in plasma samples collected from the 2002—2004 clinical studies.  The Q1 signal intensities 
of VCR and VCR-NO were monitored for a plasma standard spiked with stock solution of VCR and M1 (a) and a patient sample from the 2002—2004 study 
(b).     
Time (min)
8 10 12 14
S
i
g
n
a
l
 
I
n
t
e
n
s
i
t
y
0
1e+6
2e+6
3e+6
4e+6
5e+6
6e+6 Time (min)
8 10 12 14
S
i
g
n
a
l
 
I
n
t
e
n
s
i
t
y
0
1e+5
2e+5
3e+5
4e+5
5e+5
6e+5
Time (min)
8 10 12 14
S
i
g
n
a
l
 
I
n
t
e
n
s
i
t
y
0
2e+5
4e+5
6e+5
8e+5 Time (min)
8 10 12 14
S
i
g
n
a
l
 
I
n
t
e
n
s
i
t
y
0
1e+5
2e+5
3e+5
4e+5
ba
VCR
m/z 413.2
VCR
m/z 413.2
VCR-NO
m/z 421.2
VCR-NO
m/z 421.2
VCR
VCR-NO
VCR
VCR-NO
 193 
Time (min)
0 200 400 600 800 1000 1200 1400 1600
C
on
ce
nt
ra
tio
n 
(n
g/
m
L)
0.01
0.1
1
10
Time (min)
0 200 400 600 800 1000 1200 1400 1600
C
on
ce
nt
ra
tio
n 
(n
g/
m
L)
0.01
0.1
1
10
Time (min)
0 200 400 600 800 1000 1200 1400 1600
C
on
ce
nt
ra
tio
n 
(n
g/
m
L)
0.01
0.1
1
10
Time (min)
0 200 400 600 800 1000 1200 1400 1600
C
on
ce
nt
ra
tio
n 
(n
g/
m
L)
0.01
0.1
1
10
C
on
ce
nt
ra
tio
n 
(n
g/
m
L)
C
on
ce
nt
ra
tio
n 
(n
g/
m
L)
C
on
ce
nt
ra
tio
n 
(n
g/
m
L)
C
on
ce
nt
ra
tio
n 
(n
g/
m
L)
b
c d
a
 
 
 
 
 
 
 
 
Fig. 50.  Semi-logarithmic vincristine and M1 concentrations versus time profiles of four patients.  
Vincristine (open symbols) and M1 (solid symbols) were fitted data using non-linear regression and a 
two-compartment model (1/y2 weighting for VCR and no weighting for M1).  None of the patients were 
CYP3A5 high expressers.   
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Fig. 51.  Relative M1 content in plasma samples from rhabdomyosarcoma patients.  The M1 
concentration was plotted as a percentage of the vincristine concentration at each time point. 
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